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ABSTRACT
Studies on the retinoblastoma susceptibility gene (RB) have played a central role in the conceptual
development of the tumor suppressor gene field. Patients inheriting a mutation in the RB gene
develop the rare pediatric eye cancer retinoblastoma with 90% penetrance. In addition, somatic
mutations in the RB gene have been found in many sporadically occurring human tumors. A great
deal of insight has also been gained from studies of retinoblastoma protein (pRB) in tissue culture.
These studies have shown that the protein product plays an important role in cell cycle
coordination, perhaps by modulating some aspect of the restriction point during the G 1 phase of
the cell cycle. Despite this vast amount of information, until recently very little was known about
the normal function of RB in development. Techniques developed in the last decade have allowed
mice with targeted mutations to be created. Several groups have exploited these techniques to
create mice with germline inactivating mutations in the murine version of the retinoblastoma
susceptibility gene (Rb). Initial analysis of these mice indicated that heterozygotes did not develop
retinoblastoma, instead they develop tumors in the intermediate lobe of the pituitary and in the
thyroid. Mice homozygous for the mutant allele die between 13.5 and 15.5 days of gestation with
associated defects in hematopoiesis and neurogenesis.
The focus of this work has been on expanding the use of these mice to better understand RB
function. One surprising observation is the relatively limited tumor spectrum observed in both
mice and humans which are constitutionally heterozygous for an RB mutation. A potential
explanation for this is that other genetic alterations must occur in combination with Rb mutation to
cause tumorigenesis in most tissues. To test this model, Rb-deficient mice were crossed with a
p53 mutant strain. Animals carrying mutations in both genes are susceptible to a wider spectrum
of tumors. A potential mechanism for this cooperativity is presented which shows that at least in
one system (the developing murine lens) Rb-deficiency leads to p53-dependent apoptotic cell
death. This apoptotic induction could serve to eliminate potentially transformed cell from the
organism.
One limitation to the utility of the Rb-deficient strain was the attendant embryonic lethality. To
bypass this lethality and assess the effects of Rb-deficiency during later stages of development and
in adult mice, ES cells were created which carried targeted mutations in both copies of the Rb gene
and used them to create chimeric animals. Analysis of tissue homogenenates from these chimeras
showed that Rb-deficient cells could contribute to most tissues of the adult mouse without
pathological consequences. To further this analysis, Rb-deficient ES cells have been created which
carry a transgene directing nearly ubiquitous expression of B-galactosidase. Staining of chimeric
tissues derived from these ES cells for B-galactosidase activity has enabled us to identify and
analyze Rb-deficient cells on a single cell level within these chimeras.
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NOMENCLATURE
I have used the accepted nomenclature in referring to genes and proteins throughout this
manuscript. Gene names are italicized while the same abbreviation referring to the protein product
of the gene is not. In addition, when the gene referred to is a mouse gene (and where it is
applicable) the gene abbreviation is written as the first letter being capitalized and all subsequent
letters being lowercase (Rb and Apc). When the human counterpart is referred to all the letters in
the abbreviation are capitalized (RB and APC).
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CHAPTER 1
Tumor Suppressor Genes
20
The discovery and characterization of oncogenes in the late 1970s and early 1980s revolutionized
the study of cancer (Bishop, 1995). Cancer could now be considered as a genetic disease in which
mutations in molecularly definable genes could be linked to tumor development. Most oncogenes
were originally isolated either because their coding sequences had been coopted by retroviruses to
give them transforming potential or because their addition to normal cells caused normal growth
control mechanisms to be compromised leading to transformation (Bishop, 1985; Bishop, 1995;
Land et al., 1983; Ruley, 1983; Shih et al., 1981; Shih and Weinberg, 1982; Stehelin et al., 1976).
Because the carcinogenic effects of tumor suppressor gene mutations were usually the result of
loss of function mutations in both cellular copies of the gene (Lee et al., 1987; Levine, 1993), they
proved more challenging to isolate and characterize. The existence of tumor suppressor genes was
originally postulated on the basis of somatic cell fusion experiments in which some fusions
between transformed and normal cells lead to an inhibition of the transformed cell phenotype
(Harris et al., 1969). This observation was later expanded to show that the introduction of small
regions of individual chromosomes from normal cells could suppress the transformed properties
of some tumor cells (reviewed in Stanbridge, 1990). These data, along with the seminal work of
Knudson (described in Chapter 2) helped establish the concept that cancer could result from the
loss of negative growth control in addition to gain of function mutations in growth-promoting
oncogenes. The development of positional cloning methods in the 1980s has facilitated the
identification of many tumor suppressor genes to date.
Almost all of the tumor suppressor genes identified to date have been cloned on the basis of
inherited mutations in these genes segregating with an obvious familial cancer predisposition. The
prototypic example of the identification of the retinoblastoma susceptibility gene (RB) will be
described in detail. At least ten other tumor suppressor gene mutations identified by their
association with familial cancer syndromes have been described. Like the products of oncogenes,
the protein products of these genes participate in a wide spectrum of cellular functions. The
21
functions of these genes and the inherited cancer syndromes associated with them are summarized
in Table 1-1. Besides the RB gene, this work has focused heavily on the activities of the p53 gene.
Because of this, the identification and activities of the p53 gene will also be reviewed in detail.
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Table 1-1. Functions of human tumor suppressor genes
and tumors associated with their inactivation
(Adapted from Williams and Jacks, 1996)
Protein Features
Nuclear phosphoprotein,
Binds transcription factors
Nuclear phosphoprotein,
Transcription factor
Zinc fingers,
Transcription factor
Coiled-coil motif,
Binds B-catenin
ras-GAP activity
Membrane cytoskeletal
attachment
pl6MTSI Cyclin/cdk inhibitor
Inherited Syndromes
(Human)#
Familial retinoblastoma
Li-Fraumeni syndrome
Wilms tumor
Familial adenomatous
polyposis coli, Turcot's
syndrome
Neurofibromatosis
Type I
Neurofibromatosi s
Type II
Familial melanoma
N-CAM homology
Associated Cancers
(Human)#
Retinoblastoma; osteo-
sarcoma; breast, lung,
and bladder carcinoma
Several (50% of all cancer)
Nephroblastoma
Colon and Brain
Neurofibromatosis,
Colon carcinoma,
Astrocytoma
Vestibular Schwannoma,
Meningioma, Ependymoma
Several
Colon
VHL Inhibits transcriptional
elongation
BRCA1 Zinc finger, secreted
granin ?, nuclear protein ?
BRCA2 granin ?
von-Hippel-Lindau
syndrome
Familial breast/ovarian
cancer
Familial breast/
ovarian cancer
Renal cell carcinoma,
pheochromocytoma
Breast and ovarian
Breast and ovarian
References or reviews for the information summarized in Table 1 are as follows: RB
(Hollingsworth et al., 1993; Hollingsworth, 1993; Riley et al., 1994; Weinberg, 1992; Weinberg,
1995) and below, p53 (Greenblatt et al., 1994; Levine, 1992; Levine et al., 1991) and below, WT-1
(Hastie, 1994), APC (Miyaki et al., 1995; Polakis, 1995), NF-i (McCormick, 1995; Vishochil et
23
Gene
RB
p53
Wt-I
APC
NF-1
NF-2
DCC
al., 1993), NF-2 (Gusella et al., 1996), pi6 MTSI (Harper and Elledge, 1996), DCC (Cho and
Fearon, 1995), VHL (Duan et al., 1995a; Duan et al., 1995b; Kibel et al., 1995), BRCA1 (Holt et
al., 1996; Jensen et al., 1996; Miki et al., 1994), and BRCA2 (Jensen et al., 1996; Tavtigian et al.,
1996; Wooster et al., 1995).
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CHAPTER 2
The Retinoblastoma Gene
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Identification and cloning of the retinoblastoma susceptibility gene
Retinoblastoma is a rare tumor of the retina which develops in approximately 1 in 20,000 children
in the United States each year (Dryja, 1989; Dunphy, 1964; Weinberg, 1992). It was first reported
in the early nineteenth century, and in those relatively primitive medical times was almost always
fatal (Dryja, 1989; Dunphy, 1964; Weinberg, 1992). However, better methods of treatment
allowed survival of affected individuals, and around the turn of the century vertical transmission of
the disease was reported (DeGouvea, 1886; Dryja, 1989; Dunphy, 1964; Ridley, 1905; Weinberg,
1992). As more such cases were examined it became evident that retinoblastomas occurring in
familial clusters differed from those occurring sporadically. The inherited cases were much more
likely to occur earlier in life and present as multifocal and bilateral. In 1971, Alfred Knudson
published an analysis of the two different forms of the disease which came to several conclusions
that would lay the conceptual framework for the discovery and analysis of tumor suppressor genes
(Knudson, 1971). Knudson suggested the difference between the two types of retinoblastoma was
that in the sporadic cases two relatively rare events needed to occur to initiate tumor development,
while in the inherited cases only one event was necessary. Knudson later extended this "two-hit"
hypothesis to explain the differences between the familially associated and sporadic cases of
Wilms tumor, a childhood cancer of the kidney (Knudson and Strong, 1972).
The concept that inactivating mutations in both alleles of a single gene could explain the "two-hits"
proposed by Knudson was first advanced by Comings (Comings, 1973). Experimental support
for this idea began to emerge in 1978 when Yunis and Ramsey described the deletion of an area of
chromosome 13 (band q14) in some DNA samples derived from retinoblastomas (Yunis and
Ramsey, 1978). Five years later, several groups reported that retinoblastoma patients who were
constitutionally heterozygous for DNA markers in the 13q14 region underwent reduction to
homozygosity in this region in their tumor DNA (Bendedict et al., 1983; Cavenee et al., 1983;
Dryja et al., 1984; Godbout et al., 1984; Sparkes et al., 1983). Shortly thereafter, the cloning of the
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gene underlying retinoblastoma development was reported by Friend et al. (Friend et al., 1986) and
later confirmed by other groups (Fung et al., 1987; Lee et al., 1987b). The gene was found to span
approximately 200 kilobases of DNA in the 13q14 region (Hong et al., 1989; McGee et al., 1989).
Further analysis revealed that the gene contained 27 exons ranging in size from 31 to 1889
nucleotides (Hong et al., 1989; McGee et al., 1989). In addition, detailed examination of the
promoter region of the gene showed it to be GC rich and contain binding sites for the transcription
factors ATF, Sp-1, and E2F (reviewed in Riley et al., 1994). While the initial isolation of the gene
was dependent on the analysis of individual tumors from patients who had inherited large deletions
in the gene, it was subsequently found that a large number of retinoblastomas were actually
associated with point mutations in the RB gene (Canning and Dryja, 1989; Dunn et al., 1988; Fung
et al., 1987; Gallie et al., 1990; Horowitz et al., 1989; Kaye et al., 1990; Lee et al., 1987b; Yandell
et al., 1989). The end result of all the point mutations was to create functionally inactive pRB. The
significance of the promoter binding sequences is highlighted by the fact that several examples of
familially-associated retinoblastoma have been associated with deletions or point mutations within
these binding sites (Bookstein et al., 1990a; Sakai et al., 1992).
After the gene was cloned, several groups screened DNA from a variety of different tumor types
to examine whether RB function was lost via deletion or point mutation. Surprisingly, even
though patients who inherit a defective RB allele are not significantly predisposed to any tumors
besides retinoblastoma (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987b), osteosarcoma
(Friend et al., 1986), and perhaps pinealoblastoma (Jakobiec et al., 1977; Pesin and Shields, 1989;
Stannard et al., 1985), somatic mutations in the RB gene were shown to occur in several other
tumor types. These included some types of sarcomas (Friend et al., 1987; Shew et al., 1989;
Stratton et al., 1990) as well as carcinomas of the cervix (Scheffner et al., 1991), prostate
(Bookstein et al., 1990b), bladder (Cairns et al., 1991; Ishikawa et al., 1991; Takahashi et al.,
1991), breast (Lee et al., 1988; T'Ang et al., 1988; Varley et al., 1989), and lung (Hensel et al.,
1990; Ookawa et al., 1993; Rygaard et al., 1990; Yokota et al., 1988). In addition, mutations
affecting other genes involved in the regulation of RB protein (pRB) activity have been estimated
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to occur in a still larger spectrum of human tumors (discussed below). The data implied that pRB
played a potentially important role in growth control in many cell types besides retinoblasts.
In vitro evidence that the RB gene can directly suppress cell proliferation
The first direct evidence that RB could suppress transformation and tumorigenesis came from
studies in which RB was reintroduced into cell lines which were deficient for RB as a result of
mutation (reviewed in Riley et al., 1994). In several cases such reintroduction was shown to have
effects including the inhibition of cell proliferation in vitro, inducing changes in cellular
morphology, reducing the growth potential of cells in soft agar, and inhibiting the growth of tumor
cell lines upon injection into nude mice. Examples of tumor cell lines which are affected by the
reintroduction of RB include those derived from retinoblastomas (Huang et al., 1988; Medraperla
et al., 1991; Xu et al., 1991), osteosarcomas (Huang et al., 1988), and carcinomas of the breast
(Wang et al., 1993b), bladder (Goodrich et al., 1992; Takahashi et al., 1991), and prostate
(Bookstein et al., 1990b). Assays based on these systems, especially the ability of RB to induce
cell cycle arrest and morphological changes in the osteosarcoma cell line SAOS-2 (Hinds et al.,
1992; Qian et al., 1992), have been heavily utilized to assess aspects of RB function (see below).
Analysis of the RB gene product
The cDNA derived from the RB gene is 4757 nucleotides long and contains an open reading frame
predicted to encode a protein containing 928 amino acids (reviewed in (Riley et al., 1994;
Weinberg, 1992). Northern and subsequent Western blot analysis revealed that the gene was
expressed in an almost ubiquitous fashion (Bernards et al., 1989; Lee et al., 1987a). The predicted
molecular mass of the protein was 105 kD. However, initial analysis of pRB sequence provided
few clues to its potential function. A schematic representation of the domains discussed below is
shown in Figure 2-1.
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Figure 2-1. Characteristics of pRB
Amino
Acid # 1 250 500 750 928
Pocket (Oncoprotein/E2F binding) -
c-abl binding
* Denotes a serine or threonine within located in a cdk consensus
recognition site. Residues are 249, 252, 356, 373, 608, 612, 788,
795, 807, 811, and 821. Residue 249 is not a perfect consensus site
but has been shown to be phosphorylated in vitro by cdc2 (Lees et al.,
1991).
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The protein was first identified by Wen-Hwa Lee and colleagues in 1987 with antibodies raised
against the RB protein derived from expression in E. coli (Lee et al., 1987a). Initial analysis
revealed that the protein was present at all phases of the cell cycle suggesting that its activity was
regulated post-translationally (Chen et al., 1989; Lee et al., 1987a). Western blot analysis of cell
extracts with this antibody revealed that it recognized a number of proteins migrating between 110
and 116 kD (Ludlow et al., 1990; Shew et al., 1989). Subsequent analysis showed that these
phosphopeptides were phosphorylated exclusively on serine and threonine residues (Chen et al.,
1989; DeCaprio et al., 1988; DeCaprio et al., 1989; Furukawa et al., 1990; Lees et al., 1991; Lin et
al., 1991; Ludlow et al., 1990; Shew et al., 1989). It was later shown that many of these residues
were phosphorylated by the activity of cdk family members based on the observations that purified
cdc2 could phosphorylate pRB in vitro on many of the same sites that they were phosphorylated in
vivo (Lees et al., 1991; Lin et al., 1991; Taya et al., 1989). Furthermore, the first five of the in vitro
phosphorylated sites mapped were found to contain a consensus cdc2 recognition motif (Lees et
al., 1991). Much in vivo and in vitro evidence now supports the model that cyclin dependent
kinases are the major, if not only, kinases involved in pRB phosphorylation (described below).
The pattern of pRB phosphorylation oscillates during different stages of the cell cycle (Buchkovich
et al., 1989; Chen et al., 1989; DeCaprio et al., 1988; DeCaprio et al., 1989; Furukawa et al., 1990;
Mihara et al., 1989). During GO and early to mid Gl, hypophosphorylated forms of the protein
predominate. As the cell progresses through the restriction point late in G 1, the protein becomes
highly phosphorylated probably due to cdklcyclin kinase activity (discussed below). These highly
(or hyper-) phosphorylated forms of pRB remain through S, G2, and most of M phase. The
protein then begins to become dephosphorylated again during anaphase. This process then is
completed during early G1. Relatively little is known about the mechanisms underlying the
dephosphorylation of pRB. However, the facts that pRB was shown to interact with the catalytic
subunit of phosphoprotein phosphatase type 1 (PP-1) (Durfee et al., 1993) and that inhibitors
specific for PP-1 block pRB dephosphorylation (Hollingsworth, 1993) suggest that PP-1 may
control it.
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The RB aene product interacts with several DNA tumor virus oncoproteins
All DNA tumor viruses need to replicate their own viral genome to propagate and survive. Large
DNA tumor viruses (such as herpes simplex virus) typically encode most of the enzymes
necessary for this process and need only minor components of the cellular environment for its
completion (Knipe, 1989) On the other hand, some of the smallest DNA tumor viruses, such as
parvoviruses, have evolved the opposite replication strategy. These viruses are heavily dependent
on cellular factors for all aspects of viral replication and thus only replicate their DNA when the
cellular DNA replicates (reviewed in Dyson and Harlow, 1992).
Several DNA tumor viruses (most notably adenoviruses, papillomaviruses, and polyomaviruses)
have evolved strategies which lie between these two extremes (Dyson and Harlow, 1992). These
viruses are still heavily dependent on cellular factors, but instead of merely waiting for DNA
replication to occur, their genomes encode proteins which help stimulate infected cells to enter S
phase. These proteins include the E1A protein produced by adenovirus, the E7 protein encoded
for by the papillomavirus genome, and the large T antigens of polyomaviruses.
The E1A protein are the first polypeptides expressed from the viral genome following adenovirus
infection and have been shown to have a number of different functions (Lewis and Mathews,
1980; Nevins, 1981). In order to gain further insight into the mechanisms underlying E1A
function, two groups used antibodies derived against the E1A protein to identify cellular proteins
which interacted with E1A (Harlow et al., 1986; Yee and Branton, 1985). Remarkably, one
protein which coimmunoprecipitated with E1A was pRB (Whyte et al., 1988). Further analysis
showed that was a direct interaction. Stimulated by this observation, DeCaprio et al. showed that a
polyomavirus protein, the simian virus 40 (SV40) large T antigen, could also form a complex with
the RB protein (DeCaprio et al., 1988). Subsequently it was shown that the E7 oncoproteins of
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human papillomaviruses and large T antigens of other polyomaviruses could also interact with
pRB (DeCaprio et al., 1988; Dyson et al., 1990; Dyson et al., 1989; Munger et al., 1989).
Since E1A (Dyson and Harlow, 1992; Houweling et al., 1980; Land et al., 1983; Ruley, 1983) (as
well as SV40 large T (Livingston, 1992) and E7 (Munger et al., 1992)) could act as oncogenes and
loss of RB function was associated with the development of human tumors, a simple hypothesis
was forwarded that the binding of these proteins to pRB resulted in pRB functional inactivation
(Dyson and Harlow, 1992; Livingston, 1992; Munger et al., 1992). This would create a situation
equivalent to that seen in cells which had lost RB function via mutation. Importantly, the
hypophosphorylated forms of pRB were the only ones targeted by the viral oncoproteins
suggesting that they were the functionally active forms (Dyson and Harlow, 1992; Livingston,
1992; Munger et al., 1992). Such functional inactivation of the growth suppressing RB protein
would help drive the infected cell into S phase and facilitate viral replication.
This model of viral oncoprotein and pRB function has been supported by several lines of
experimental work which themselves have revealed important insights into RB function. First, the
regions of the viral oncoproteins which mediate binding to pRB are necessary for full viral activity
(Dyson and Harlow, 1992; Livingston, 1992; Munger et al., 1992). In addition, the regions of
pRB which bind to the viral oncoproteins (referred to as the "pocket" region) have been shown to
be favored sites for point mutations associated with human tumors (Hu et al., 1990; Huang et al.,
1990; Kaelin et al., 1990). This implied that the viral oncoproteins were targeting a region of pRB
which normally acted in a growth inhibitory manner.
The RB gene product binds to E2F. a cellular transcription factor
Work during the mid-1980s had shown that the E1A could dissociate complexes containing the
cellular transcription factor E2F resulting in the release of free E2F (Bagchi et al., 1990; Nevins,
1992). E2F was originally identified as a component of the adenovirus E2 promoter transcription
35
complex (Nevins, 1992) and has subsequently been shown to have the ability to stimulate cellular
proliferation and transactivate promoters of many genes which are thought to play a role in
stimulating cell cycle progression. A partial list of genes which contain putative E2F target sites
in their promoters include dihydrofolate reductase (Blake and Azizkhan, 1989; Hiebert et al.,
1991), thymidine kinase (Kim and Lee, 1991), DNA polymerase ax (Pearson et al., 1991), c-myc
(Hiebert et al., 1989; Thalmeier et al., 1989), N-myc (DePinho et al., 1986; Mudryj et al., 1990),
cdc2 (Dalton, 1992), B-myb(Lam and Watson, 1993), PCNA (Lee et al., 1995a), and cyclin E
(Ohtani et al., 1995).
Since E1A both bound pRB and caused the release of free E2F from higher order complexes,
several groups tested whether binding of E1A released pRB from an interaction with E2F which
allowed E2F to perform its cellular functions. In 1991, four groups reported that this indeed was
the case (Bagchi et al., 1991; Bandara and La Thangue, 1991; Chellappan et al., 1991; Chittenden et
al., 1991). E2F was shown to bind to hypophosphorylated form of pRB and be released upon
E1A binding to pRB. The binding site for E2F within the pRB protein was found to map partially
to the E1A-binding site (the pocket) and also to another area C-terminal to the pocket (see Figure
2-1).
The simple model that emerged from these studies was that pRB normally inhibits cell cycle
progression by binding to and negatively regulating the activity of E2F complexes (Nevins, 1992).
While in general this model has proven to be accurate, it has become necessarily more complex
due to several observations in recent years. A great deal of accumulating evidence suggests that
besides simply negatively regulating E2F activity, pRB may actually repress transcriptional activity
from certain promoters via its association with promoter sites through its E2F interaction (since
E2F complexes have specific DNA binding activity) (Weintraub et al., 1995; Weintraub et al.,
1992). To add another level of complexity to the equation, E2F has been shown to be a dimeric
complex between one E2F and one DP subunit (reviewed in (La Thangue, 1994). The first E2F
subunit, E2F- 1 was cloned in 1992 . Subsequently, the identification of four other E2Fs (E2F 2-
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5) has been reported (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995; Ivey-
Hoyle et al., 1993; Lees et al., 1993; Sardet et al., 1995). In addition, multiple genes encoding for
DP subunits have also been identified, although relatively little has been reported about their
functions (Girling et al., 1994; Girling et al., 1993).
Consistent with the model that pRB inhibits cell cycle progression, overexpression of E2F-1 has
been shown to be sufficient to drive arrested cells into S phase (Johnson et al., 1993).
Furthermore, SAOS-2 cells overexpressing E2F-1 are able to overcome the block in cell cycle
progression induced by pRB introduction (Qin et al., 1995).
As discussed below, the different E2F subunits appear to confer specificity of each complex to
associate differentially with different pRB-related proteins. Whether the different E2F subunits (or
even the DP subunits) direct E2F complexes to specific promoters remains to be determined.
pRB can interact with a number of cellular proteins
Besides its binding to E2F complexes, pRB has been reported to interact, at least in vitro, with
several other cellular proteins. In general, these proteins appear to interact preferentially with the
hypophosphorylated form of pRB. A partial list of these proteins includes the transcription factors
c-myc (Rustgi et al., 1991), c-abl (Welch and Wang, 1993), elf-i (Wang et al., 1993a), Id-2
(Iavarone et al., 1994), myoD (Gu et al., 1993), myogenin (Gu et al., 1993), PU.1 (Hagemeier et
al., 1993), ATF-2 (Kim et al., 1992), UBF (Cavanaugh et al., 1995), and BRG-1 (Dunaief et al.,
1994) as well as D-type cyclins (Dowdy et al., 1993; Ewen et al., 1993; Kato et al., 1993), the
protein phosphatase PP1-cx2 (Durfee et al., 1993), mdm2 (Xiao et al., 1995), and the human
homolog of a yeast ras regulatory protein MSI1 (Qian et al., 1993). The importance of these
individual interactions or their physiological relevance in modulating pRB function is not clear in
many cases.
37
Extending the concept of the pRB:E2F interaction, a model that has been suggested based on the
ability of pRB to interact with this plethora of cellular transcription factors is that pRB acts as a
gatekeeper for the initiation of cell cycle progression (Hollingsworth et al., 1993; Hollingsworth,
1993; Riley et al., 1994; Weinberg, 1995). In the hypophosphorylated state it binds to and inhibits
a number of these transcription factors. Upon stimulation of cell cycle progression by external
signals, the machinery to phosphorylate pRB is activated resulting in hyperphosphorylated pRB
and the coordinated release and activation of these transcription factors. The fact that pRB
becomes hyperphosphorylated coincident with the restriction point (Weinberg, 1995), the point
after which mammalian cells are committed to going through the cell cycle to the next G 1 phase
(Pardee, 1989), further supports this model.
RB is a member of a multigene family
Work on DNA tumor virus oncoproteins also impacted the retinoblastoma field in another
significant way in helping establish that RB is actually one of a three member gene family which
share significant functional and structural homology. The work which lead to this understanding
was based again on studies of proteins which could be shown to interact with DNA tumor virus
oncoproteins by coimmunoprecipitation. Some of the same mutant versions of E1A (as well as
large T antigen) which had lost the ability to interact with a number of the other
coimmunoprecipitating proteins (Dyson and Harlow, 1992). Among these were proteins referred
to by their estimated molecular weight, p107 and p130. The genes encoding for p107 (Ewen et al.,
1991) and p130 (Hannon et al., 1993; Li et al., 1993; Mayol et al., 1993) have now been cloned.
The three family members share considerable homology (see Figure 2-2 and reviewed in
(Cobrinik, 1996).
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Figure 2-2.
Structural Homology Between Members Of The Rb-gene Family
RBE[Z
n130 I
p107 L
U
Homology whose functional relevance is unknown
Homology in the E1A/large T/E7/E2F binding site
Homology between the spacer regions (cdk/cyclin binding site) of p107 and p130
(Adapted from Li et al.. 1993)
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Further analysis of the protein products of these genes has confirmed that they do share functional
characteristics with pRB. Besides the shared ability to bind to DNA tumor virus oncoproteins
which was the basis for their identification, the proteins also bind to members of the E2F family of
transcription factors with pRB having been shown to bind to E2F complexes containing E2F-1,
-2, -3, or -4 (Bagchi et al., 1991; Chellappan et al., 1991; Fagan et al., 1994; Helin et al., 1993;
Helin et al., 1992; Hiebert et al., 1992; Horio et al., 1993 ; Kaelin et al., 1992; Krek et al., 1993;
Lees et al., 1993; Moberg et al., 1996) and p107 and p130 binding to complexes containing E2F-4
or -5 in vivo (Beijersbergen et al., 1994; Hijmans et al., 1995; Moberg et al., 1996; Sardet et al.,
1995; Vairo et al., 1995). The distribution of these complexes has been shown to change during
progression through the cell cycle (Chittenden et al., 1993; Cobrinik et al., 1993; Moberg et al.,
1996; Schwarz et al., 1993; Shirodkar et al., 1992). pl30:E2F complexes make up the majority of
E2F complexes during GO and early G1. During mid to late G1, pRB becomes the major E2F
binding partner, while during late G1 and S p107 becomes the predominant binding partner.
Further support for grouping these gene products into a gene family comes from analysis of the
cellular effects of reintroduction or ectopic expression of these genes. As briefly mentioned above,
the introduction of the retinoblastoma gene into several cell types suppressed aspects of the
transformed phenotype. Introduction of pl07 and p130 into tumor cell lines has shown that they
also have the ability to suppress aspects of the transformed phenotype when overexpressed.
However, the mechanism underlying this suppression appears to differ among the RB-family
members. For example, while the ability of RB to suppress colony formation when introduced
into SAOS-2 cells can be overcome by overexpression of E2F-1, while the ability of pl07 to
suppress colony formation is unaffected (Zhu et al., 1993). In addition, some cell lines are
differentially sensitive to suppression by pRB-family members. For example, colony formation
and proliferation in the cervical carcinoma cell line C33-A is not inhibited by the introduction of
RB, but it inhibited by p107 (Zhu et al., 1993). Another example is the glioblastoma cell line
T98G in which colony formation is inhibited by p130 but not by p107 or RB (Claudio et al.,
1994).
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The suggestion that pl07 and p130 play roles in suppressing aspects of cellular transformation is
difficult to reconcile with other observations. The most important of which is that despite great
efforts to identify human tumors carrying mutations in p107 and/or p130, no evidence for any
such mutations has been reported. It should be noted, however, that it has been suggested that
p130 may be a mutational target during the development of nasopharyngeal tumors in Chinese
garment workers (Claudio et al., 1994; Mascola et al., 1992). Whether p130 will be the important
target of these mutational events remains to be seen. In addition, the creation of mice carrying
targeted mutations in the p107 and p130 genes (see Appendices C and E) has revealed that mice
deficient for either one of these genes fail to show any tumor predisposition (see Appendix C and
(Cobrinik et al., 1996)). Extending this even further, mice heterozygous for a mutation in one of
the genes and completely deficient for the other (eitherpl07+/-;pl30-/- orpl]07-/-,pl30+/-) still
do not display any predispositions to tumor development (Cobrinik et al., 1996).
Determining why p107 and p130 can suppress aspects of transformation in vitro but inactivating
mutations in these genes have not been associated with human or murine cancer remains a key
question in the RB field. Perhaps one explanation for this apparent paradox could be that the in
vitro assays are based on overexpressing the proteins. Such overexpression could lead to these
proteins simply acting as a surrogate for pRB by binding to E2F complexes which normally only
bind to pRB. This could result in the inhibition of these complexes and lead to growth arrest.
While this scenario remains possible, the fact that coexpression of E2F- I1 can overcome
suppression by RB but not by p107 is strong evidence against this (Zhu et al., 1993).
Undoubtedly the availability of reagents derived from p107, p130, and Rb-deficient mice will
allow a better understanding of the functions of these proteins in the future.
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Regulation of pRB phosphorylation
The cellular machinery involved in regulating the phosphorylation status of pRB (as well as p107
and p130) has become well understood in the last several years (see Figure 2-3). Cell cycle
progression is controlled by the regulated activity of cyclin-dependent kinases (cdks) (Morgan,
1995). Cyclin dependent kinases were originally identified in yeast and amphibians and
subsequently found to comprise a multigene family in mammals (Meyerson et al., 1992; Morgan,
1995). Three of these (cdk2, cdk4, and cdk6) have been recognized to play important roles in
progression through the GI phase of the cell cycle (Sherr, 1994). The catalytic activity of these
serine-threonine kinases is positively regulated by their association with cyclin proteins, a family of
which at least 7 different subfamilies have been recognized in mammals based on structural
homology and function (Hunter and Pines, 1994; Sherr, 1993; Sherr, 1994). In terms of
progression from G1 to S phase, D type cyclins (via their association with cdk4 and cdk6) and
Cyclin E (through its association with cdk2) play important roles (Draetta, 1994; Sherr, 1993;
Sherr, 1994). Both of these cyclin/cdk complexes phosphorylate and presumably inactivate RB
function (Draetta, 1994; Hatakeyama et al., 1994; Hunter and Pines, 1994; Sherr, 1993; Sherr,
1994) and overexpression of both Cyclins D and E can abrogate the block in cell cycle progression
induced by RB (Hinds et al., 1992). Cyclins A and B are thought to play important roles in the
progression of cells through S and G2/M (Pines, 1995). Cyclin H is a component of the cdk-
activating kinase complex (Fisher and Morgan, 1994; Makala et al., 1994; Matsuoka et al., 1994),
while the functions of Cyclins C and G have not been determined (Pines, 1995).
Recent data suggests that the only role of D type cyclins (of which three have been identified) in
cell cycle control may be in regulating the phosphorylation status of pRB. An elegant set of
experiments by Jiri Bartek and colleagues has shown that microinjection of antibodies which
inactivate D type cyclins inhibits cell cycle progression only in cells which contain functional
retinoblastoma protein (Lukas et al., 1995).
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The importance of these regulatory proteins (as well as the pRB pathway in general) is emphasized
by the fact that alterations of cdk and/or cyclin expression by chromosomal translocation, gene
amplification, or mutation has been observed in many human tumors (Adelaide et al., 1995;
Arnold et al., 1992; Motokura and Arnold, 1993; Motokura et al., 1991; Rosenberg et al., 1991;
Wolfel et al., 1995; Zukerberg et al., 1995). In addition, analysis of mice deficient for specific D
type cyclins are beginning to offer new insights into RB function. For example, mice deficient in
cyclin D1 exhibit reduced perinatal size and viability, retinal abnormalities associated with
decreased retinal size, and a failure to induce proliferation in the breast epithelium in response to
pregnancy (Sicinsky et al., 1995). It is tempting to speculate that a failure to inhibit the activity of
pRb in these cell types depends specifically on the presence of cyclin D1 (but not D2 or D3).
Further evidence suggesting a role for D type cyclins in development and tumorigenesis come
from observations of transgenic mice overexpressing Cyclin D1 in the breast (Wang et al., 1994).
These mice are predisposed to the development of mammary adenocarcinomas. In addition,
coexpression of cyclin D1 and myc in lymphoid tissue can induce lymphomagenesis (Bodrug et
al., 1994; Lovec et al., 1994).
The kinase activity of these cyclin/cdk complexes is itself a target of complex regulation. Besides
their required association with cyclins for kinase activity, cdks also require the phosphorylation of
an internal threonine residue (Thrl60 in CDK2) for activity (Solomon, 1994). The
phosphorylation of these residues in these cdks is controlled the cyclin/cdk activating kinase
(CAK) (Solomon, 1994). CAK was found to be a heterodimer of yet another cyclin/cdk pair
(cdk7 and Cyclin H) (Fisher and Morgan, 1994; Makala et al., 1994; Matsuoka et al., 1994).
Furthermore, the activity of the CAK is partially controlled by the activity of a yet unidentified
kinase. In addition to this level of regulation, cdk activation also requires the removal of inhibitory
phosphates from Thrl4 and Tyrl5 by cdc25 phosphatases (Hoffman and Karsenti, 1994).
The activities of cyclin/cdk complexes are also controlled by their association with so-called cyclin-
dependent kinase inhibitors (CDI). The WAF1/CIP/ISDI1/p21 is a CDI encoding gene (El-Deiry
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et al., 1993; Harper et al., 1993; Noda et al., 1994; Xiong et al., 1993) activated at the
transcriptional level by the p5 3 tumor suppressor gene protein (El-Deiry et al., 1993). Its
activation leads to its association with cyclin/cdk kinases and their subsequent inactivation. Two
other genes closely related to p21 (but not transcriptionally induced by p53), p27 (Polyak et al.,
1994; Toyoshima and Hunter, 1994) and p57 (Lee et al., 1995b; Matsuoka et al., 1995), have also
been recently identified.
The INK4 (Inhibitors of cdk4 kinase) family of proteins are CDIs which specifically inhibit the
kinase activity of cyclin D associated cdks. The family presently includes p15, p16 , p18, and p19
(Chan et al., 1995; Guan et al., 1994; Hannon and Beach, 1994; Hirai et al., 1995). The best
studied member of this family is p16, a gene known to be mutated in a wide variety of cancers,
and has been shown to be a strong inhibitor of cell cycle progression through G1. The p16 locus
has also been shown to be very complex due to the fact that an unrelated growth suppressing gene
(pl 9 ARF1) is also transcribed from the same locus (Quelle et al., 1995). Further experiments on
p16 have suggested that its ability to block cell cycle progression is dependent on the presence of
pRB in the cell (Lukas et al., 1995; Medema et al., 1995). p1 8 also appears to act through pRB to
induce cell cycle arrest (Guan et al., 1994; Hirai et al., 1995).
To a large extent studies on RB function have been performed in tumor cell lines known to contain
or lack RB function (for example SAOS-2 and U20S cells). While these experiments are
valuable, they are often difficult to interpret since tumor cells undoubtedly have undergone a
number of genetic changes in order to become transformed and adapted for tissue culture growth.
In addition, very little was known about the normal physiological role of Rb during differentiation
and development. The ability to create mice with targeted mutations has revolutionized the field of
molecular biology, and in this specific case allowed a better understanding of the normal role of Rb
in development and tumor suppression.
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Methods for creating mice carrying targeted gene inactivations in the germline
Coincident with the developments in understanding the regulation and function of the
retinoblastoma protein, techniques for the creation of targeted alterations in the mouse genome
were being developed. One of the seminal events in the development of these techniques came in
1981 when two laboratories reported the isolation of a cell population derived from the inner cell
mass of blastocysts (Evans and Kaufman, 1981; Martin, 1981). This population could be grown
almost indefinitely in culture and when injected into the blastocoel of another blastocyst could
contribute to many tissues in the resulting chimeric mice (Bradley et al., 1984). Since these
embryonic stem (ES) cells could contribute to the germline of these chimeras, if methods to create
specific mutations in these cells could be developed, it would be theoretically possible to create
murine strains carrying any desired mutation for subsequent analysis. However, the nature of
recombination in mammalian cells made this task difficult. Unlike yeast, in which exogenous
DNA vectors preferentially integrate into the most homologous chromosomal locus, integration
into the mammalian genome is a more random process (Mansour et al., 1988; Rothstein, 1983;
Shortle et al., 1982; Struhl, 1983). Thus given the size of the murine genome, the probability that a
targeting vector would integrate into the homologous site was so low that it was not practical or
rational to screen the number of independent clones necessary to uncover the rare homologous
integrant. Thus, it was obvious that some method to select or at least enrich for the rare
homologous recombinants would be necessary. Although HPRT was the first successfully
targeted gene in ES cells and subsequently in the mouse germline (Doetschman et al., 1987;
Doetschman et al., 1988; Hooper et al., 1987; Kuehn et al., 1987; Thomas and Capecchi, 1987;
Thompson et al., 1989), the method of selecting against HPRT expression in ES cells was not
applicable for selecting for targeted inactivations in genes present in two copies in the ES cell
genome (HPRT is X-linked and most ES lines used are male). In addition, loss of HPRT gene
function could be selected for under specific conditions in ES cells; a condition not generalizable to
most genes.
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In 1988, Mario Capecchi and his colleagues reported a method to selectively enrich for
homologously targeted ES cells clones which has now become standard in the field. This method,
referred to as positive-negative selection (Mansour et al., 1988), is designed to both positively
select for ES cell clones with have integrated the targeting vector anywhere in their genome and
select against clones into which the targeting vector has randomly integrated into the genome. To
do this, the targeting vector is designed to include a neomycin resistance (neo) gene flanked by
sequences homologous to the gene being targeted. When the vector integrates into the
homologous site it provides a method to select for vector insertion (resistance to G418 conferred
by the neo gene) and is usually designed to inactivate the gene of interest. The targeting vector also
contains a copy of the Herpes Simplex Virus thymidine kinase (HSV-tk) gene on at least one end
of the vector (outside the region of homology) (Mansour et al., 1988). Since a majority of non-
homologous recombination events occur via an integration mechanism which results in the
incorporation of the ends of the targeting vector into the genome while homologous events occur
via a mechanism which incorporates only the regions flanked by homologous sequences, selection
against the presence of the HSV-tk gene will enrich for the presence of homologous recombinants.
This selection is done by adding the nucleoside analog gancyclovir to the culture media. Since
HSV-tk is more permissive in its substrate requirements than the endogenous tk gene, it (but not
the endogenous tk) will phosphorylate gancyclovir which allows it to be incorporated into the
DNA of the cell eventually compromising the cell's viability (Mansour et al., 1988).
Creation of mouse strains with mutations in tumor suppressor genes
Thus, by the end of the 1980s techniques for the introduction of inactivating mutations into the
mouse germline had been developed to a point where their use was practical. Since tumor
suppressor gene mutations associated with disease were almost always loss of function mutations
(Knudson, 1993) and since the gene targeting technology at the time allowed the relatively easy
production of mouse strains with inactivating mutations, they were logical targets for such
experiments. Besides the construction of strains carrying targeted mutations in Rb and p53 (both
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of which will be discussed in detail below), reports of murine strains in almost all other tumor
suppressor genes have been reported. A summary of the effects of these mutations on murine
tumorigenesis and development is shown in Table 1-2. While some of these strains develop
similar diseases to their human counterparts (Apc and p53) (see Tables 1-1 and 2-1), most of them
display phenotypes that are quite different. For example, the most extreme example is illustrated
by the differences between mice and humans heterozygous for an inactivating mutation in the
Wilms tumor gene (Haber and Housman, 1992; Hastie, 1994; Kreidberg et al., 1993). While
children who inherit a mutation in the gene are develop Wilms tumor with extremely high
penetrance, mice heterozygous for a targeted inactivated mutation do not show any tumor
predisposition. More detailed analysis of the differences in targeted gene disruption phenotypes
between humans and mice will be needed to further increase the utility of the mice for modeling
human disease syndrome and perhaps will shed insights into the molecular functions of these
proteins themselves.
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Table 2-1. Effects of mutating murine homologs of human tumor suppressor genes
Gene Murine Heterozygote
Phenotype
Rb Pituitary and
Thyroid tumors
p53 Sarcomas,
Lymphomas,
several others
Wt-1 No phenotype
Apc Multiple colon
polyps (depending on
allele)
Nf- Pheochromocytoma
Myeloid leukemia
Nf-2 Sarcomas
pl6MTSI Sarcomas and
lymphomas
Murine Homozygous
Mutant Phenotype
Embryonic lethality
(e13.5-15.5)
Defects in erythropoiesis
and neurogenesis
~10% embryonic
lethality with
exencephaly; Viable
animals develop
lymphomas, sarcomas,
and other tumors
Embryonic lethality
(e13.5), Defects in
pericardial and urogenital
development
Early embryonic lethality
(e6.5) depending on allele
Embryonic lethality
(e13.5), Defects in heart
development
Early embryonic lethality
(e8.0)
Sarcomas and
lymphomas
References
This work and (Clarke et al.,
1992; Harrison et al., 1995;
Hu et al., 1994; Jacks et al.,
1992; Lee et al., 1992; Lee et
al., 1994)
Appendix A and
(Armstrong et al., 1995;
Donehower et al., 1992;
Harvey et al., 1993; Jacks et
al., 1994a; Purdie et al.,
1994; Tsukada et al., 1994)
(Kreidberg et al., 1993)
(Dove et al., 1994; Fodde et
al., 1994; Moser et al.,
1990)
(Brannan et al., 1994; Jacks
et al., 1994b)
(McClatchey et al., 1996)
(Serrano et al., 1996)
DCC ??
VHL ??
BRCA1 No phenotype Embryonic lethality
(e 11.5); neuroepithelial
defects
(Gowen et al., 1996)
BRCA2 ??
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References or reviews that describe the functions of these genes and their association with human
cancer can be in Table 1-1.
Initial analysis of mice carrying an inactivating mutation in the Rb gene
In 1992, several groups reported the use of these techniques to create a mouse with an inactivating
mutation of the retinoblastoma susceptibility gene (Clarke et al., 1992; Jacks et al., 1992; Lee et al.,
1992). The mice used for the experiments described in this thesis were made by Tyler Jacks when
he was a post-doctoral fellow in the laboratory of Robert Weinberg (Jacks et al., 1992). This strain
and the other two reported strains exhibited very similar phenotypes. Animals constitutionally
heterozygous for an Rb mutation do not develop retinoblastoma, instead they develop tumors of
the intermediate lobe of the pituitary (Harrison et al., 1995; Hu et al., 1994; Jacks et al., 1992).
These growth of the pituitary tumors eventually resulted in the death of the mice between 10 and
18 months of age. It was subsequently shown that they are also susceptible to the development of
medullary thyroid carcinoma (see Chapter 4). In both of these tumor types, the remaining wild-
type allele of Rb is absent from the tumor DNA in almost all cases examined. Mice homozygous
for the inactivating mutation in Rb are not born, instead they die between days 13.5 and 14.5 of
mouse gestation (which is around 20 days). Just prior to the time of death the animals appear
severely anemic in that they are noticeable paler than control littermates and display significant
amounts of edema. By gross examination the liver also appears smaller. Histological examination
of the embryos reveal that the liver is indeed smaller and hypocellular. Examination of tissue
sections stained with hematoxylin and eosin shows that some aspect of central and nervous system
development is also defective since these tissues contain areas of hypocellularity associated with
ectopically placed mitotically active cells and small, dark staining pyknotic cells. The presence of
pyknotic cells is diagnostic of apoptotic cell death (discussed in more detail below). These patterns
of defects are consistent with the previous analysis of Rb expression. While Northern blot
analysis showed that the gene was expressed at least at low levels in all tissues examined, the
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highest levels of expression are seen in the fetal brain and liver at about 12.5 days of gestation
(Bernards et al., 1989).
Fetal liver hematopoiesis is defective in Rb-deficient embryos
Murine hematopoiesis is characterized by the presence of several distinct stages. The initial
production of red blood cells begins around day 6 or 7 of development within the blood islands of
the yolk sac (Dzierzak and Medvinsky, 1995; Moore and Metcalf, 1970). At around day 8.5,
blood cells derived from these islands begin to enter the primitive embryonic circulatory system
(Dzierzak and Medvinsky, 1995; Moore and Metcalf, 1970). These yolk sac-derived erythrocytes
are nucleated and form the majority of cells in the circulatory system until day around day 11
(Dzierzak and Medvinsky, 1995; Moore and Metcalf, 1970). At this time the next site of
hematopoiesis, the fetal liver, begins to contribute erythrocytes to the circulatory system (Moore
and Metcalf, 1970; Tavassoli and Yoffey, 1983). Fetal liver derived erythrocytes are enucleated
and much smaller in size relative to yolk sac derived erythrocytes. The fetal liver remains the
dominant hematopoietic organ until later in development when the sites of hematopoiesis shift to
the bone marrow and spleen (Tavassoli and Yoffey, 1983).
Rb-deficient embryos appear normal up to 12.5 days of development indicating that yolk sac
hematopoiesis is occurring efficiently enough to support viability. However, it should be noted
that Clarke et al. did note a minor defect in yolk sac lineage of Rb-deficient embryos (Clarke et al.,
1992). The appearance of pale, edemic embryos later in gestation coincident with the time that
fetal liver hematopoiesis becomes predominant led all three groups to undertake a detailed
examination of the circulation and fetal liver (Clarke et al., 1992; Jacks et al., 1992; Lee et al.,
1992). Analysis of peripheral blood from these embryos revealed the persistence of yolk sac
derived erythrocytes suggesting that hematopoiesis from the fetal liver was not occurring
efficiently enough to make the switch from nucleated (yolk sac-derived) to enucleated (fetal liver-
derived) erythrocytes in the circulation.
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As previously described, livers from control littermates at 13.5 days were densely packed with
cells while livers from mutant embryos were smaller and obviously hypocellular. The underlying
cause of the defect was not clear. In an attempt to better define the defect, Jacks et al. tested the
ability of liver cells derived from 12.5 day Rb-deficient embryos to differentiate in vitro (Jacks et
al., 1992). The plating of these cells in conditions favoring erythroid differentiation suggested that
the Rb-deficient livers differed from wild-type livers in this assay. Hemoglobinized colonies
derived from Rb-deficient liver cells appeared pale in color relative to controls. In addition, an
examination of the cells within these colonies revealed that unlike colonies derived from wild-type
cells, colonies derived from Rb-deficient cells did not produce mature, enucleated erythrocytes
with high efficiency. These results were interpreted at the time to indicate that Rb-deficient
erythroid precursors were intrinsically defective in their ability to reach terminal, end-stage
differentiation (Jacks et al., 1992). Subsequent work in our laboratory suggests that this is not the
case. Firstly, analysis of chimeras derived from Rb-deficient ES cells reveals that Rb-deficient
cells can indeed differentiate into mature red blood cells which appear normal (data presented in
Chapter 5). In addition, the ability of cells from Rb-deficient fetal livers to rescue lethally-
irradiated adult mice from death (at least in the short term) also shows that Rb-deficient cells are
capable of differentiating into mature and functional red blood cells (K. Macleod and T. Jacks,
unpublished). The apparent inconsistency of these results with the previously published in vitro
differentiation results could be explained by a defect in the hematopoietic microenvironment of Rb-
deficient fetal livers. Such a model would suggest that the Rb-deficient cells used in the in vitro
experiment were not intrinsically defective; instead they were defective at the time they were
removed from the embryo because they did not receive a necessary environmental signal to allow
them to efficiently differentiate in vitro or in vivo. When these cells are placed in the presence of a
microenvironment which is composed at least partially (see Chapter 5) or fully (in the case of
lethally-irradiated wild-type mice) of wild-type cells such a signal is provided allowing at least
some level of normal differentiation.
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Rb-deficient embryos displav defects in neurogenesis
The initial analysis of Rb-deficient embryos also revealed the presence of defects in the developing
nervous system. One possible explanation for the presence of these defects was that they were
secondary to the anemia (and subsequent hypoxia) caused by the defect in fetal liver
erythropoiesis. The fact that neurological defects could be noted as early as 12.5 days of
development, prior to the time in which the fetal liver deficit significantly compromises viability
suggested that this was not the case (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992).
Further analysis by Lee et al. confirmed this (Lee et al., 1994). They showed the underlying cause
of the neural defect was the inappropriate proliferation of Rb-deficient neurons which should have
been permanently withdrawn from the cell cycle. During normal cell differentiation in the central
nervous system, cell division is restricted to an area adjacent to the ventricular spaces (the
ventricular zone). When the cells begin to terminally differentiate they withdraw from the cell
cycle and migrate away from the ventricular zone into zones in which further differentiation takes
place (intermediate zone). Rb-deficient embryos are characterized by the presence of large
numbers of mitotically active cells (measured by incorporation of the nucleotide analog BrdU) in
the intermediate zone. Furthermore, the hypocellularity in the zones of the central nervous system
distal to the ventricular zone can be explained by the fact that the ectopically proliferating cells are
eliminated from the organism by the process of programmed cell death or apoptosis. The
association of Rb-deficiency with apoptotic induction will be a central concept of the work
presented so a brief discussion of the process is included.
Apoptosis
While molecular mechanisms underlying cell proliferation and differentiation have long been the
focus of detailed study in biological research, the concept that cells have intrinsic mechanisms with
which they can induce their own destruction (programmed cell death) has only recently been fully
appreciated. The process of programmed cell death (apoptosis) is clearly different from cell death
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induced by severe physical trauma (necrosis) (Kerr et al., 1972). In fact, during normal
development large numbers of cells are eliminated by this process. The very term apoptosis
(derived from the ancient Greek words used to refer to the falling of leaves from trees) was coined
to emphasize the normal physiological nature of the process (Kerr et al., 1972). The steps
associated with apoptosis were initially analyzed via electron microscopy and are well described
(Kerr et al., 1972). The earliest event in the process has been described as the condensation of
nuclear chromatin into condensed masses. Chromatin condensation is also associated with
cytoplasmic contraction. Plasma membrane integrity is not compromised; however, protrusions
off the surface of the cell (blebs) become apparent. These blebs eventually enclose organelles and
other components of the cellular cytoplasm which facilitates their phagocytosis by adjacent cells.
In the later stages of the process, nuclear disintegration occurs resulting in characteristic
nucleosomal ladders which can be detected via agarose gel electrophoresis. Another common
method for the detection of apoptosis is based on the fact that cells undergoing the process
fragment their DNA. By utilizing an enzyme (DNA terminal transferase) which can incorporate
labeled (usually biotinylated) DNA onto the ends of DNA fragments followed by subsequent
staining for the incorporation of biotin, cells undergoing the terminal stages of the process can be
identified. The basic concept outlined above is the basis for the TdT-mediated dUTP-biotin nick-
end labeling (TUNEL) assay (Gavrieli et al., 1992).
As previously mentioned, the physiological importance of apoptosis has only recently been
appreciated. Much of the information that has established its importance originated from work
performed on the nematode worm, Caenorhabditis elegans (C. elegans). Over 20 years ago, all
the cellular divisions and lineage relationships in the development of C. elegans were cataloged
(Sulston and Horvitz, 1976). This painstaking process revealed that a significant number of cells
were eliminated during C. elegans development (reviewed in Ellis et al., 1991; Hengartner and
Horvitz, 1994b; Horvitz et al., 1994). Subsequent mutagenesis of the organism produced mutants
in which these cell deaths no longer occurred as well as mutants in which extensive cell death
occurred. The genes mutated in these screens have been identified in recent years and have been
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found to have well conserved homologues in mammalian systems (Ellis et al., 1991; Hengartner
and Horvitz, 1994b; Horvitz et al., 1994). The incredible conservation of genes regulating the
death inducing pathways emphasized the physiological importance of apoptosis. The
demonstration that overexpression of Bcl-2, the human homolog of the C. elegans death inhibitory
gene ced-9 (Hengartner and Horvitz, 1994a; Vaux et al., 1992), via chromosomal translocation
was a relatively common event in B cell lymphomagenesis (reviewed in Reed, 1994) lead to the
realization that interference with these important pathways could lead to tumorigenesis. The role of
the p53 gene in the induction of this process will be described in detail in the following chapter.
Rb-deficiency leads to apoptosis in a variety of contexts
The induction of apoptosis in inappropriately proliferating Rb-deficient neurons was described
above. In addition, the defect in fetal liver hematopoiesis in Rb-deficient embryos is also
associated with apoptosis. Fetal livers from 13.5 to 14.5 day Rb-deficient embryos are
characterized by the presence of large numbers of apoptotic cells as judged by both the presence of
pyknotic nuclei and TUNEL-positive cells (K. Macleod and T. Jacks, unpublished). The relevant
effected cell type(s) still await identification and characterization. Many other situations where Rb-
deficiency or inhibition of Rb function have been associated with the induction of p53 so the
discussion of those will be reserved until the following chapter.
Overall goals of this work
The overall goal of this work is to expand the utility of Rb-deficient mice to gain a greater
understanding of Rb function. It is hoped that this will facilitate the development of more effective
strategies for the prevention and/or treatment of a large number of human cancers. Within this
broad context two major lines of investigation have been pursued in depth. The first, and more
central line of investigation deals with trying to understand why mice (and humans) who carry a
defective allele of Rb are not highly susceptible to a wider range of malignancies. This seems to
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run counter to the observation that pRB plays an important cell cycle regulatory role in most cell
types examined. In addition, somatic mutations in RB have been associated with the development
of many tumor types in humans. The body of work presented here addresses this question by
showing that in many tumors mutations in other genes can act in concert with Rb mutations to
induce tumorigenesis. The best example of that is the work presented in Chapter 3 on the
cooperative tumorigenesis seen in mice carrying germline mutations in both Rb and p53.
The second, less central goal of this work, has focused on explaining how Rb-deficient embryos
can progress to such a relatively advanced stage of development. This again seems inconsistent
with the proposed role of pRB as a nearly universal negative regulator of cell cycle progression.
Data presented in Appendix C suggests that the presence of the RB-related genes p107 and p130
may compensate for the loss of Rb and allow development to 13.5 days.
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CHAPTER 3
The p53 tumor suppressor gene
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While this work focuses primarily on the role of the Rb gene in suppressing murine
tumorigenesis, it relies heavily on the use of mice carrying a targeted mutation in the p53 gene.
For this reason, the identification and functions of the p5 3 gene will be reviewed.
In the seven years since it was recognized to be a tumor suppressor gene, p5 3 has been perhaps the
most intensely studied gene in the field of oncology. The fact that mutations in p53 have been
estimated to occur in over 50% of all human cancers (Greenblatt et al., 1994; Hollstein et al., 1991)
emphasizes the importance of learning more about its functions.
Identification of the 1p53 protein and gene
In 1979, two groups reported that a 53 kD protein (p53) associated with large T antigen in cells
infected with the SV40 polyomavirus (Lane and Crawford, 1979; Linzer and Levine, 1979). Since
the protein appeared to share no antigenic determinants with large T antigen and could be detected
in cells not infected with SV40 it was thought to be the product of a cellular rather than a viral
gene.
The gene encoding p53 was cloned in the early 1980s by several groups independently (reviewed
in Levine, 1992). Subsequent analysis showed the gene was located on human chromosome
17pl3.1 where it spanned 20 kB, while in mouse it is found on chromosome 11. Eleven exons
are present in both humans and mouse, the first of which is untranslated. The gene is extremely
well conserved through vertebrate evolution with five regions of the protein showing extensive
(90-100%) homology from Xenopus to human (Levine, 1992; Levine et al., 1991; Soussi et al.,
1987; Soussi et al., 1988) These regions in the corresponding protein product are indicated in
Figure 3-1.
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Figure 3-1. Characteristics of the p53 protein. The amino acid numbers are noted at the top.
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As expected, the amino acid sequence of p53 is also highly conserved. For example, the human
and mouse proteins share 81% homology(Lane and Benchimol, 1990; Levine, 1992; Levine et al.,
1991; Michalovitz et al., 1991; Soussi et al., 1987; Soussi et al., 1988). Analysis of the p53
protein reveals that it has the hallmarks of a transcription factor (see Figure 3-1). The first 75
amino acids of the 393 residue protein can be fused to a heterologous DNA binding domain and
stimulate transcription from a heterologous promoter (Fields and Jang, 1990; Raycroft et al.,
1990). This region also has the characteristic structure of a well described transcriptional activation
domain, the "acidic blob" (Lane and Benchimol, 1990; Levine, 1992; Michalovitz et al., 1991).
Most of the central region of the protein is required for sequence specific DNA binding. The
protein has been shown to recognize a consensus nucleotide sequence of TGTCCT(X)5-8 TGCCT
where X is any nucleotide (Kern et al., 1991). Finally, the C terminus of the protein has been
shown to be involved in non-specific DNA binding and required for oligomerization. As
previously mentioned, alternative splicing in the mouse, but not human, gene can generate a
protein with an altered C terminus (Wu et al., 1993a).
Analysis of mRNA expression suggests that p53 is expressed in all tissues, but with the highest
levels found in the spleen and thymus (Reich and Levine, 1984; Schmid et al., 1991). Based on
this expression pattern, it was expected that deficiency for p53 would have profound effects on
murine development. As discussed below and in Appendix A, this was not the case.
p53 was originally characterized as an oncogene and later as a tumor suppressor gene
Analysis of many transformed cells revealed that p53 levels were elevated relative to normal cells
and that more p53 could be detected in rapidly dividing cells relative to arrested cells(Lane and
Benchimol, 1990; Levine, 1992; Levine et al., 1991; Michalovitz et al., 1991). In addition, it was
found that the clones of p53 available in the early 1980s could immortalize primary rat cells (Lane
and Benchimol, 1990; Levine, 1992; Levine et al., 1991; Michalovitz et al., 1991) Furthermore,
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these clones could also transform these cells in collaboration with oncogenic ras and cause
primary cells to become independent of platelet-derived growth factor for growth (Lane and
Benchimol, 1990; Levine, 1992; Levine et al., 1991; Michalovitz et al., 1991).
In vivo data also supported the classification of p53 as an oncogene. Introduction of these p53
clones enhanced tumor formation and increased the metastatic potential of tumor cell lines when
they were injected into nude mice (Lane and Benchimol, 1990; Levine, 1992; Levine et al., 1991;
Michalovitz et al., 1991).
Some of the first reports which suggested that p53 may not as an oncogene during tumorigenesis
came from studies during the mid 1980s by Benchimol and colleagues who were examining the
induction of erythroleukemia by the Friend virus in mice (reviewed in (Johnson and Benchimol,
1992). This work showed that many leukemia clones did not express p53 and this was often
associated with rearrangements within the p53 gene (Chow et al., 1987; Mowat et al., 1985). In
1989 several reports solidly established that p53 had the characteristics of a tumor suppressor gene
rather than an oncogene. It was reported that many of the experiments showing that p53 could
transform primary cells in cooperation with other oncogenes (primarily activated ras) had been
performed with mutant clones of p53 (Finlay et al., 1989; Hinds et al., 1989; Lane and Benchimol,
1990; Levine, 1992; Levine et al., 1991; Michalovitz et al., 1991). Transformation assays
performed with wild-type versions of the p53 cDNA showed that it could not cooperate with ras to
transform primary cells. The model proposed at the time to explain the earlier results was that
some mutant versions of p53 encoded for proteins possessing dominant negative effects. This
model has subsequently received substantial support. p53 is found normally in a homotetrameric
complex (Kraiss et al., 1992; Kraiss et al., 1988; Milner and Medcalf, 1991) and some mutated
versions of the protein have been shown to alter the activity of the tetramer when cotranslated with
wild-type protein (Milner and Medcalf, 1991). Furthermore, the overexpression of p53 observed
in many cell lines and tumors is related to the fact that many dominant negative alleles actually
increase the stability of the protein. This is presumably due to the fact that such mutations alter the
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structure of the protein so it can no longer be recognized by the cellular machinery which normally
limit it's half-life (Lane and Benchimol, 1990; Levine, 1992; Levine et al., 1991; Michalovitz et al.,
1991).
Also in 1989, a report on the genetic alterations underlying colorectal tumorigenesis showed that
the p53 gene was commonly mutated in adenomatous and malignant colorectal tissues (Baker et
al., 1989). Subsequent examination of a multitude of human tumors has revealed p53 mutations
to be perhaps the most common alteration seen (Greenblatt et al., 1994; Hollstein et al., 1991). For
example, about 75% of colon carcinomas (Baker et al., 1989) and 50% of carcinomas of the breast
(Baker et al., 1989; Davidoff et al., 1991; Prosser et al., 1990; Varley et al., 1991) and lung (Chiba
et al., 1990; Hensel et al., 1991; Iggo et al., 1990; Takahashi et al., 1989) have been shown to
contain p53 mutations. A representative, though not exhaustive list of the cancers in which p53
mutations have been identified includes cancers of the anus (Crook et al., 1991), bladder
(Sidransky et al., 1991), pancreas (Ruggeri et al., 1992), brain (Nigro et al., 1989), esophagus
(Hollstein et al., 1990; Hollstein et al., 1991), stomach (Tamura et al., 1991), liver (Bressac et al.,
1991; Hsu et al., 1991), ovary (Kohler et al., 1993), uterus (Tsuda and Hirohashi, 1992), skin
(Nelson et al., 1994; Ziegler et al., 1994), prostate (Isaacs et al., 1991), and lymphoid system
(Ahura et al., 1989; Gaidano et al., 1991), as well as soft tissue sarcomas and osteosarcomas
(Diller et al., 1990; Miller et al., 1990; Mulligan et al., 1990; Stratton et al., 1990).
Inheritance of a p53 mutation in humans is associated with Li-Fraumeni syndrome
Li-Fraumeni syndrome is characterized by an inherited predisposition to several tumor types
including sarcomas as well as carcinomas of the breast and brain (Li et al., 1988). Families who
carry such a predisposition present a pedigree in which a dominantly inherited gene results in
tumorigenesis at a relatively young age. A molecular analysis of such families revealed that
affected individuals had inherited a defective allele of the p53 gene (Malkin et al., 1990; Srivastava
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et al., 1990). These inherited mutations cause the loss of function in the allele and subsequent loss
of the remaining wild-type allele is associated with the development of tumors.
p53 is targeted by other DNA tumor virus oncoproteins
The realization that SV40 large T antigen associated with both pRB and p53 lead to the
investigation of whether other DNA tumor viral genomes encode proteins capable of associating
with p53. These analyses revealed that certain strains of human papillomavirus encoded a version
of the E6 protein which can be shown to associate with p53 (Werness et al., 1989). Further
analysis has shown that this association leads to a decrease in the stability of p53 by promoting its
degradation through the actions of the ubiquitin-dependent proteolytic system (Scheffner et al.,
1990). Adenovirus also encodes a protein, the ElB 55 kD, which interacts with p53 and inhibits
its function (Sarnow et al., 1982; Yew and Berk, 1992). In addition, the E1B 19 kD protein
affects p53 by an indirect mechanism (Debbas and White, 1993).
Cellular functions of D53
Shortly after p53 was identified as a tumor suppressor gene, several groups demonstrated that not
only did wild-type p53 could actually inhibit transformation. Examples of this include studies
which showed that the wild-type p53 gene could suppress transformation induced by the
cooperative activities of mutant p53 alleles and other oncogenes (like activated ras) (Lane and
Benchimol, 1990; Levine, 1992; Levine et al., 1991; Michalovitz et al., 1991). A great deal of
subsequent analysis has suggested that p53 may regulate key aspects of the cellular response to
DNA damage by inducing growth arrest or apoptosis in response to it. Additional data has
indicated that p53 function may play a role in maintaining genomic stability.
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The first report linking p5 3 function to the induction of apoptosis was published in 1991 (Yonish-
Rouach et al., 1991). In this work, a temperature sensitive allele of p53 was shown to rapidly
induce apoptosis at the permissive temperature in the myeloid leukemia cell line Ml. Subsequent
studies reinforced this concept. For example, reintroduction of wild type p53 into colon carcinoma
cell lines also induces apoptosis (Shaw et al., 1992). In addition, work on the DNA tumor virus
oncoproteins which bind to p53 indicate that their function may be to inhibit p53 function in order
to prevent the induction of an apoptotic program in virally infected cells. For example, expression
of E1A in several cell types grown under various conditions results in the induction of p53 -
dependent apoptosis, a process inhibited by coexpression of E1B 55 kD (Debbas and White,
1993; Lowe and Ruley, 1993).
Another significant development in our understanding of p53 function came from the
demonstration that p53 protein levels were substantially increased in fibroblasts which had been
exposed to ionizing radiation (Kastan et al., 1991). Though a similar observation using UV
irradiation was reported in 1984 (Maltzman and Czyzyk, 1984), the rediscovery of it by Kastan et
al. in 1991 was a critical development. This same group went on to show that the induction of p53
protein levels in fibroblasts lead to an arrest of the irradiated cells (Kastan et al., 1992).
The creation of mice carrying targeted inactivating mutations in the p53 gene (described below and
in Appendix A) provided a valuable resource of reagents to further test p53 function. One of the
best examples is work on the role of p53 in apoptotic cell death of T lymphocytes. During
development in the thymus, self-reactive T cells undergo programmed cell death in the thymus
(Robey and Fowlkes, 1994). This process can also be induced in immature thymocytes
(CD4+;CD8+) by a number of treatments including exposure to glucocorticoids (Schwartzman
and Cidlowski, 1994) and ionizing radiation (MacDonald and Lees, 1990). In immature
thymocytes derived from p53-deficient animals apoptotic induction induced by ionizing radiation
but not by glucocorticoid treatment is abrogated, while in wild-type thymocytes this apoptotic
induction by ionizing radiation is associated with a rapid increase in the accumulation of the p5 3
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protein (Clarke et al., 1993; Lowe et al., 1993). This work not only served to more closely link
p53 function with the induction of apoptosis but together with the work of Kastan illustrated that
the induction of p53 could result in different effects depending on the cell type.
Studies ofp53-deficient embryonic fibroblasts derived from the knockout mice also played a key
role in our understanding of p53 gene function. Introduction of EIA into these fibroblasts leads to
the induction of p53-dependent apoptosis following growth in low serum, treatment with ionizing
radiation, or exposure to chemotherapeutic drugs such as adriamycin, etoposide, and 5-fluorouracil
(Lowe et al., 1993). Furthermore, the p53 genotype of tumors derived from murine embryonic
fibroblasts transformed with EJA and oncogenic ras highly correlates with the induction of an
apoptotic program after treatment of the tumors with ionizing radiation or certain chemotherapeutic
drugs (Lowe et al., 1994). Other examples which implicate the induction of an apoptotic program
with the tumor suppressive function of p53 are described in this work and in the discussion of
Chapter 4.
While the idea that the role of p53 in the induction of apoptosis could explain many aspects of its
tumor suppressive functions is generally accepted, another model for the role of p53 in tumor
suppression also has solid experimental support. Importantly, the absence of p53 has been
correlated with genomic instability in established cell lines and in murine embryonic fibroblasts
(MEFs) derived from p53-deficient mice or fibroblasts derived from Li-Fraumeni patients
(Livingstone et al., 1992; Yin et al., 1992). In addition, p53-deficient MEFs have recently been
recently reported to display abnormal centrosome amplification (Fukasawa et al., 1996). This
abnormality significantly effects mitotic fidelity and is consistent with an important role for p53 in
maintaining genomic integrity.
Experiments in animal models have also supported a role for p53 in maintaining genomic
integrity. Transgenic mice in which expression of the Wnt-1 oncogene is directed to the mammary
by the influence of the mouse mammary tumor virus LTRs develop tumors in the mammary
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(Tsukamoto et al., 1988). When these mice were intercrossed with p53-deficient mice, analysis of
Wnt-1 induced mammary tumors in p53-deficient versus wild-type mice revealed that p53-
deficient tumors exhibited less fibrotic tissue and occurred with a reduced latency (Donehower et
al., 1995). More importantly, analysis of DNA derived from these tumors by comparative
genomic hybridization indicated that p53-deficient tumors contained significantly increased levels
of chromosomal abnormalities relative to wild-type tumors (Donehower et al., 1995).
Creation of mouse strains with a targeted disruption in .53
As described above, reagents derived from p53-deficient mice have proven to be valuable reagents
for the study of p53 function. Analysis of the mice themselves has also provided valuable
information about the physiological roles of p53. In 1992 Donehower et al. reported the surprising
observation that mice deficient for p53 were developmentally normal but susceptible to the
development of several tumor types (predominantly thymic lymphomas and sarcomas during the
first six months of life (Donehower et al., 1992). Subsequently three other groups (including our
laboratory in work described in Appendix A) reported similar results (Donehower et al., 1992;
Jacks et al., 1994; Purdie et al., 1994; Tsukada et al., 1994). It should be noted that further work
performed by our laboratory (Appendix A) and confirmed by others has shown that a small but
significant percentage ofp53-deficient embryos develop and succumb to exencephaly (Armstrong
et al., 1995; Sah et al., 1995). This suggests that p53 may play a role in normal embryonic
development. Even better evidence for a developmental role comes from studies of mice which
contain a targeted disruption in the p53 target gene Mdm2 (described below).
The molecular mechanisms of p53 function
Several lines of evidence suggest that the role of p53 as a species specific transcription factor
underlies its tumor suppressive capacities. Reported transcriptional targets for p53 include the
genes encoding for the cyclin dependent kinase inhibitor p21 (El-Deiry et al., 1993), mdm2 (Barak
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et al., 1993; Perry et al., 1993; Wu et al., 1993b), gadd45 (Kastan et al., 1992), cyclin G (Okamoto
and Beach, 1994), bax (Miyashita and Reed, 1995), IGF-binding protein (Buckbinder et al., 1995),
and muscle creatine kinase (Weintraub et al., 1991). The implications of p21 and mdm2 induction
is discussed below. The potential p53-dependent induction of bax, a cell death promoter via its
inhibitory actions on bcl-2 (Oltvai et al., 1993) , and Gadd45 (Kastan et al., 1992) also have
important implications for p53 function. Additional evidence which suggests that p53 acts as a
transcription factor to suppress tumorigenesis include the fact that many of the mutations seen in
human tumors abrogate the specific DNA binding ability of p53 (Ko and Prives, 1996).
Recently the question of whether the transcriptional activity of p53 is necessary for its tumor
suppressing functions has been the subject of great debate. Three studies reported recently have
suggested that transcriptional transactivation by p53 is not necessary for p53-dependent apoptosis
to occur. Two of these studies rely on the use of transcriptional and translational inhibitors and
show that p53 retains the ability to induce apoptosis in their presence (Caelles et al., 1994; Wagner
et al., 1994). The third study reports that p53 mutants which have lost the ability to
transcriptionally transactivate retain the ability to induce apoptosis (Haupt et al., 1995). Another set
of studies suggest that p53 transcriptional transactivation is required for apoptotic induction. One
study shows that a p53 clone carrying two point mutations in the transactivation domain which
renders it unable to stimulate transcription is also defective in inducing apoptosis (Sabbatini et al.,
1995). In another study microinjection of different p53 mutants into p53-deficient cells has shown
a strong correlation between the presence of a functional transactivation domain and the ability to
induce apoptosis (Attardi et al., 1996). Sorting out these conflicting reports will be of great
importance in the future.
As discussed in Chapter 2, p2 1 (also referred to as WAF1, SDI1, and CIP1) has been shown to
inhibit the kinase activities of most cyclin dependent kinases. Despite the suggestion that p21 is a
major downstream target of p53, only in human prostate tumors have p21 mutations been detected
(Gao et al., 1995). Furthermore, p21-deficient mice appear normal and no tumor predisposition
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has been noted to date (Brugarolas et al., 1995; Deng et al., 1995). Interestingly, MEFs derived
from p21-deficient embryos show a partial defect (relative to p53-deficient MEFs) in inducing G1
arrest in response to ionizing radiation (Brugarolas et al., 1995; Deng et al., 1995). This suggests
that p21 may be an important effector of p53 function, but that other p53 targets or activities are
important in p53 responses (see model in Figure 3-2).
85
igurae 3-2. p53 pathway
mdm2
bcl-2
r mdm2
b ax
Irradiation or
other signal p53
-pax
F other ta rget s
Qp21)
Key
Positive regulation
Negative regulation
Promoter
86
ftk-
Jp2 1
B----a
I
The mdm2 gene is transcriptionally transactivated by p53 and the resulting protein product has
been shown to associate with and potentially inactivate p53 function. This has lead to the model
that mdm2 is a major component of a negative feedback loop which serves to inactivate p53
function (Figure 3-2). This model has received extremely solid experimental support from
experiments in knockout mice. Deficiency for Mdm2 results in early embryonic lethality(Jones et
al., 1995; Montes de Oca Luna et al., 1995). When mice deficient for both Mdm2 and p53 are
created they complete development and are normal fertile adults save for the fact that they develop
the same tumor spectrum seen in p53-deficient mice (Jones et al., 1995; Montes de Oca Luna et
al., 1995). This suggests that p53 overactivity is not compatible with development and that the
only role of mdm2 may be to act in a p53 negative feedback loop.
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CHAPTER 4
Cooperative Tumorigenesis Between Rb And p53 Mutations
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One explanation for the lack of widespread tumorigenesis in the Rb heterozygotes was that while
heterozygosity followed by subsequent loss of the wild type allele might predispose many tissues
to tumorigenesis, loss of only Rb function was insufficient for tumor induction in most tissues.
That is, other genetic events may have to occur in combination with Rb-deficiency in order to
observe tumor development in some tissues. This is is consistent with observations that the
development of most tumors is the result of multiple genetic changes ("multi-hit" carcinogenesis)
(Vogelstein and Kinzler, 1993; Weinberg, 1989). One obvious candidate for a genetic event that
could cooperate with RB mutation to induce tumorigenesis was the inactivation of the p53 tumor
suppressor gene.
The rationale for expecting loss of Rb and p53 function to cooperate in tumorigenesis came from
several sources. The first line of evidence is based on the fact that many human tumors have been
shown to be associated with mutations in both RB and p53. These tumor types include sarcomas
and carcinomas of the lung, breast, cervix, and pancreas (see below). Perhaps the best example of
the concomitant loss of function being implicated in tumorigenesis comes from analysis of
cervical carcinoma tumor cell lines (Scheffner et al., 1991). Human papillomaviruses can be
detected in approximately 85% of human cervical cancers. The expression of the HPV proteins
E6 and E7 has been shown to result in the functional inactivation of p53 and pRB respectively.
Thus, no selection for mutations in either RB or p5 3 should occur during the process of
tumorigenesis if HPV is present. Indeed, all five HPV positive cervical carcinoma cell lines
(HeLa, C4-II, SiHa, CaSki, and Me 180) examined had wild type RB and p53. In contrast, both
HPV negative cell lines examined (C33-A and HT-3) contained mutated p53 and RB genes.
The second line of evidence to suggest that mutations in both RB and p53 could act synergistically
in tumorigenesis was inferred from the studies on DNA tumor viruses (papillomavirus,
adenovirus, and polyomavirus) described in detail in the previous chapters. In all three cases the
activities of the oncoprotein(s) which bind to pRB and p53 are necessary for efficient viral
replication.
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Finally, several in vitro experiments support this idea. For example, several studies have shown
that overexpression of the E2F-1 protein can result in p53-dependent apoptosis (Melillo et al.,
1994; Qin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994). This overexpression of E2F-1
is presumably equivalent to the loss of RB function since this would also lead to excess free E2F-1
associated complexes. In addition, introduction of the E1A gene into certain cell types can induce
p53-dependent apoptosis under certain conditions (Debbas and White, 1993; Lowe et al., 1994b;
Lowe and Ruley, 1993).
After the initial analysis of the Rb and p53 mutant mouse strains was completed, the possibility
that mutations in Rb and p53 could cooperate in tumorigenesis was tested by intercrossing the
strains of mice to generate animals carrying mutations in both genes. The generation of these mice
revealed that such cooperative tumorigenesis did exist and the report follows
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The tumour suppressor genes Rb and p53 are mutated in several types of human
cancer, and many tumour types carry mutations in both genes. To study how these
genes normally function, we and others have created mouse strains with Rb and p53
mutations. Here we describe the phenotypic effects of combined germline mutations in
these two tumour suppressor genes. Mice mutant for both genes have reduced viability
and exhibit novel pathology including pinealoblastomas, islet cell tumours, bronchial
epithelial hyperplasia and retinal dysplasia. These data indicate that mutations in Rb and
p53 can cooperate in the transformation of certain cell types in the mouse.
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Tumour suppressor gene mutations occur frequently in
the development of human cancer'. The retinoblastoma
susceptibility gene (RB) and p53 are two of the best
studied ofthese genes. In humans, inheritance ofa defective
allele of RB strongly predisposes to retinoblastoma2-2, a
childhood tumour of the eye. The gene is also subject to
somatic mutation during the development of
osteosarcomas, soft tissue sarcomas, and carcinomas of
the breast, lung and bladder5 . p53 is mutated at high
frequency in the development of many sporadic human
cancers6 and germline mutations in p53 are associated
with Li-Fraumeni syndrome7 '6 .
Work from a number of systems has suggested that the
coupled inactivation of p53 and pRb may be important
for transformation in some instances. For example, several
DNA tumour viruses, including SV40, adenovirus and
high transformingstrains ofhuman papillomavirus encode
proteins that bind and presumably inactivate both pRB
and p53, and both of these functions are required for
efficient transformation by these viral proteins in vitro
and in vivo(ref. 9 and refs within). Also, several human
tumour types, including certain sarcomas2, ` "'- and
carcinomas of the lung" -'5 , breast' 6-20 , cervix2"'22 and
pancreas23 show a high frequency of mutation of both p53
and RB. While mutations in RB and p53 occur in the
development of many human tumours, the mechanism
by which these genes normally suppress tumorigenesis is
not clear. The RB gene product is thought to act by
negatively regulating the passage of cells through the G 1
phase of the cell cycle 24, while p53 has been implicated in
negative growth regulation"' 25-28, response to DNA
damage2 9,30 and the induction of cell death""'- .
To develop systems to study the activity of Rb and p53,
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we and others have created mouse strains with targeted
disruptions in their murine homologues3'' 0. Germline
mutations in Rb and p53 each predispose mice to
cancer; 3739-". Animals heterozygous for an Rb mutation
develop intermediate lobe pituitary tumours (ref. 37 and
B.O.W., L.R., R.T.B. & T.J., unpublished observations)
within the first 9-15 months of life, and medullary
carcinoma of the thyroid occurs in approximately three
quarters of these animals (B.O.W., L.R., R.T.B. & T.J.,
unpublished observations). Animals homozygous for an
Rb mutation die in utero between 13.5 and 15.5 days with
defects in fetal haematopoiesis and widespread neuronal
cell death " 8 .The tumour incidence in mice heterozygous
for a p53 mutation is approximately 25% at 16 months of
age 40'4, with the most common tumour types being sarcoma
and lymphoma. In both Rb heterozygous and p53
heterozygous mice, tumorigenesis usually involves the
loss of the remaining wild-type allele of Rb or p5337 ,40 ,4 1.
Germline homozygosity for a p53 mutation causes an
even more pronounced cancer susceptibility; 90% ofp53-
deficient animals develop one or more tumours by three
to six months of age"3 '.
Generation of Rb+/-;p53+/- and Rb+/-;p53-/-mice
To investigate possible cooperative effects on
tumorigenesis of germline mutations in Rb and p53, we
mated animals heterozygous for the Rb "' mutation37 with
animals homozygous for the p531 mutation 40 to generate
a series of animals heterozygous for both mutations
(Rb+/-;p53+/-). These mice were subsequently
intercrossed to yield animals heterozygous for the Rb
mutation and homozygous for the p53 mutation
(Rb+/-;p53---). Both sets of double-mutant mice were
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Fig. 1 Survival of mice with mutations
in p53 and Rb. a, Graph summarizing
the viability of 50 Rb+/-;p53+/-
animals relative to 50 Rb+/-;p53+/+
and 100 Rb+/+;p53+/- animals. The
mean age of survival (at which 50% of
the animals had died) was 267 days
for Rb+/-;p53+/- mice and 325 days
for Rb+/-;p53+/+ mice. At 489 days,
75% of Rb+/+;p53+/- mice were still
alive. b, Graph summarizing the
viability of 33 Rb +/-;p53 -/- animals
relative to 50 Rb+/+; p53 -/- animals.
The mean age of survival was 115
days for Rb+/-;p53-/- and 142 days
for Rb+/+;p53-/-mice.
carefully monitored and animals exhibiting ill health were
killed and subjected to complete necropsy.
Analysis of Rb+l-;p53+/- mice
The mean age of survival of the Rb+/-;p53+/- animals
was slightly reduced compared to animals heterozygous
for the Rb mutation alone (9 months versus 11 months)
(see Fig. la). However, the tumour spectrum in these
animals was largely the same as that observed in the Rb
heterozygotes. Each of67 Rb+-;p53+/-animals developed
intermediate lobe pituitary tumours and approximately
75% of these mice were also found to have medullary
thyroid tumours (Table 1). Additional tumours were
detected in seven Rb+/-;p53+/- animals: one
leiomyosarcoma, three anaplastic sarcomas, two islet cell
carcinomas, and one pinealoblastoma. The development
of sarcomas was not particularly surprising, as animals
heterozygous for p53 alone are susceptible to this tumour
type40,41, but the three anaplastic sarcomas in the double
Table 1 Incidence of pathological lesions in mice with different
combinations of Rb and p53 mutations
Tumour/lesion Rb+/-  p53' /-  p53-/- Rb'-; p53 +- Rb'; p53-1-
Pituitary 100% (204) 0% (44) 0% (56) 100% (67) 94% (16)
Thyroid 70% (27) 0% (3) 0% (8) 83% (12) 60% (15)
Lymphoma 0% (204) 25% (44) 71% (56) 0% (67) 39% (42)
Sarcoma 0% (204) 57% (44) 21% (56) 6% (67) 43% (37)
Islet cell 0% (21) 0% (8) 0%(9) 14% (14) 23% (30)
Pineal 0% (204) 0% (44) 0% (56) 1%(67) 40% (42)
Bronchial 4% (25) 0% (14) 0% (9) 8% (12) 38% (26)
hyperplasia
Retinal 0% (>20) 0% (8) 7% (14) 0% (2) 41% (17)
dysplasia
For each type of lesion the incidence is noted, by percentage, with the number of
individual animals analysed for that lesion in parentheses. The presence of some
tumour types (pituitary, thymic lymphoma, pinealoblastoma and sarcomas) could be
assessed by gross necropsy while other lesions (thyroid, islet cell, and bronchial
hyperplasia) were detected following histological examination. When a lesion was
observed upon necropsy, a piece of tumour tissue was removed for analysis by
Southern blotting. Retinal dysplasia was initially diagnosed by ophthalmoscopic
examination and subsequently confirmed histologically. Pathological lesions found
only in animals with mutations in both Rb and p53 are emphasized by boldface. In
addition to the novel tumour types shown, a urethral gland carcinoma (a tumour type
not observed in p53-/- animals) was also observed in one Rb+/-; p53-/- animal.
Although thymic lymphoma and several different types of sarcomas are the
predominant tumours found in p53-/- and p53+1- animals, other tumours occur at a
lower frequency which have not been included here. Refer to ref. 39-41 for a more
complete list of the tumour spectrum of these animals.
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heterozygotes were more aggressive and arose at an earlier
age than those occurring in the single-mutant animals.
Tumours of the islet cells of the pancreas or the pineal
gland have not been detected in animals with individual
mutations in Rb or p53 (Table 1).
We next used Southern blotting to examine the state
of the wild-type alleles of Rb and p53 in tumours from
Rb+/-;p53+/- animals. Previously, we have shown that
loss of the wild-type allele of Rb occurs during the
development of nearly all pituitaryand thyroid tumours
in Rb heterozygotes (ref. 37 and B.O.W., L.R. & T.J.,
unpublished data), and this was also true in the double
heterozygotes. Absence of the DNA fragment associated
with the wild-type Rballele was observed in 17/18 pituitary
tumours and 6/6 thyroid tumours isolated from these
animals (Fig. 2 and data not shown). p53 mutation
occurred rarely in these tumour types, however, as just
one of 15 pituitary tumours and one of six thyroid tumours
had lost the wild-type allele of p53 (Fig. 2 and data not
shown). Given that the majority of the Rb+/-;p53+/-
animals developed tumours in which the wild-type allele
of p53 was maintained, we can not readily explain their
reduced viability compared to the Rb heterozygotes (Fig.
I a). In contrast, in each of the six more distinctive tumours
that arose in this population of animals (three anaplastic
sarcomas, two islet cell tumours and one pinealoblastoma),
the wild-type alleles of both Rb and p53 were absent (Fig.
2 and data not shown). Thus, the elimination of function
ofthese two tumour suppressor genes appears to accelerate
tumorigenesis in certain tissues in the mouse.
Analysis of Rb+l-;p53-I- mice
The cooperative effect of germline mutations in Rb
and p53 was more apparent from the phenotype of
Rb+/-;p53-/- animals. The mean age of survival ofanimals
with this genotype was four months (one month less than
that of animals homozygous for the p53 mutation alone),
and none of them lived beyond six months of age (Fig. 1 b).
Moreover, the Rb+/-;p53-/- animals typically developed
numerous distinct tumour foci, with one animal displaying
15 separate lesions affecting eight different tissues. We
assume that the reduced viability in this population of
animals resulted from their increased tumour burden.
As shown in Table 1, Rb+/-;p53-/- animals were
susceptible to those tumour types associated with mutation
of either Rb or p53 as well as the novel tumours that
resulted from the inactivation of both genes noted in the
double heterozygotes. Thus, islet cell tumours and
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Fig. 2 Status of Rb and p53 in tumours of doubly mutant mice. a, Loss of the wild-type allele
of p53 in tumours from Rb+/-:p53+/- mice. The wild-type allele of p53 is absent in the islet
cell tumour of the pancreas (Pa), the anaplastic osteosarcoma (S) and one of the pituitary
adenocarcinomas (Pt) shown. The wild-type allele is retained in the other two pituitary
tumours and in all three thyroid (T) tumours shown. The positions of the wild-type (wt) and
mutant (mut) p53 alleles, as well as the p53 pseudogene (Y) are shown. In total, the wild-
type allele of p53 was absent from 1/15 pituitary adenocarcinomas, 1/6 medullary thyroid
carcinomas, 3/3 anaplastic sarcomas, 2/2 islet cell tumours and 1/1 pinealoblastomas
examined from Rb+/-;p53+/- mice. b, Loss of the wild-type Rb allele in tumours from Rb+/-
;p53+/- mice. Representative DNA samples from pituitary adenocarcinoma (Pt), medullary
thyroid carcinoma (T), anaplastic osteosarcoma (S) and islet cell tumour of the pancreas (Pa)
are shown. In all the tumour types shown the wild-type allele of Rb is absent. The positions
of the wild-type (wt) and mutant (mut) alleles are indicated. In total, loss of the wild-type Rb
allele was noted in 17/18 pituitary adenocarcinomas, 6/6 medullary thyroid carcinomas, 3/3
anaplastic sarcomas, 2/2 islet cell tumours, and 1/1 pinealoblastomas examined from Rb+/-
;p53-I- animals. c, Loss of the wild-type Rb allele in tumours from Rb+/-;p53-/- mice.
Representative DNA samples from pituitary adenocarcinoma (Pt), medullary thyroid
carcinoma (T), fibrosarcoma (S), pinealoblastoma (Pn) and lymphoma (L) are shown. In the
pituitary adenocarcinoma, the fibrosarcoma, one of the three lymphomas and all four of the
pinealoblastomas, the wild-type allele of Rb is absent or greatly reduced. The positions of
the bands corresponding to the wild-type (wt) and mutant (mut) Rb alleles are shown. In
total, loss of the wild-type Rb allele was noted in 3/3 pituitary adenocarcinomas, 1/1
medullary thyroid carcinomas, 7/7 pinealoblastomas, 3/3 islet cell tumours, 3/3
undifferentiated sarcomas and fibrosarcomas, 1/7 thymic lymphomas and 0/4
haemangiosarcomas examined from Rb+/-;p53-/- mice.
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pinealoblastomas were observed in approximately 20%
and 40% of these animals, respectively. In the three islet
cell tumours from which DNA was available and in 7/7
pinealoblastomas, loss of the wild-type allele of Rb
accompanied tumorigenesis (Fig. 2 and data not shown).
We also observed three cases of sarcoma in the Rb+/-
;p53-/- mice in which the wild-type Rb allele was lost. In
contrast, inactivation of Rbwas infrequent in development
of lymphomas in these animals (1/7 tumours examined),
and none of four cases ofhaemangiosarcoma tested showed
loss of the wild-type allele of Rb (Fig. 2 and data not
shown).
Histological analysis revealed more subtle lesions that
were specifically associated with the Rb+/-;p53-/-
genotype. Approximately 40% of these animals were found
to have small foci of basally localized epithelial cells
present in bronchi and bronchioles, possibly pulmonary
endocrine cells. These regions of bronchial hyperplasia
(Fig. 3c,d) are histologically similar to some aspects of the
recently described human condition, idiopathic diffuse
hyperplasia of pulmonary endocrine cells4". A direct
relationship between these lesions and small cell lung
cancer, in which both Rb and p53 are frequently
mutated"-", has not been established. Also, approximately
40% of the Rb+/-;p53-/- mice were found to have
pathological changes in the retina (Table 1). However,
these focal lesions consisted of areas of retinal dysplasia
(or abnormal architecture) as opposed to hyperplasia (see
Fig. 3c). It is not possible to determine whether these
lesions would develop into true retinoblastomas, since
the Rb+/-;p53+/- animals succumb to other tumours by
two to six months of age.
Discussion
The data presented here demonstrate that certain tissues
in the mouse are susceptible to transformation upon
inactivation of both the p53 and Rb tumour suppressor
genes. This provides the first example of cooperativity
between two tumour suppressor gene mutations in murine
tumorigenesis. These observations are consistent with
those made previously in other systems. For example,
several DNA tumour viruses encode proteins which bind
to and presumably inactivate both p53 and pRB:
adenovirus EIA and human papillomavirus (HPV) E7
bind pRb, adenovirus E1B and HPV E6 bind p53, while
SV40 large T antigen binds both proteins(reviewed in ref.
9). Also, concomitant mutations of RB and p53 are found
in several human tumour types'6 °-23
We present three models which could account for the
cooperative tumorigenic effects of germline mutations in
both Rb and p53 (Fig. 4). All three models assume that
pRb normally functions as a negative regulator of cell
growth, perhaps by inhibiting the activity of bound
transcription factors 2 , and that Rb mutation directly
contributes to cellular transformation. The different
models address various proposed functions for p53:
negative growth regulation"' 25-28 , response to DNA
damage"9 '3 0 and the induction of cell death31 -3'. In the first
model (Fig. 4a) Rb and p53 negatively regulate cell growth
in a redundant fashion and thus the loss ofboth is necessary
for tumorigenesis in the susceptible tissues. The second
model (Fig. 4b) is based on the proposed role for p53 in
maintaining genomic stability29'30 ' 3-4s. Thus, the absence
of p53 might lead to an increased rate of the loss of the
wild-type allele of Rb in the relevant cell types. Here p53
mutation indirectly affects tumourigenesis by elevating
the overall mutation rate. Our final model (Fig. 4c) derives
from recent observations that p53 is required for the
apoptotic death of cells expressing the adenovirus EIA
oncogene46,47.Like the expression ofE 1 A (which sequesters
pRb (ref. 9) along with other cellular proteins), Rb
mutation might result in a state of abnormal cell cycle
regulation in which cells become prone to p53-dependent
apoptosis. Elimination of p53 function would allow these
cells to escape the apoptotic program and progress through
tumorigenesis. According to this view, tumour suppression
by p53 is a more active process that rids the animal of cells
that have already acquired growth-promoting mutations.
Consistent with the third model (Fig. 4c), in the context of
the developing embryo, absence of Rb function does
result in widespread cell death36-38 . Finally, these models
are not mutually exclusive and p53 mutation could
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Fig. 3 Novel pathology present in Rb +/-; p53 -/- animals.
a, Pinealoblastoma (P) growing in normal brain (N). These
tumours are highly invasive and aggressive. b, Higher
power view of a pinealoblastoma showing very
pleiomorphic and mitotically active cells (arrow). c, Typical
hyperplasia of pulmonary epithelial cells. The proliferative
cells form a polyp (arrow) projecting into the lumen of a
bronchiole. d, Higher power view of bronchial hyperplasia(H). Note the transition of normal bronchial epithelium (E)
into the hyperplastic region (H). e, Islet cell adenoma (I) is
shown with normal exocrine pancreas (E) noted. f, Area of
retina (R) in contact with lens (L). A dysplastic rosette
(delineated by arrows) lined by photoreceptor cells is seen
overlying the intact pigment epithelial layer. Magnifications:
e, 40x; a, c, d and f, 1 00x; b, 400x.
accelerate tumorigenesis via more than one mechanism.
Of particular interest in this study was the absence of
retinoblastoma in mice with germline mutations in both
p53 and Rb. Unlike humans-', mice heterozygous for an
Rb mutation are not predisposed to this tumour type."'
However, retinal expression of the SV40 large T antigen,
which complexes with both pRb and p53 (ref. 9), can
cause retinoblastoma in the mouse' ".'. The fact that the
Rb+/-;p53-/- mice did not develop retinoblastoma may
suggest that still other functions of SV40 large T antigen
(for example, binding to p107 (refs 50, 51)) are required
for retinal transformation. Alternatively, the retinal
dysplasia observed specifically in the doubly mutant
animals might represent a precursor lesion for frank
retinoblastoma; the death of these animals due to the
development of other tumour types would preclude the
further development of these retinal lesions. The fact that
the Rb+/-;p53-/- animals are susceptible to
pinealoblastoma is also interesting in this regard, since
there are histological and physiological similarities between
the pineal gland and the retina"2 . In addition, a small but
significant number of familial retinoblastoma patients
develop pinealoblastoma, a condition known as trilateral
retinoblastoma"--;.
Finally, it is widely held that most human cancers result
from the accumulation of several genetic changes,
including the activating mutations in oncogenes and the
loss of function mutations in tumour suppressor genes"'.
The data reported here clearly support this "multi-hit"
model of carcinogenesis and implicate the mutational
inactivation of p53 and Rb as important events in this
process. The development of additional mouse strains
with germline mutations in other tumour suppressor
genes coupled with the large number of transgenic strains
expressing dominantly acting oncogenes W will allow the
systematic evaluation of various mutant combinations
and a further dissection of multi-hit carcinogenesis in the
whole animal.
Fig. 4 Models for cooperativity between Rb and p53
mutations. Three models are presented which address the
cooperative tumorigenic effect of germline mutations in
both Rb and p53. a, p53 and Rb function redundantly in
negative growth regulation requiring mutational inactivation
of both genes. b, Absence of p53 function increases Rb
mutation rate. c, Loss of the p53-dependent apoptosis
pathway allows Rb-/- cells to survive and proliferate.
These models are described in more detail in the text. Note
that the models are not mutually exclusive, and the
observed cooperative effects could result from more than
one of them.
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Methodology
Genotyping of animals. Animals were genotyped from tail DNA via
PCR using three primer systems previously described for the Rbxs3
(ref. 37) and p531 (ref. 40) mutations.
Southern analysis oftumour DNAs. Tumour samples were surgically
removed and DNA was prepared by standard methods. For
determination of Rb status, tumour DNA was digested with Pstl and
hybridized with a probe derived from the second intron of the Rb
gene (see ref. 37). p53 status was analysed by digesting tumour DNA
with EcoR1 and Stul and hybridizing with a 3' cDNA probe (probe
B in ref. 40). For one islet cell tumour, PCR methods were used to
genotype the tumour DNA (see above).
Histological analysis. Tissues were surgically removed, fixed in 10%
neutral buffered formalin, embedded in paraffin, sectioned at 6 pmn
and stained with haematoxylin and eosin prior to microscopic analysis.
Retinal examination byindirect ophthalmoscopy. Pupillary dilation
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was achieved by topical application of 2.5% phenylephrine HCI and
0.4% tropicamide (1 to 1 dilution with BSS (Massachusetts Eye and
Ear Infirmary Formulary)) to each eye. The pupils were fully dilated
within 5 min. The retina was then examined using a standard,
indirect-ophthalmoscope headpiece in conjuction with 90, 78 or 60
diopter condensing lenses depending on the desired magnification
and field. The mouse was not anaesthetized, but was immobilized by
an assistant to enable the entire retina to be quickly examined. (S.M.,
manuscript in preparation).
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The occurrence of novel tumor types in mice carrying mutations in both Rb and p53 proved that
mutations in other genes was necessary for tumorigenesis associated with Rb-deficiency in many
tissues. It will be of interest to see whether mutation in other genes such as the p53 transcriptional
target gene p21 (see Chapter 3) can cooperate with Rb mutations in a similar manner.
The incidence of islet cell tumors and pinealoblastoma-like tumors has also been observed in mice
expressing SV40 large T antigen specifically in these tissues (reviewed in Van Dyke, 1994). The
fact that expression of large T antigen induced tumorigenesis in many tissues not affected in Rb+/-
;p53-/- mice suggests that other aspects of the multifunctional large T antigen are important in
tumor induction in these tissues (for example the choroid plexus) (reviewed in Van Dyke, 1994).
As stated in the discussion of the above reprint, there were several models which could explain the
mechanism for this synergy in tumorigenesis. All three models assumed that pRb acts as a
transcription factor to inhibit cell proliferation (Hollingsworth et al., 1993: Weinberg, 1995). One
model was that both Rb and p53 simply regulated aspects of negative growth control (Baker et al.,
1990; Diller et al., 1990; Martinez et al., 1991; Mercer et al., 1990; Michalovitz et al., 1990) and
that loss of both was necessary for deregulated growth and proliferation.
A second model for the cooperativity was based on the proposed function of p53 as the guardian
of the genome (Baker et al., 1990; Diller et al., 1990; Lane, 1992; Martinez et al., 1991; Mercer et
al., 1990; Michalovitz et al., 1990). The support for this model of p53 function was outlined in
Chapter 2. In this model, p53 mutation would play a passive role in tumorigenesis by simply
increasing the rate at which the wild-type allele of Rb is lost. Thus, the loss of p53 function would
not be necessary for tumor formation in these tissues. While we have no evidence that can
definitively exclude this model, the fact that none of several hundred Rb heterozygous mice created
in our laboratory have developed the tumor types seen in the strains carrying mutations in both Rb
and p53 argue against this model. If p53 were only acting to increase the rate at which the wild-
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type allele of Rb was lost, a small percentage of Rb+/- mice would be expected to develop these
tumors even when they had two normal genomic copies of p53.
The third model we proposed was that elimination of p53-dependent apoptosis of Rb-deficient
cells in these tissue types was the underlying reason for the need to have mutations in both Rb and
p53. By this model, Rb-deficiency would simply lead to the p53-dependent elimination of Rb-
deficient cells in these tissues. Only by abrogating this apoptotic program could Rb-deficient cells
survive and go on to form tumors. This idea was based in large part on the work of Scott Lowe, a
graduate student working in our laboratory as well as the laboratories of Earl Ruley and David
Housman. Expression of adenovirus ElA in wild-type mouse embryonic fibroblasts (MEFs)
resulted in the induction of apoptosis when the cells were grown in low serum or subjected to
doses of ionizing radiation or certain chemotherapeutic drugs (Lowe et al., 1993). However,
expression of E1A from MEFs derived from p53-deficient embryos did not result in apoptosis
under these same conditions (Lowe et al., 1993). Since one of the major functions ascribed to
E1A is its binding and inactivation of pRB (Whyte et al., 1988), a plausible explanation for the
observations was that loss of Rb function can lead to p53-dependent cell death under certain
conditions. We hypothesized that the cooperative tumorigenesis may be based on a similar
mechanism; the abrogation ofp53-dependent apoptosis in certain Rb-deficient tissues.
Because we had observed lens defects associated with Rb-deficiency (see Chapter 4), we decided
to analyze the events of lens differentiation in Rb-deficient embryos. To facilitate this, we
established a collaborative effort with Sharon Morgenbesser and Ronald DePinho, who had a great
deal of experience working with the lens as a system to study developmental events (Serrano et al.,
1996). Assays to study the coordination of proliferation, cell death, and differentiation were
utilized to examine how Rb-deficiency affected lens differentiation. Analysis of lenses from Rb-
deficient embryos revealed mitotically active lens fiber cells undergoing apoptosis. This cell death
was found to be p53-dependent when embryos deficient for both Rb and p53 were generated.
This work is shown in the following paper.
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p53-dependent apoptosis
produced by Rb-deficiency
in the developing mouse lens
Sharon D. Morgenbesser*, Bart 0. Williarst,
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* Department of Microbiology and Immunology,
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THE retinoblastoma tumour-suppressor gene (RB) has been impli-
cated in negative growth regulation, induction of differentiation,
and inhibition of cellular transformation'. Homozygous inactiva-
tion of the Rb gene in the mouse leads to mid-gestational lethality
with defects in erythropoiesis and neurogenesis 2-4. Here we
describe the effects of the Rb-deficient state on the development
of the ocular lens. The regional compartmentalization of growth,
differentiation and apoptosis in the developing lens provides an
ideal system to examine more closely the relationships of these
processes in vivo. We demonstrate that loss of Rb function is
associated with unchecked proliferation, impaired expression of
differentiation markers, and inappropriate apoptosis in lens fibre
cells. In addition, we show that ectopic apoptosis in Rb-deficient
lenses is dependent on p53, because embryos doubly null for Rb
and p53 show a nearly complete suppression of this effect. This
developmental system provides a framework for understanding the
consequences of the frequent mutation of both RB and p53 in
human cancer.
In an effort to establish a biological system to study Rb func-
tion, we and others have used gene targeting to inactivate Rb in
the mouse 2 4. Mice heterozygous for the Rb '' allele (Rb- -) are
grossly normal but are highly predisposed to the development of
pituitary adenocarcinomas, and inheritance of two mutant Rb
alleles (Rb- -) results in lethality at 13--15 days of gestation3.
: To whom correspondence should be addressed
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To characterize more precisely the role of Rb in the transition
from active proliferation to end-stage differentiation as well as
to investigate the pathological consequences of alterations in this
process, we examined the effects of Rb deficiency on ocular lens
development 5. During normal mouse lens development, follo•w-
ing lens vesicle formation on embryonic day 11.5 (El 1.5), lens
cells positioned on the posterior wall of the vesicle withdraw
from the cell cycle and elongate in an anterior direction into the
vesicle. By E14.5. elongation is complete and results in a lens
consisting of postmitotic differentiated fibre cells that are
covered anteriorlt by a layer of proliferating, immature epithelial
cells (Fig. la). For the purposes of this study, it is important
to note that although lens epithelial cells occasionally undergo
apoptosis, lens fibre cells do not"; (Fig. 4a).
Histological analysis of Rb.... lenses from E12.5 E14.5
revealed a significant increase in the number of nuclei as well as
occasional mitotic figures in the lens fibre cell compartment
(Fig. la, h). That loss of the Rb protein is associated with
inappropriate progression through S-phase in lens fibre cells was
confirmed by the large number of cells positive for 5-bromo-2'-
deoxyuridine (BrdU) throughout the lens fibre cell compartment
in Rb- - embryos (Fig. 2b), but not in wild-type controls (Fig.
2a). Given that withdrawal from the cell cycle appears to be a
requirement for normal differentiation in many cell types, we
examined whether continued proliferation in Rb lens fibre
cells affected their ability to differentiate terminally. Although
loss of Rb appeared to have a minimal impact on the gross
morphological formation of the lens, the highly organized paral-
lel and extended array of normally differentiated lens fibre cells
was altered and replaced by a disordered arrangement in Rb
lenses (Fig. la, b).
As normal lens fibre cell development is dependent upon the
proper temporal and spatial expression of a, P and y-crystallins
and the major intrinsic protein of the lens fibre plasma mem-
brane. MIP26 (refs 8, 9). Immunofluorescence was used to assay
the expression of these stage-specific proteins. Lack of Rb pro-
tein did not appear to affect the regional distribution of a-
crystallin. an early-stage marker, although the level of staining
was mildly reduced in the Rb lenses relative to wild-typecon-
trols (Fig. 3a. b). In contrast, expression of P- and y-crystallins
and MIP26. the late-stage markers8 '0, was markedly
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decreased in the Rb-- - lens (Fig.3. c --h). The more severe reduc-
tion in the levels of late-stage markers relative to that of an
early-stage marker coupled with the formation of an intact lens
structure suggests that the more advanced aspects of differentia-
tion, rather than commitment, are perturbed in the Rb- - mouse
lens.
Previous histological analysis of Rb-deficient embryos
revealed widespread cell death in the peripheral and central
nervous systems2" .Confocal microscopic analysis of propidium-
iodide-stained wild-type and Rb- - lens sections verified the
presence of hallmark features of apoptosis, including nuclear
fragmentation and chromatin condensation along the nuclear
envelope, in many Rb-'- lens fibre cells (data not shown). To
establish further that the mechanism of lens fibre cell death was
apoptosis. rather than necrosis, we assayed for the presence of
excessive DNA 3'-OH ends using the TdT-mediated dUTP-
biotin nick-end labelling (TUNEL) method". As anticipated.
there was a complete absence of TUNEL-stained nuclei inwild-
type lenses (Fig. 4a). In contrast, nuclear staining in many lens
fibre cells of Rb - lenses confirmed the presence of apoptosis
in this compartment (Fig. 4b) and provided thefirst clear evi-
dence that the massive cell death that characterizes the Rb-
deficient phenotype occurs via this programmed mechanism.
Studies in cultured cells have established that p53 is required
for apoptosis associated with deregulated growth' 2 '". However.
it is also clear that apoptosis can proceed via p53-dependent
FIG. 1 Morphological development of lenses in E13.5 wild-type and
mutant embryos. a, Wild-type; b, Rb - ; c, p53 --/ ; and d, Rb /-; p53 -/
eye sections. Lenses are oriented with the anterior surface facing the
upper right corner. Scale bar, 80 pm. Abbreviations: e, anterior epithellal
layer; f, lens fibre cells. The morphology of the Rb- ' lens was indis-
tinguishable from the wild-type (data not shown).
METHODS. Embryos were fixed, sectioned parallel to the optic nerve,
and stained with haematoxylin and eosin as described (S.D.M. et al.,
manuscript submitted). Embryos were genotyped from placental DNAs
by PCR as described for the RBX3' allele3 and the p53'- null allele19.
FIG. 2 Lens cell proliferation in E13.5 wild-type and mutant embryos.
a, Wild-type; b, Rb/ -; c, p53-- '-; and d, Rb-/-; p53 -/ - eye sections.
Orientation and scale bar as in Fig. 1. Arrows indicate representative
peroxidase-stained, BrdU' nuclei. Abbreviations as in Fig. 1, and r,
retina. Nuclear-associated staining was not observed in the lens fibre
cell compartment of Rb' embryos (data not shown).
METHODS. Embryos were exposed to BrdU in utero, fixed in formalin,
embedded in paraffin, sectioned parallel to the optic nerve, and the
sections assayed by indirect immunoperoxidase methods using an anti-
BrdU/DNA antibody (S.D.M. et al., manuscript submitted). In control
experiments, nuclear-associated staining was not detected when the
anti-BrdU antibody was not included in the assay (data not shown).
NATURE - VOL 371 - 1 SEPTEMBER 1994 107
FIG. 3 Cellular differentiation in lenses derived from E14.5 wild-type
and mutant embryos. Wild-type (a, c, e, g) and Rb-deficient (b, d, f, h)
lenses were assayed for expression of a-(a, b), P-(c, d) and y-crystallin
(e, f), and MIP26 (g, h). Orientation and abbreviations as in Fig. 1.
Magnification, x 37. In the normal lens, a-crystallin is first observed at
the lens vesicle stage and continues to be expressed in both epithelial
and fibre cells8, whereas expression of fj- and y-crystallins and MIP26
begins at E12.5 and is restricted to differentiated lens fibre cells8s. 0 .
Expression of the crystallins and MIP26 In Rb' / lenses are indis-
tinguishable from that in wild-type embryos (data not shown).
METHODS. Embryos were fixed, sectioned parallel to the optic nerve,
and coronal sections assayed by indirect iinmunofluorescence with
polyclonal antisera against a-, P- and y-crystallin, and MIP26 (S.D.M.
et al., manuscript submitted). Sections stained with the same antibody
were photographed with equivalent exposure times. The specificity of
these antibodies was confirmed by the absence of staining when the
respective preimmune sera were used (data not shown).
73
!
~-~ '-,
f :3'
a
LETTERS TO NATURE
FIG. 4 Apoptotic cell death in lenses from E13.5 wild-type and mutant
embryos. a, Wild-type; b, Rb / ; c, p53 / ; and d, Rb ' ; p53 " eyes.
Orientation and scale bar as in Fig. 1. Arrows indicate representative
peroxidase-stained, TUNEL- nuclei. The dark rim posterior to the retina
Is the pigmented layer, and is not due to the extension of free 3'-OH
groups by the TUNEL assay. Abbreviations as in Fig. 2. b And d are
representative lens sections of three Rb ' and 3 Rb : p53
embryos, respectively. To estimate the number of apoptotic cells per
lens section in each embryo, peroxidase-stained nuclei were counted
on five sections from the centremost region of the lens and were aver-
aged. Rb / embryos averaged 12.4, 15.75 and 25.6 apoptotic nuclei
per lens section each, whereas Rb / , p53 / embryos averaged 0.6,
1.0 and 1.6. To quantify the reduction in apoptosis in Rb , p53 len-
ses relative to Rb / lenses, the results for all three Rb lenses and
for all three Rb / , p53 / - lenses were then averaged and compared.
For Rb -/ ' and Rb / -, p53-/- lenses, the mean is 17.92_= 5.6 and
1.07+0.41 apoptotic nuclei per lens section, respectively, giving a
reduction of 94%. Nuclear staining was not observed in the lens fibre
cells compartment of Rb ' embryos (data not shown).
METHODS. Embryos were fixed and coronal sections assayed for the
presence of DNA free 3'-OH groups using a modified version of the
TUNEL assay (S.D.M. et al., submitted). In control experiments, nuclear
staining was absent when TdT and biotinylated deoxyuridine were
excluded from the assay (data not shown).
or -independent pathways, even in the same cell type"' "' To
determine whether apoptosis resulting from the lack of Rh in
the lens was dependent on p53, we produced embryos deficient
for both of these genes (Rb- -; p53- - ref. 19) and examined
lens development therein at the most advanced stage possible
(E13.5--E14.0). The percentage of TUNEL-stained nuclei in
Rb- ; p53- - lenses was significantly diminished (by 94%)'
compared to that observed in age-matched Rb - embryos
(Fig. 4b, d), indicating that apoptosis in Rb-deficient lens fibre
cells was p53-dependent. The reduction in apoptosis in double-
mutant embryos did not correlate with any detectable changes
in the rate of lens fibre cell proliferation (Fig. 2d). or in the
degree of impaired morphological (Fig. ld) and molecular
differentiation (data not shown), nor were there any abnormali-
ties in lens development in embryos deficient for p53 only (Figs
I c, 2c and 4c).
Our results establish a role for Rb in the development of the
ocular lens. In particular, lens fibre cells lacking Rb do not
withdraw from the cell cycle before the initiation of end-stage
differentiation. These abnormally proliferating cells fail to
express normal levels of late-stage differentiation markers and
ultimately die by apoptosis. From the analysis of the most
advanced lenses from embryos doubly mutant for Rb and p53.
we can conclude that the death of the Rb-deficient lens fibre cells
is p53-dependent. This result is reminiscent of the requirement
for p53 for apoptosis in cells expressing the adenovirus E IA
oncoprotein 4"S 5, which sequesters member of the pRb family as
well as other cellular proteins- '20,2
We haxe also obserxed abnormal dexelopment and extensixe
apoptosis in lenses of chimaeric mice composed of both Rh-
deficient and x ild-t pe cells. indicating that this process is lens-
cell autonomous-2 . Moreoxer. Ae have shown that forced
expression of a c-mnvc transgene also leads to deregulated lens
fibre cell growth. but. in contrast to the effects noted here. these
cells express normal levels of late-stage differentiation markers
and do not undergo apoptosis (S.D.M. and R.A.D.. manuscript
submitted). Therefore. the pathological consequences of Rh
deficiency max not be accounted for simply by ectopic mitotic
activity.
The consequences of null Rb and p53 mutations on lens cell
growth and death presented here hae important implications
for understanding the mechanism through which inactixation of
their human counterparts may collaborate in human carcino-
genesis. Many tumour types exhibit mutations in both RB and
p53 (ref. 19 and references therein) and mice that are Rh"
p53- - develop a wider range of tumours at earlier ages than
mice that are either Rh- or p53 alone". indicating that null
mutations in both Rh and p53 can cooperate to bring about
malignant transformation, and. that in some cell tlpes. inacti•a-
tion of both genes may be required. Moreoxer. the abilit% of
several viruses to transform cells in culture- and cauec
tumours in the mouse lens-' - requires xiral oncoproteins that
bind to and inatixate both pRb and p53. Due to the attendant
lethalit, of the Rh : p53 embrios. x'e xwere unable to
observe tumorigenic consequences of these two mutations in the
deeloping mouse lens.
Our results shox that although loss of Rh is suffticient to
deregulate lens cell proliferation, this actixates a p53-dependent
programme that leads to the efficient elimination of these
abnormally growing cells. This dexelopmental stud, proxlde.,
strong corroborating in Cwvo ex idence that p53 may function a,
a tumour suppressor by promoting the death of pre-malignant
cells which could eventuall, compromise the organism.
Note added in prool: Follo ming submission of this paper. Pan
and Griep -' reported that expression of the pRb-binding protein
HPV E7 in the postnatal mouse lens led to effects similar to those
described here in the dex eloping Rh-deficient lens. Moreover. co-
expression of HPV E6 led to a reduction in apoptosis and to
lens tumour formation.
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The work described above illustrated that cells lacking p53 could survive under conditions (Rb-
deficiency) where normal cells would not. However, because the embryos deficient in both Rb
and p53 die shortly after the time this analysis was done (at approximately 13.5 to 14.5 days p.c.),
it could not be determined whether this survival would eventually lead to tumorigenesis.
However, work from other groups has supported the idea that the inappropriate survival of these
cells could result in tumorigenesis. Work from the laboratory of Anne Griep has shown that
concomitant expression of HPV E6 and E7 proteins driven by a lens specific promoter leads to the
development of lens tumors in the mouse (Pan and Griep, 1994). Expression of only E7 leads to
the induction of apoptosis in the lens during development, causing the formation of cataracts in
adult transgenic mice (Pan and Griep, 1994). While these experiments are a nice extension of the
work presented here, they are complicated by several factors, the most important being that E7 and
E6 bind to and affect the function of many other proteins besides pRb and p53. As discussed
previously, E7 is able to bind to and presumably inactivate the pRB-related proteins p107 and
p130. In addition, recent evidence suggests that it can also bind to and positively affect the activity
of AP-1. E6 has been shown to interact with the putative calcium binding protein ERC-55 (Lowe
et al., 1994a) and also affect the activity of telomerase in a manner independent of its ability to bind
to p53 (Helin et al., 1993). Furthermore, more recent work by the Griep laboratory has shown that
while apoptotic cell death induced by E7 (and by extension probably Rb-deficiency) is p53-
dependent before day 13.5, E7-induced lens fiber cell apoptosis at later stages of development is
blocked by E6 expression, it is not abrogated by p53-deficiency (Pan and Griep, 1995). This
illustrates that other functions of E6 play roles in the abrogation of apoptosis. Perhaps the
utilization of the aphakia blastocyst complementation assay (Liegeois et al., 1996) with ES cells
deficient for different combinations of the pocket proteins and p53 will help to clarify some of
these issues (see Appendix E).
Aside from the lens, studies in other systems have also supported the idea that p53-dependent cell
death is induced by inhibition of Rb (or Rb family function) and that abrogation of this apoptotic
response can result in tumorigenesis. Transgenic mice expressing HPV E7 specifically in the
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retina exhibit widespread apoptotic cell death in the developing retina (Howes et al., 1994). When
this same transgene in present in p53-deficient mice, retinoblastoma is observed (Howes et al.,
1994). Thus, deficiency for both p53 and Rb-family function results in tumorigenesis in this
tissue. In this case, however, some evidence suggests that loss of multiple members of the Rb
gene family is necessary for tumorigenesis as Rb+/-;p53-/- mice do not develop retinoblastoma.
Indeed, mice carrying mutations in both Rb and p107 develop severe retinal dysplasia (see
Appendix C). This coupled with the observation of milder retinal dysplasia in Rb+/-;p53-/- mice
may indicate that loss of all three proteins' functions may be necessary to cause murine
retinoblastoma.
Perhaps the most direct demonstration of p53-induced apoptosis suppressing tumorigenesis
associated with Rb-deficiency is reported by Symonds et al. (Symonds et al., 1994). SV40 T
antigen expressed specifically in the choroid plexus epithelium induces choroid plexus tumors
(Van Dyke, 1993). A truncated form of T antigen which retains the ability to bind Rb-family
members but lacks the capacity to complex with p53 (TruncT) induces choroid plexus tumors with
longer latency when expressed in the same way as wild-type T antigen (Chen et al., 1992).
Examination of the choroid plexus epithelium of these animals (TruncT) revealed both excessive
mitotic activity and widespread apoptosis (Symonds et al., 1994). The apoptosis, but not the
excess proliferation was abrogated when this transgene was expressed in a p53-deficient
background (Symonds et al., 1994). In addition, tumor latency in the p53-deficient background
was reduced relative to the tumors occurring in p53 wild-type animals. In the most revealing
observation, animals carrying the TruncT transgene and heterozygous for the p53 mutation exhibit
high levels of proliferation and apoptosis in the choroid plexus epithelium, but exhibit nodular
regions of tissue in the choroid plexus epithelium with dramatically reduced amounts of apoptosis.
This is associated with a increased rate of tumor growth. In these regions it can be shown that the
wild-type allele of p53 has been lost (Symonds et al., 1994).
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CHAPTER 5
Use of Chimeric Mice to Assess Effects of
Rb-Deficiency in Adults
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While the creation of the Rb-deficient mouse strain yielded many insights into the role of Rb in
murine development and tumorigenesis, the embryonic lethality associated with germline
homozygosity for Rb-deficiency somewhat limited the strain's utility. In order to overcome this
limitation and examine how Rb-deficiency would affect later stages of development, we created
ES cells with both copies of the Rb gene carrying targeted inactivating mutations and injected them
into blastocyst to create chimeric mice composed partially of cells derived from the Rb-deficient
ES cells. We correctly assumed that the presence of wild-type cells in the chimeras would rescue
the Rb-deficient cells from their normal embryonic lethality in Rb-deficient embryos and allow
Rb-deficient cells to form portions of many adult tissues. Not only did we feel that this would
allow a more complete examination of the effects of Rb-deficiency on mouse development, but it
would also allow us to address one possibility for why Rb heterozygotes do not develop more
widespread tumorigenesis. This was that loss of the wild-type allele of Rb did not occur at a
sufficient rate in some tissues (perhaps because of a small target size) to allow tumors to form. By
seeding adult tissues with cells already deficient for both copies of Rb, we expected to see an
enhancement of tumorigenesis.
The chimeric mice analyzed in this experiment were generated from ES cells with both copies of
the Rb gene disrupted by two successive rounds of gene targeting. A schematic representation of
the chimera generation process is shown in Figure 5-1.
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Figure 5-1. Fb-DKO chimera
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Because the ES cells are derived from the 129/Sv (129) strain of mice and the blastocysts are
derived from the C57/B16J (B6) strain, the cells derived from these two different founders in the
chimeras contain several polymorphic strain differences. These polymorphisms were exploited to
examine these chimeras. The most obvious difference between the two strains is that mice of the
129 strain are agouti while mice of the B6 strain are black (Bradley, 1987). While this is useful for
identification of chimeras (and the identification of germline derived offspring from these
chimeras), it reveals nothing about the level of chimerism in any other tissue (although one usually
assumes a general positive correlation between the level of coat color chimerism and contribution
to the internal organs). In this study, we took advantage of two other differences in the strains
which were polymorphisms in the glucose phosphate isomerase (GPI) locus (Bradley, 1987) and
in the hemoglobin locus (Whitney III, 1977). GPI is an enzyme which because of its necessary
role in the glycolytic pathway, is present at relatively high concentrations in all living cell types
(Bradley, 1987). The 129 and B6 isoforms of the proteins differ enough that they can be
electrophoretically separated (Bradley, 1987). By making homogenates of various chimeric
tissues, and then running them on a cellulose acetate plate, the two isoforms can be separated and
the relative amounts of each isoform in the homogenates can be quantitated. This analysis showed
that all adult tissues contained contribution of Rb-deficient cells. While this result was interesting,
one must keep in mind that the GPI assay measures contribution at the level of tissues. Because
we had no way of identifying Rb-deficient cells at the cellular level via immunohistochemistry or
other methods, the analysis was limited to the tissue level of resolution. This limitation will be
addressed in detail in the following chapter.
While the data from the GPI assay demonstrated that Rb-deficient cells were present in all tissues
examined, it did not address whether this contribution resulting in normal appearing tissue. To
examine this question, extensive histological analysis was undertaken. Surprisingly, this analysis
showed that only a limited number of tissues (lens, pituitary, cerebellum, adrenal, and liver)
exhibited noticeable pathological changes.
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In addition to the GPI polymorphism, red blood cells derived from the two mouse strains contain
different isoforms of the B-chain of hemoglobin which can be electrophoretically separated in a
manner similar to that of GPI (Whitney, 1977). Because of the hematopoietic defect noted in Rb-
deficient embryos (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992), and the limitations of
the GPI assay (see below), this assay was used to unambiguously assay for the presence of Rb-
deficient red blood cells in the adult chimeras. In perhaps the most surprising aspect of these
experiments, the presence of significant levels of Rb-deficient red blood cells in adult chimeras
was confirmed. The report of this work follows.
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chimeric mice with limited histopathological
consequences
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Homozygosity for a mutation in the Rb tumor sup-
pressor gene causes mid-gestation embryonic lethality
in the mouse. Using a two-step targeting protocol,
we have constructed Rb homozygous mutant mouse
embryonic stem cells and used them to create chimeric
animals partially composed of Rb-deficient cells.
Analysis of these chimeras demonstrates widespread
contribution of the mutant cells to adult tissues,
including the retina and mature erythrocytes. Despite
the presence of large numbers of Rb-deficient cells in
most tissues of these mice, they are remarkably normal
but do exhibit certain histological defects including
cataracts, hyperplasia of the adrenal medulla, and
enlarged cells in the cerebellum and the liver. Like
animals heterozygous for the Rb mutation, the chimeras
develop tumors of the intermediate lobe of the pituitary,
and the rate of pituitary tumorigenesis is greatly
accelerated.
Key words: embryonic lethality/mouse/Rb tumor sup-
pressor gene/tumorigenesis
Introduction
The development of many human tumors is associated
with mutations in tumor suppressor genes (Knudson.
1993). One of the best studied of these genes is the
retinoblastoma susceptibility gene (RB). In humans,
inheritance of a defective allele of the RB gene strongly
predisposes to pediatric eye cancer. retinoblastoma (Friend
et al., 1986: Fung et al., 1987: Lee et al.. 1987). The
gene is also mutated during the development of sporadic
retinoblastomas as well as osteosarcomas, soft tissue
sarcomas, and carcinomas of the breast. lung and bladder
(Friend et al., 1986, 1987; Fung et al.. 1987: Lee
et al., 1987; Harbour et al., 1988; E.Y.-H.P.Lee et al.,
1988; T'Ang et al., 1988; Yokota et al., 1988; Varley
et al.. 1989: Bookstein et al.. 1990b; Hensel et al., 1990).
Introduction of wild-type RB into varicus tumor cell lines
which have lost endogenous RB function can inhibit
tumorigenicity and cell cycle progression or induce cell
senescence (Huang et al., 1988: Bookstein et al., 1990b;
@ Oxford University Press
Qin et al., 1992). These results provide direct evidence
that this gene can act to limit cell proliferation and that
its loss contributes to the decontrolled growth associated
with these tumor cell types.
To study the function of RB in more detail, we and others
have created mouse strains carrying germline mutations in
its murine homolog. Rb (Clarke et al., 1992: Jacks et al.,
1992: Lee et al.. 1992). Analysis of animals heterozygous
for the targeted disruption revealed no evidence of pre-
disposition to retinoblastoma. However, the heterozygous
animals were highly susceptible to adenocarcinoma of
the pituitary. with -90% of the animals developing this
tumor by I year of age (B.O.Williams. L.Remington.
R.T.Bronson and T.Jacks. unpublished data). In addition.
heterozvgotes are susceptible to medullary thyroid
carcinoma, with 70% of animals developing this
tumor by 1 year of age (B.O.Williams. L.Remington.
R.T.Bronson and T.Jacks. unpublished data). As with
human retinoblastoma (Friend et al., 1986: Fung et al..
1987: Lee et al.. 1987). pituitary and thyroid tumorigenesis
in these mice was accompanied by the mutation of the
wild-type allele of Rb (Jacks et al., 1992: B.O.Williams,
L.Remington. R.T.Bronson and T.Jacks. unpublished data).
The Rb mutant mice also provided the opportunity to
study the role of this tumor suppressor gene in normal
development. Homozygosity for the Rb mutation was
shown to cause embryonic lethality between days 13.5
and 15.5 of gestation (Clarke et al., 1992: Jacks et al..
1992: Lee et al.. 1992). Death was associated with defects
in the production of mature erythrocytes in the liver and
widespread cell death in the central nervous system. The
development of other tissues, including the retina, appeared
to occur normally in the Rb-deficient embryos.
The analysis of homozygous mutant embryos has
suggested a requirement for Rhb in normal development of
at least erythroid and neuronal tissues. Due to the attendant
lethality. however, it was not possible to determine what
effects, if any, the absence of Rb function would have on
normal development or neoplasia at later stages of gesta-
tion or postnatally. To address these issues, we have
created embryonic stem (ES) cells that are homozygous
for the Rb mutation and injected them into wild-type
blastocysts, yielding chimeric animals. Due to the contribu-
tion of the wild-type cells from the host embryo, many
of these chimeras escape the mid-gestation lethality caused
by germline Rb homozygosity and develop to birth. This
has allowed us to assess the pathological and tumorigenic
effects of the widespread presence of Rb-deficient cells in
later stages of development and in adult life.
Results
Construction of homozygous mutant ES cells and
generation of chimeric animals
Rb homozygous mutant (Rb-DKO) cells were created
using a two-step targeting protocol (te Riele et al., 1990).
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First. hetero)/ gous D3 ES cells (G(os•ler c• al.. 1986)
(derived from strain 129/s,%) were constructed u,,ingL an
Rb targeting %ector carrI\mn a neom\,cin resistance gene
(nieo) (Jacks et al., 1992). The survi\, ng wild-tipe Rb
allele present in a single heterozygous ES cell clone .was
then re-targeted using a second vector, identical to the
first except that a hygromycin resistance gene (hIvgr) was
substituted for the neo gene (Figure 1A). Rh-DKO cells
were identified by Southern blotting following selection
in G418, hygromycin and gancyclovir.
As shown in Figure IB, resulting homozsgous mutant
cells lack the band corresponding to the wild-type Rb allele
and contain instead an additional fragment repreenting the
Rb-hygro mutation. Of 173 ES cell clones resistant to the
three drugs, six were found to be homozy gous for the Rh
mutation, with the herpes simplex % irus thynidtine kinae
(HSV-TK) counterselection (Mansour el al.. 1988) pro\ id-
ing an -6-fold enrichment for correctly targeted clones.
Thus, the efficiency of targeting the second Rb allele was,,
approxiinatelx one in 173 hl gromn cin-resi,,tant cell clone.
similar to that observed for the first round of gene targetirn
(Jacks et al.. 1992). Consistent with earlier analists of
embryos homoyvgous for the original R/C' mnutatiton
(Jacks et at.. 1992). the Rh-DKO ES cells \ ere alo found
to lack detectable Rb-encoded protein (pRh) hi Western
blotting (data not shown).
Three independently derl\ed Rh-DKO ES cell clones
were then injected into C57B1/6 blastocists to create
chimeric animals. For comparison, several chimeras \ ere
also generated using the parental heterozx gous ES cell
clone. Given the lethality caused by germline homoiz gos-
ity for the Rb mutation, we assumed that injection of the
standard 12-15 ES cells per blastoc\st (Bradlex. 1987)
might lead to embryonic lethality and reduced the number
of Rh-DKO cells injected per blastoc,,, st to approximrnatel
eight. A systematic analysis of the effects of injection of
different numbers of mutant cells was not performed.
Contribution of Rb-DKO cells to adult tissues
The contribution of the Rh-deficient cells to chimeric
animals could be estimated from the extent of agouti coat
color (the product of the Rb-deficient 129/SV ES cells)
and was found to range from -30 to 60%. In addition, we
wished to determine the percent contribution of mutant
cells to the internal tissues of these chimeras. The Rb-
DKO ES cells are homozygous for the a allele of glucose
phosphate isomerase (GPI-Isa' , encoding GPI-IA) while
cells of the C57B1/6 host embryo are homozNgous for
GPI-Isb (encoding GPI-1B)(Lyon and Searle,. 1990) Thus,
by using cellulose acetate electrophoresis and stainine for
the specific enzyme activity of the two isoforms (Bradle\.
1987), we could determine the relative contribution of the
Rhb -/- cells to individual tissues (Figure 2A). More than
35 tissues from 14 Rb-DKO chimeras and five controls
were examined usine this assay.
As summarized in Figure 2B, we observed significant
contribution of the Rb-DKO cells to all adult tissues
examined, including liver, thymus, spleen. kidney and
muscle. These data indicate that Rb function is not required
for the differentiation of cells in many adult tissues.
However, since the GPI assay only measures the percent
contribution to the tissue as a whole, it is not possible to
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nn tlon he txon 3 mutation creates twiO tan[dem terlllllnation odon'
and a nooCel P1il (Pi recognition ,ite (Jacks et al. 1992) The
renmaruting ,ld-t\pe tllele in the hetero.m'eous or SKO) ES cell wa,,
then subjected to a second round of grene targetiong with a \ectot
identical to the first except that the h,,gronmcin remsttance gene
S/th\ir,io replaced neto ti eii targetrng \ector). ,ielding the Rh-deiicient
itr DKO) ES cells Both targeting \ectors contain the herpes smplex
Siru', tht midine kinase gene (HSV'-TK to pro\ ide countersele•titon
(Mansour er t a 19881 A-s indicated b, arrows, the drug selecutn
genes are in the opposite transcriptional orientation from Rh The
lengths ot homolog\ to Rh in both targeting lectors, are 1 I kh
upstream of the drug resistance gene and 8 5 kb downstream (Jacks
et ai . 1992). Clones were ,creened by Southern blotting of Pstl-
digested cenomic DNA using probes A and B (bosed) Lengths of
tele\ant PJlti restriction tralgments are indicated (B) Southern hlots ot
Rh-mutant ES cell,, PIl-dige,,ted genomric DNA isolated from ,kild-
t\ pe ES cells,,, the parental SKO ES cell clone and sexeral DKO IS
cell clones was hhribndled to probes A (left) and B (right) show n ,n
panel A Poitions of the wild-tipe (WT) neo and hitN ,io mutant
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Fig. 2. GPI isoenzyme analysis (A) GPI activity assa% ,IAsates from
several tissues isolated from Rh-DKO chimeras wvere separated by
cellulose acetate electrophoresis and stained for GPI actiiýty as
described in Materials and methods. Tissues shown are retina (R).
cerebellum (C), spinal cord (S), red blood cells (E), bone marrow (M)
and tail (T). Rb-DKO cells (derived from strain 129/Sv) expiess the
GPI-IA isoform, while host C57BL/6 cells produce GPI-lB The
migration of the two isoforms is shown in control lanes of 129/S
tissue (129) and C57BI/6 tissue (B6) and is indicated on the left. (B)
Quantification of tissue contnbution of Rb-DKO cells Graph shows
the average contribution (by percentage) of Rb-defictent cells to
representative tissues isolated from Rb-DKO chimeras The number of
animals from which each tissue was examined is indicated in
parentheses The lowest and highest values of Rb --/- contilbution to
tissues in Individual chimeras were the following cerebellum (low of
2.5%, high of 54 4%), retina (22.9%, 30 2%). red blood cells (1 84,
64.8%), liver (4 3%, 83 9%), thymus (22 8%/c, 60 3%), eye (33 2%}.
61.1%), spleen (13 7%, 66.3%), kidney (49 9%/•, 77 9 ), leg muscle
(37 5%, 78.7%) and adrenal (61.2%, 97.7%). A list of the 36 different
tissues tested in total is provided in Maternals and methods
conclude that all cell types within that tissue can differenti-
ate in the absence of Rb function.
As reported previously, embryos homozygous for an
Rb mutation die at 13.5-14.5 days in utero with defects
in hematopoiesis and neurogenesis (Clarke et al., 1992;
Jacks et al., 1992; Lee et al., 1992). Thus, it was of
particular interest to examine the ability of Rb-deficient
cells to contribute to these tissues in the Rb-DKO chimeras.
As shown in Figure 2B, GPI isoenzyme analysis clearly
demonstrates significant contribution by the Rb-deficient
cells to at least some portions of the adult brain, spinal cord
and red blood cell (RBC) compartment. The percentage of
Rb-deficient cells in the cerebellum (and other central
nervous system tissues) was consistently among the lowest
of all the tissues examined (Figure 2B, data not shown).
However, this pattern was also observed in chimeras made
from ES cells heterozygous for the Rb mutation (data not
shown), and, therefore, presumably reflects the relative
single--io. l
major-*. p
minor-*.
Fig. 3. Normal erythropoesis in Rb-DKO chimeras (A) (-globin
isoforms Blood proteins from an Rh-DKO chimera and 129/Sv and
C57B1/6J controls weie separated bý cellulose acetate electrophorests
and stained as indicated in Materials and methods The presence of
Rb-deficient erqthroid cells in the Rh-DKO chimeras is verified by the
production of the 129/S\-specific Hb major and Hb minor species, Hb
single (produced by stram C57B1/6 red blood cells) is also evident in
the chimera. (B) Normal erythrocytes A tpical blood smear (stained
with Wnght-Glemsa) from an Rh-DKO chimera shows normal red
blood cells and a lack of nucleated erythrocytes Blood smears from
control chimeras generated from ES cells heterozygous for the Rb
mutation were indistinguishable from those derived from Rb-DKO
chineras (data not shown)
ability of the ES cell-derived donor cells to compete with
the cells of host embryo during organogenesis.
The rather extensive contribution of the Rb-deficient
cells to the RBC compartment was unexpected in light of
the observed inhibition of erythropoiesis in Rb homo-
zygous mutant embryos (Clarke et al., 1992; Jacks et al.,
1992: Lee et al., 1992). In order to confirm that the GPI-
IA signal measured from the purified RBC fraction was
derived from Rb-deficient erythrocytes (rather than some
contaminating cell type), we assayed for the presence of
the Hb major and Hb minor forms of 3-globin produced
by the Hbbd haplotype of strain 129/sv (Whitney, 1977).
As shown in Figure 3A, erythrocytes isolated from strain
C57BL/6 animals produce Hb single (encoded by the
Hbb b haplotype), which is separable from the 129/sv-
specific Hb major and Hb minor species. The RBC fraction
isolated from Rb-DKO chimeras clearly contains all three
3-globin forms (Figure 3A), indicating the presence of
Rb-deficient hemoglobinized cells. Peripheral blood
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Fig. 4. Histopathology. (A) Hyperplastic nodule (T) in the adrenal medulla of an Rb-DKO chimera: normal medulla (M) and cortex (C) are
indicated. (B) High magnification of a section through the retina of an Rb-DKO chimera with normal outer nuclear (O). bipolar cell (B). and
ganglionic cell tG) layers. (C) Section of whole eve of an Rb-DKO chimera showing a cataract (C) in the lens (L) and normal retina (R). (D)
Section of normal eve of a newborn control chimera with lens (L) and retina (R) indicated. (E) Section of eye of a newborn Rh-DKO chimera
showing abnormal lens (L) architecture and an early cataract (C): retina iR) is also noted. (F) Higher magnification view of area boxed in panel E.
Disorganized lens fiber cells are shown at the bottom. dying cells with pyknotic nuclei in the middle and cellular debris above. (G) Section of an
Rb-DKO chimera liver showing cells with abnormally enlarged nuclei (arrows). (H) Normal cerebellum from a control chimera. The granular cell(G), molecular (M) and Purkinje cell layers (P) and normal Purkinje cells (arrowI are indicated. (1) Abnormal cerebellum in an Rb-DKO chimera.
Ectopic and enlarged Purkinje cells are shown (arrows) along with reduced granular cell layer (G). Magnification: panels A. B and F-I. 2(X)x:
panels C-E, -50x.
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smears from the Rb-DKO chimeras further confirmed that
the cells producing the 129/s\-specific 0-globin \were
indeed mature erythrocytes (Figure 3B). Notably. there
was no increase in the percentage of nucleated RBC in
these animals compared with controls. Thus. it is clear
that Rb-deficient erythroid cells, whose development is
inhibited in an Rh homozygous mutant embryo, can
develop normally when in the environment of wild-
type cells.
Histological and pathological consequences of Rb
deficiency
The analysis described above indicates a surprisingly large
percentage of Rb-deficient cells in mans tissues of the
adult chimeras. Howe\ er. these data do not address %k hether
the development of these mutant cells occurred normall\.
In particular. it was possible that the Rh-deficient cells
might be defective in reaching or maintaining endstace
differentiation which could produce pathological 'and
tumlorigenic consequences in somen tissues. Therefore. % e
undertook a detailed histopathological characterllation of
a number of tissues in the chimeric animals to determine
whether their development x\\as. in fact. full\ normal. For
all of the tissues examined by GPI anal\ sis. a sample was,
fixed, processed and examined b\ standard histological
methods.
For the majority of tissues anal zed. the Rh-DK()
chimeras were indistinguishable from controls. In four
tissue types. however, the presence of Rh-deficient cells
produced obvious abnormalities. When the adrenal
medullae of four Rb-DKO chimeras were examined histo-
logically. all four were found to contain multiple small
nodules of hyperchromatic cells. indicatixe of preneo-
plastic lesions (Figure 4A). In addition, in ,ix of eight
animals examined, areas of the cerebellar cortex had
displaced Purkinje cells. most of which had enlarged
nuclei (Figure 4H and 1). In the affected cortical areas.
the granular cell layer w as also abnorniall thin ( Ficgure 4H
and I). This defect in cerebellar differentiation is Interesting
considering the widespread neuronal cell death seen in
Rh homozygous mutant embryos. The liters of sex eral
Rb-DKO chimeras also contained hepatocstes x\ith
abnormally enlarged nuclei (Figure 4G).
Finally. the most consistent abnormality obserned in
the Rh-DKO chimeras involked the lens of the eve: each
of these animals developed bilateral cataracts ( Figure 4C).
These cataracts were characterized b\ posterior migration
of the lens epithelium associated with bladder cell forma-
tion and. in some cases. calcification. Most animals showed
e\idence of cataract formation at the time the eses
opened (- 1 week of age). and seseral new•borns examined
histologically already had obvious lesions in the lens. The
lenses of chimeric newborns were highly disorganized
and contained large numbers of pyknotic cells. indicative
of apoptosis (Figure 4E and F). None of these defects were
observed in control chimeras made from heterozN gous ES
cells. Despite a measurable contribution of Rh-deficient
cells to the eyes. including crude retinal preparations
(Figure 2A and B). we haxe not obser\ed ans esidence
of retino-blastoma in the Rb-DKO chimeras. Moreoser.
the retinal architecture appeared normal (Figure 4B ). Thus.
the absence of Rh function alone does not lead to the
outgrowth of clones of transformed cells in the mouse
retina.
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Pituitary tumorigenesis
At 3-4 months of age the Rh-DKO chimeras exhibited
sexere w asting and became moribund. Autopsy revealed
severe adenocarcinoma of the pituitary. the same tumor
observed in animals heterozygous for the Ri ,-/' mutation
(Jacks et cal.. 1992). Immunohistochemical analysis per-
formed on three of these tumors indicated that they arose
from the intermediate lobe of the pituitary. The tumors
stained positi.ely w ith antibodies directed against the
hormones ci-melanocite stimulating hormone (MSH). 3-
endorphin and adrenocorticotropic hormone (ACTH) (all
produced in the intermediate lobe) and not for markers
specifti ,'or other lobes of the pituitarl including thyroid
stimulating hormone (TSH) and prolactin (Fiure 5. data
not show, n . This pattern of staining , as also obser\ ed vw ith
pituitarA tumors from Rb'fr heteroz, gotes (data not show n).
The ax erage age at kx hich Rb-DKO chimeras manifested
the effects of pituitar\ tumorigenesis xxas -4 months
(F-iure 6). A 10() chimeras that kxere not sacrificed at
earlier ages fobr other purpoes CX eentuall dC\eloped this,
tumor. Thus. the latenc\ of tulmoml•enesisl obscrIed in1 the
Rh-l)K() chimeras is retil reduced relati\c to the Rh'
hletero/ gotes. mo(,st of hih SUlCCll umb to pllitar\ tllllmrs
at -9-- () months of age (Fleure 61. Interest0n)li. in both
Rh hetero'l/iotes and the Rh-DKO chimeras. the time
\\ Indo\x duringc -hich most animals are affected is remarllk-
bibl\ narrow and \ el11-defined i FIlure 6). Thus. it appears
that the absence of Rh accelerate's the death of the Rh-
D)K( chimeras trelatixe to Rh -/ - mice) caused hb
pituitary tumorigenesis. Although "e hae also obserx ed
preneoplatic lesions in the adrenal glands of some Rh-
DKO chimeras. it is notex\orth\ that there are relatlxel
fe\\ tissues' in \\hich homo/x gouis inactilation of Rb
CILIses oOncocenic trans,formantion.
Discussion
MIutant alleles of the RB gene are found in a \arlet\ of
huminan tunLors. Including the retinal tumiors in w\hich this
gene aas, first characterl/ed. osteoslrcomnlas. carcinomasN
of the lung. bladder and breast (Friend e( al/.. 1986. 1)987:
Fuing et al.. 1987: W.H.Lee eti ta.. 1987: Harbour ci aii..
1988: E.Y.-H.P.Lee et til.. 1988: ".Ang et ai.. 1988:
Yokota er ta.. 1988: Varle\ et il.. 1989: Bookstein et al..
199(o: Hensel et al.. 1990()1. For this reason, the RB gene
has been thought to function as an important negatIxc
regulator of cell proliferation in these \arious tissues. An
e\ en more ,\ idespread in\ oIl ement in grossth regulation
has been suggested b1 the almost ubiquitous expression
of this gene in the tissues of the mouse (Bernards et ai..
1989: Szekel\ et ial.. 1992) and the growth inhibitor\
effects of exogenous RB expression (Huang et alt.. 1988:
Bookstein er alc.. 1990a: Qin et tal.. 1992). The RB
protein is found to undergo phosphorylation in mid/late
G1 (Buchko\ ich et cal.. 1989: Chen et al.. 1989: DeCaprlo
et ail.. 1989) and this phosphorlation has been connected
\%ith the functioning of cvclins and associated kinases
(Lees er ci.. 1991: Lin er al.. 1991: Hinds et al.. 1992:
Dowd\ er al.. 1993: Ewen et aci.. 1993) Moreoer. pRb
has been shown to associate with a number of DNA tumor
\irus oncoproteins (DeCaprio er alc.. 1988: Whyte et ai..
1988: D, son et al.. 1989) and cellular transcription factors.
most notably E2F (Chellappan et ial.. 1991: Rustgi et aci..
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TSH
Fig. 5. Immunohistochemn,,tr, of pittHtar> tumorn, ecSon ot pitL0tar Ltrom an Am R)-DKO hi merta staLned \th hemato\h\in and cosim (H & F)
showmng tumor (T). brain (B) and a large hCmatomna (H ) ['umoT t0 ssues t'ln po-sii\ \i ith antubodies aeainst the hot mones,, u-MISH, 3-endorphin
(0-end) and ACTH (not showmn) produced in the intCmettdiae lobhe of tile pituat,\ anrd Mnot ith antibodCies or th\roid ,stinmulating hormone (TSH or
other markers, of the antenIot p tlltatN. IncludiiL' pi)laLLn 'no "no\\1 i
1991: Gu et a!.. 1993: Hagemeier et al.. 1993). Taken
together. these various lines of el idence impl\ that pRb
regulates progression through a critical point in the cell
growth cycle.
The resulting model of pRb as an important controller
of proliferation and transformation in a \wide \ ariet\ of
cell types is difficult to reconcile with the obserations
presented here. The present work describes the creation of
chimeric mice, many of whose tissues are morphologically
normal yet contain large proportions of Rb-deficient cells.
These mice are largely developmentally normal and ,sur-
vive until 3-4 months post parnm, at which time they
die from the effects of adenocarcinomas of the pituitarv.
In a separate series of experiments, we ha\e also been
able to produce apparently normal Rb-deticient B and T'
lymphocytes using the RAG-2 blastocy st complementation
assay (Chen et al., 1993). Thus, the accumulated data
suggest that Rb is dispensable for the development and
maintenance of the differentiated state of most cell t pes,,
in the mouse. This extends the earlier obser\ ations w hich
showed that mouse embryos homnozygous5 for an Rh
mutation develop normally until day 13 of gestation, at
which point they die. apparently because of a defect in
erythropoiesis (Clarke et al., 1992: Jacks et al.. 1992: Lee
et al., 1992). It is important to note that w hile the data
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Figu. 6. \ iabit\ of Rh-DKO chimetras Giaph summatres the mabihit\
ot 11 Rh-DK) chimerat and 25 antmal heteroCgouls for a germhnt e
MutLmon in Rh Hetcro/io,te,, ire intbred on the i29/S\ cenetie
backgtround Data point,, itelect the time at v.hich an1,ma1 s hCa1mC
moibund and ýeie ,iacticed due to the effects ot intermnedate lobe
piUltu I \ um111_,
Effects of Rb-deficient cells in adult mice
presented here suggest that Rb-deficient cells are capable
of contributing to all tissues of the adult mouse, the ability
of these cells to differentiate into every cell type within
a given tissue cannot be determined at this time. Therefore,
it remains possible that there are certain cells in the animal
that cannot be formed in the absence of Rb function.
Moreover, the survival of embryos that are composed
largely of Rb-deficient cells may still require the contribu-
tion of wild-type cells to one or more critical cell lineages
during development.
One of the more unexpected results of this analysis was
the high percentage of Rb-deficient erythrocytes in the
peripheral blood of chimeric animals. Due to incomplete
differentiation in vitro of erythroid precursors isolated
from the livers of Rb homozygous mutant embryos. ve
had previously suggested that the requirement for Rb in
erythropoiesis was cell autonomous: that is, the function
of the Rb gene was required within erythroid precursor
cells in order for them to differentiate normally (Jacks
et al., 1992). However, we now consider it more likely that
the absence of Rb function does not affect erythropoiesis by
directly inhibiting differentiation of ervthroid cells per se
but. rather, by affecting the ability ot' other cell types to
create an environment allowing survival and differenti-
ation. For example. the absence of Rb function might
prevent stromal cells from producing one or more critical
growth, differentiation or survival factors essential for
normal erythroid differentiation. In the chimeras, the wild-
type cells derived from the host embryo could 'rescue'
the differentiation of the mutant cells by supplying the
necessary extracellular factor(s) to the microenvironment.
The previously described inefficient in vitro differentiation
of Rb-deficient precursors might be explained by a pre-
existing defect due to their failure to receie appropriate
environmental signals prior to their removal from the
embryo. Furthermore, the apparently normal development
of other Rb-deficient cell types could also be affected by
the presence of wild-type cells in the chimeras.
According to Knudson's two-hit model of retinal tumori-
genesis, the development of human retinoblastoma is
dependent on two rate-limiting steps (Knudson, 1971),
which are now understood to be the successive inactivation
of two copies of the Rb gene (Friend et al., 1986: Fung
et al., 1987: Lee et al., 1987). Since mice heterozygous
for an Rb mutation do not develop retinoblastoma, we
and others have proposed that the loss of function of Rb
is not sufficient to transform the relevant cell type in the
mouse retina (Clarke et al.. 1992; Jacks et al., 1992; Lee
et al., 1992). Alternatively, the absence of retinoblastoma
in these animals could reflect the relatively small number
of susceptible cells in the retina of the mouse, which
would be expected to decrease the likelihood of the second
hit in Knudson's model. Having found that the Rb-DKO
chimeras (in which a measurable fraction of retinal cells
are already homozygous for an Rb mutation) also do not
develop retinoblastoma. we now strongly favor the notion
that the relevant cell type in the mouse is refractory' to
the loss of Rb function. This implies that the transformation
of this cell type in the mouse requires additional genetic
events and may explain why sporadic retinoblastoma has
never been reported in mice (or indeed in any other species
besides our own). Mice expressing SV40 T antigen do
develop retinoblastoma at high frequency (Windle et al.,
1990: al-Ubaidi et al.. 1992), suggesting that some of the
multiple activities of this viral oncoprotein beyond its
ability to bind and sequester pRb (DeCaprio et al., 1988)
contribute to retinal cell transformation.
Mice heterozygous for the R •,"t mutation are highly
predisposed to intermediate lobe pituitary tumors (Jacks
et al., 1992). Tumorigenesis appears to require the inactiva-
tion of the wild-type Rb allele, and the average age of
sacrifice (from the effects of the tumor) is -10 months.
In the Rb-DKO chimeras, the rate of tumorigenesis is
increased: these animals become moribund from the effects
of the pituitary tumors by 4 months of age. Thus, as
predicted from Knudson's model (Knudson. 1971). the
remoal of a rate-limiting step (the inactivation of the
wild-type allele of Rh) accelerates the rate of tumor
development. This increased rate could result from the
more rapid formation of a single tumor focus or the
combined effects of several distinct foci. By sacrificing
animals at progressively earlier ages. it should be possible
to determine the number of foci that contribute to tumor
growth in both the heterozygotes and the Rb-DKO chi-
mieras. The strikingly precipitous decline in the siurxtIal
of the Rh-DKO chimeras during a narrow I\ indow of time
indicates that few. if any. additional stochastic esents
are required for the transformation of the cells of the
intermediate lobe of the pituitar\.
Finally. given the frequent mutation of the Rb gene in
human cancer and the proposed importance of this gene
in cell cycle regulation (Weinberg, 1992). we had antici-
pated that seeding an animal with large numbers of Rb-
deficient cells would result in widespread tumorigenesis
but found that tumorigenesis is limited to the pituitary
gland and the adrenal medulla. In order to produce more
profound effects on tumorigenesis (and development) it
may be necessary to inactivate simultaneously two or
more members of the Rb family of genes which now
includes the genes encoding p107 (Ewen et al., 1991) and
p130 (Cobrinik et al.. 1993: Hannon et al.. 1993: Li
et al.. 1993).
Materials and methods
Creation of Rb-DKO ES cells
Heterozygous ES cells (Jacks et al.. 1992) were electroporated with an
Rh targeting sector containing a hygromycin resistance gene in place of
the neonlcmin resistance gene of the original targeting vector, described
in Jacks et al. ( 1992). The hgromycin gene is under the control of the
PGK promoter and polyadenilation sequences (te Riele et al. 1990).
The conditions for electroporation in the second round of gene targeting
were identical to the first (Jacks et al. 1992). Following electroporation.
cells were plated in the absence of a feeder layer, and selected with
300 pg/ml G418. 125 Ig/ml hygromycin and 2 giM gancyclosir.
Colonies %ere selected and expanded for DNA analysis and subsequent
blastocyst injection.
Southern blot analysis
Preparation of genomic DNA and Southern blotting were performed
exactly as described (Jacks et al., 1992) using ' 2P-labeled probes
indicated in Figure IA.
Generation of chimeric mice
Blastocqst injection and creation of chimeric mice were performed as
described (Bradley. 1987) except that eight to 10 ES cells were injected
per blastocyst.
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Histological analysis of tissues
Tissues were surgically removed, fixed in Bouin's solution, dehydrated
in graded alcohol solutions, embedded in paraffin, sectioned at 6 CPm
and stained with hematoxylin and eosin.
Immunohistochemistry
Tissues fixed in Bouin's solution were stained with polyclonal antibodies
to prolactin and TSH (generously provided by Salvatore Raiti of the
National Hormone and Pituitary Program at the University of Maryland
School of Medicine with the National Institute of Diabetes and Digestive
and Kidney Diseases), 3-endorphin, a-MSH and ACTH (BioGenex
Laboratories). Immunohistochemistry was performed using appropriate
secondary antibodies (BioGenex Laboratones) and a biotin-streptavidin-
peroxidase-based staining kit with a diaminobenzidine substrate (Bio-
Genex Laboratories)
Retinal isolation
Crude retinal isolates were obtained by removing the cornea and lens
with a circumferential incision behind the limbus. Retinal tissue was
first excised along with the attached optic nerve and further dissected
away from it.
Preparation of red blood cell fractions
Whole blood in anticoagulant was diluted 2-fold in phosphate buffered
saline, layered onto two volumes of Ficoll- Hypaque (H1stopaque- 1077
Sigma) and centrifuged at 3500 g for 20 mmin at room temperature. The
pellet, enriched for RBC, was collected, platelets remain at the top
of the gradient while lymphocytes and monocytes are enriched at
the interphase.
GPi assay
Separation and detection of GPI isoenzymes was performed essentiallN
as described (Bradley, 1987). Titan III Zip Zone cellulose acetate plates
(Helena Laboratories) were soaked in Tris-glycine buffer (25 mM Tnris.
200 mM glycine, pH 8.5) for 20 min prior to application of samples
Samples were prepared by diluting tissues with -10 vol of water, and
were then crudely homogenized: cells were then lyved by three rounds
of freezing and thawing. Most samples were then further diluted 10-fold
with distilled water. Purified RBC were diluted a total of 1:5. Samples
were electrophoresed in triplicate in a Zip Zone chamber (Helena
Laboratories) for 1.5 h at 150 V at 40 C, and stained as described
(Bradley, 1987). Relative levels of the two GPI isoforms were quantified
by densitometry with an LKB 2222-010 UltroScan XL linear denlsito-
meter. Tissues analyzed included cerebellum, cerebrum, medulla
oblongata, crude retinal isolate, epididymis, RBC, lung, tongue, bone
marrow, testis, liver, uterus, optic nerve, thymus, diaphragm, colon, eye,
lymphocytes and monocytes, spleen, tall, cecum, stomach, bladder.
atrium, ventricle, salivary gland, small intestine, ovary. kidney. leg
muscle, seminal vesicle, trachea/thyroid, prostate, esophagus. pancreas.
fifth cranial nerve and adrenal gland.
Hemoglobin assay
Cellulose acetate electrophoresis of cystamine-modified hemoglobins
was performed essentially as described (Whitney, 1977: Pevny et al..
1991). Purified RBC were added to 75 ml of cystamine lysls buffer
(12.5 mg/ml cystamine dihydrochloride. 1 mM dithiothreitol, 0.55%
ammonium hydroxide) and agitated to lyse the RBC. Samples were
applied to Titan III cellulose acetate plates (Helena Laboratories)
(previously soaked for 10 min in an electrophoresis buffer of 0.18 M
Tris, 0.10 M boric acid, 0.002 M EDTA) and run for 40 min at 300 V
The plates were placed in staining solution (1% Ponceau S. 5%
trichloroacetic acid) for 10 mi and rinsed in three changes of 5% acetic
acid for 10 min each. Plates were then immersed in 100% ethanol for
10 min, then in clearing solution (30% acetic acid, 70% methanol) for
5 min, and finally baked at 550C for 5 min.
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One of the most surprising observations from this work was that the presence of Rb-deficient cells
in many adult tissues did not result in more widespread tumorigenesis. One notable exception was
in the adrenal medulla, where hyperplastic lesions were observed. This suggests that most cells do
not rely on the presence of the Rb protein for negative growth control or are capable of
compensating for Rb-deficiency via some unknown mechanism. Perhaps the related genes p107
and p130 are involved in this compensation (see Appendix D).
The lack of widespread tumorigenesis also suggests that the loss of the wild-type allele of Rb in
heterozygous mice is not a rate-limiting step during most murine tumorigenesis. This also implies
that the cooperative effects of Rb and p53 mutations in tumorigenesis is not due to a simple
increased rate in the loss of the wild-type allele of Rb, since these chimeras do not develop the islet
cell tumors, pinealoblastomas, and other pathology seen specifically in the Rb+/-;p53-/- mice (see
Chapter 3).
Perhaps the most important observation from them these experiments the indication that at least
some defects noted in Rb-deficient embryos could be rescued by the presence of wild-type cells.
The fact that Rb-deficient red blood cells could be formed and were not noticeably abnormal
suggested that the something in the microenvironment of the chimeric fetal liver allowed the
maturation of Rb-deficient cells. Kay Macleod, a post-doctoral fellow in our laboratory, has
extended this observation by showing that fetal livers from Rb-deficient embryos could
reconstitute the hematopoietic systems of lethally-irradiated adult mice. This again illustrates that
the defect in fetal liver hematopoiesis is at some level a non-cell autonomous defect. However, the
situation is more complex than this as these reconstituted hosts die at about 4-6 months after the
rescue, implying that the Rb-deficient cells, for whatever reason, are not fully normal.
While the GPI and hemoglobin polymorphism assays allowed the assessment of contribution of
Rb-deficient cells to the tissues of the chimeras of the animals, no mechanism for assessing the
contribution of Rb-deficient cells at the cellular level existed. Ideally, one would like to stain tissue
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sections for the presence of Rb-deficient cells to conclusively prove which cell types within tissues
to which Rb-deficient cells could contribute. Attempts at staining for Rb-protein were not
successful (data not shown) as no good antibodies existed at that time to do good
immunohistochemistry in the mouse. In fact, only one group has reported such an analysis in the
mouse, and this was in the context of a very specialized system. In addition, in situ hybridization
analysis for the presence of neomycin mRNA have proven unsuccessful to date in this and other
chimeric mouse models (T. S. Shih, personal communication). Thus, to further increase the utility
of this system for studying Rb function (as well as other genes functions) we needed to develop
method to overcome this problem. Our approach to this problem is the subject of the following
chapter.
129
Literature Cited
Note: Additional citations relevant to this chapter are included on page 126-127.
Bradley A. (1987). Production and analysis of chimaeric mice. In: Teratocarcinomas and
embryonic stem cells: a practical approach, E. J. Robertson, (Oxford, England: IRL Press).
Clarke AR, Maandag ER, van Roon M, van der Lugt NMT, van der Valk M, Hooper ML, Berns
A and te Riele H. (1992). Requirement for a functional Rb-1 gene in murine development. Nature.
359: 328-330.
Jacks T, Fazeli A, Schmidt E, Bronson R, Goodell M and Weinberg R. (1992). Effects of an Rb
mutation in the mouse. Nature. 359: 295-300.
Lee EY-HP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, Herrup K and Lee W-H. (1992). Mice
deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature. 359:
288-295.
Whitney JB. (1977). Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine.
Biochem Genet. 16: 667-672.
130
CHAPTER 6
Derivation And Analysis Of Chimeras Created From
Rb-Deficient; ROSA -26 Positive ES Cells
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One method to identify Rb-deficient cells in the context of a chimeric embryos was to introduce a
marker into the ES cells whose presence could be identified by some simple technique. Since the
lac Z gene (which encodes the bacterial B-galactosidase protein) had been used in a number of
contexts to assess gene expression it seemed a logical candidate for such a marker (Bonnerot and
Nicolas, 1993). It has several advantages including being a stable protein, having no mammalian
homolog to create potential background problems in staining, and its presence can be determined
by staining with 5-Bromo-3-chloro-2-indolyl-galactosidase (X-gal), which when cleaved by B-
galactosidase leaves a bright blue precipitate (Bonnerot and Nicolas, 1993).
The ROSA-26 mouse strain was created during a experiment designed to identify genes which
were expressed in developmentally interesting ways (Friedrich and Soriano, 1991). In this
approach, Friedrich and Soriano designed a promoterless vector that contained a gene which
encoded a fusion protein of B-galactosidase and the neomycin resistance gene product. After this
vector (termed ROSA-Bgeo for reverse orientation splice acceptor BGal-neo fusion protein) was
electroporated into ES cells, clones were selected in the presence of G418. These clones were then
injected into blastocysts to create chimeric mice, and the chimeras subsequently bred to generate
mice which contained the integrated transgene in their germline. While several of these transgenic
lines were expressed in spatially and temporally specific ways, other lines (most notably ROSA-
26) caused widespread, high levels of B-gal expression (Friedrich and Soriano, 1991).
Furthermore, when this single-copy insertion was bred to homozygosity, no phenotypic affect was
seen in the mice (Friedrich and Soriano, 1991).
In order to overcome the limitations of chimeric analysis outlined in the last chapter, I chose to
cross Rb heterozygous mice to these ROSA-26 mice described. Females from such matings were
ovariectomized at 2.5 days post-coitus and injected with Depa-provera (Sigma). This prevents
blastocysts from implanting in the uterus(Robertson, 1987), which normally occurs around day 4
after fertilization. Such delayed-implantation blastocysts are then recovered from the females 4
days later and plated onto irradiated mouse embryonic fibroblasts (Robertson, 1987). For reasons
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not understood, such delayed blastocysts provide better production of embryonic stem cells. After
3-4 days in culture, the inner cell mass portion of the blastocyst is picked off the plate, trypsinized,
and disaggregated onto fresh feeders (Robertson, 1987). The disaggregated ICMs are then
monitored and colonies with the characteristic ES cell morphology are subcloned and grown up.
Once these cells were isolated, they were used to create chimeric animals. This process in
summarized in Figure 6-1.
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Tissues and tissue sections from these animals were then stained with X-gal to identify and
analyze Rb-deficient cells at the single cell level. It should be pointed out that while the ROSA-26
B-galactosidase expression pattern is reported to be ubiquitous (Friedrich and Soriano, 1991),
results obtained in this study suggest that it is not. In addition, subcellular localization of the B-
galactosidase protein differs dramatically between cell types. Work presented in this chapter is
ongoing and will be continued by others in the future.
Materials and Methods
Identification of animals carrying the ROSA-26 transgene
Mice containing the ROSA-26 transgene were identified in one of two ways. One method was to
obtain a small piece of ear tissue with an ear punch and stain it for the presence of B-galactosidase
activity. This was done by first rinsing the tissue in PBS and then placing it in staining solution
(Friedrich and Soriano, 1991) at 37 degrees for 2-8 hours. ROSA26 positive animals were
identified by the ear turning blue in the stain. A second method for identifying ROSA-26 mice is
based on a PCR assay. Tail DNA isolated as described above was assayed in a PCR reaction
using the following primers (ROSA-F=5'-TTTCCACAGCTCGCGGTTG-3' and ROSA-R=5'-
GATCCGCCATGTCACAGA-3'). The conditions of the PCR reaction (except for the primers)
were identical to those described in Chapter 3 and Appendix A for p53 PCR genotyping. It should
be noted that both methods only allow identification of animals carrying the transgene and do not
allow identification of whether the carriers are heterozygous or homozygous carriers of the single
copy transgene.
Derivation of ES cell clones from intercrosses
Animals carrying the desired genotypes (in this case Rb heterozygotes carrying the ROSA-26
transgene were crossed and pregnancy detected by the presence of a vaginal plug. The date of
135
vaginal plug detection is noted as day 0.5. At day 2.5 the female is ovariectomized and injected
with 0.1 ml of 10 mg/ml Depa-Provera; both of which inhibit the implantation of blastocyst into
the uterus (creating delayed implantation blastocysts) (Robertson, 1987). At day 6.5, the females
are sacrificed and the uterine horns flushed with blastocyst media (Robertson, 1987). The
individual delayed blastocysts are then plated onto individual 24 well wells (coated with 0.1%
gelatin) with ES feeders previously plated on them at a density of 1 x 106 cells per well. These ES
feeders were created by deriving murine embryonic fibroblasts (carrying a neomycin resistance
allele) and irradiating them with 6 grays of ionizing radiation. After 3-4 days in culture (in ES
media) the delayed blastocysts have attached to the feeders and the inner cell mass (ICM) has
grown out from the site of attachment. ES media is then removed from the well and replaced with
PBS, after which the ICM is removed from the well with a finely pulled glass pipette or plastic
pipette tip and added to approximately 50 microliters of ES trypsin (Robertson, 1987). After
being placed at 37 degrees for 5-10 minutes the ICM is further disaggregated into single cell
suspension by repeatedly being pulled up and down into a pipette. The suspension is then added to
a fresh gelatinized 24 well well containing ES feeders as before. The wells are then monitored
over the course of the next 10 days and colonies with the appropriate ES cell morphology are
removed from the well in a manner analogous to how the ICM was disaggregated (described
above) and plated onto fresh wells with ES feeders and expanded. Upon expansion, cells were
frozen in liquid nitrogen in ES freezing media (Robertson, 1987). Expanded clones were also
cultured in the absence of ES feeders on gelatinized plates in order to obtain DNA samples for
genotype analysis as described above.
Identification of clones
The status of Rb genotype was initially determined via a PCR assay previously described and
confirmed via Southern blot analysis. ROSA-26 status was determined by a PCR assay using the
following primers and conditions. Determination of the sex of the cell lines was determined via a
PCR based assay with primers directed against the Y specific gene Zfy (Page et al., 1987). The
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presence of a Zfy specific band in the assay was interpreted as the cell line being male while the
absence of the band was interpreted as the cell line being female.
Preparation of ES cells for blastocvst injection
ES cell clones were thawed onto gelatinized plates in the absence of ES feeders. (Wells or plates
were gelatinized by pipetting 0.1% gelatin on them for five minutes and then aspirating off the
gelatin.) After thawing the cells were grown for at least 18 hours in ES media supplemented with
LIF (Robertson, 1987). When blastocysts were ready for injection (see below), the ES cells were
trypsinized, pelleted, and resuspended in blastocyst media (Robertson, 1987) at a concentration of
60,000 to 100,000 cells per ml.
Blastocyst isolation
Blastocysts were isolated from females treated in one of two ways. Naturally mated C57/Bl6J
females (over 7 weeks of age) were mated to males of the same strain. Three days after the
detection of the vaginal plug, the females were sacrificed and blastocysts isolated by removing the
uterus and flushing it with blastocyst media. Blastocysts were also isolated from superovulated
females (Fraser, 1993). For superovulation, 3-6 week old C57/B16J females were injected
intraperitoneally with 5 IU of pregnant mare serum. Forty-eight hours later the females were
intraperitoneally injected with 5 IU of human chorionic gonadotrophin and housed with males of
the same strain. Females were then treated in the same manner as described above after the
detection of the vaginal plug the next morning.
Iniection
Blastocyst injection was performed essentially as previously described (Bradley, 1987). For these
experiments (unless otherwise noted), 8-12 ES cells were injected into each blastocyst.
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Implantation
Implantation was done as previously described (Bradley, 1987). For these experiments between
6-9 blastocysts were implanted into each uterine horn of pseudopregnant Swiss Webster female
mice (Taconic Farms).
Whole mount staining and vibratome sectioning of chimeric tissues
Another method used early in the analysis of these chimeras was to utilize a vibratome to cut fresh
pieces of tissue into thin slices which could then be stained for B-galactosidase activity. In this
method, embryos or tissues were immersed in fix solution (see below) for 30-45 minutes and then
washed three times in wash solution (see below) for 10 minutes per wash. The tissues were then
placed in stain solution (see below) either at room temperature for 15-18 hours or at 4 degrees
Celsius for 24-48 hours. If desired, tissues were then processed for paraffin embedding and
sections cut at 5 microns on a microtome. Sections were then deparaffinized, counterstained with
nuclear fast red or eosin, dehydrated and mounted with coverslips (see Chapter 4). While this
method was useful for some applications, the inability of the X-gal staining solution to penetrate
more than a few microns into the tissue necessitated the use of frozen section staining in the
majority of cases.
Solutions for Lac Z staining (M. Henkemeyer and T. Pawson. personal communication)
Phosphate buffer (pH=7.3)
115 ml 0.1M sodium phosphate monobasic
385 ml 0.1M sodium phosphate dibasic
Fix solution
0.4 ml 25% Gluteraldehyde
2.5 ml 100 mM EGTA (pH=7.3)
0.1 ml 1 M magnesium chloride
47.0 ml Phosphate buffer (pH=7.3)
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Wash buffer
0.4 ml 1 M magnesium chloride
2.0 ml 1% sodium desoxycholate
2.0 ml 2% NP-40
195.6 ml 0.1 M Phosphate buffer (pH=7.3)
Stain solution
2.0 ml 25 mg/ml X-gal dissolved in di-methyl formamide
0.106 g potassium ferrocyanide
0.082 g potassium ferricyanide
48.0 ml Wash buffer
Generation of frozen sections
Pregnant females at various stages of gestation were sacrificed and the embryos removed via
cesarean section and placed into phosphate buffered saline (PBS). A small piece of tissue was
removed from the tail of the embryo and stained in X-gal stain to identify chimeric embryos prior
to cutting frozen sections. The remainder of the embryo was placed in 4% paraformaldehyde at 4
degrees Celsius for 30 minutes. The embryos were then washed in PBS (again at 4 degrees
Celsius) for 30-45 minutes during which time the PBS was changed three times. After this, the
embryos were placed in PBS containing 30% (weight/volume) sucrose at 4 degrees Celsius for at
least 18 hours. The embryos were then prepared for cryostat sectioning by immersing them in
OCT (Tissue-Tek; Elkhart, IN) and then freezing them in a beaker of isopentane immersed in
liquid nitrogen. The embryos in OCT were then attached to a cryostat chuck and frozen sections
were cut at a thickness of 5-10 microns. Prior to X-gal staining the sections were post-fixed in 4%
paraformaldehyde in PBS for five minutes and then washed twice in PBS (5 minutes each time).
Sections were then incubated in X-gal stain solution overnight at room temperature in a dark,
humidified container. X-gal stain was the following: (PBS with 1 mg/ml 4-chloro-5-bromo-3-
indolyl-B-galactoside (X-gal), 4 mM Potassium ferrocyanide, 4 mM Potassium ferricyanide, and
2 mM magnesium chloride). After the staining was completed the sections were washed in PBS
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and then rinsed in distilled water. The sections were then counterstained with nuclear fast red for 5
minutes and then rinsed in distilled water, followed by rinses in increasing grades (80, 90, and
100%) of ethyl alcohol. The slides were then rinsed twice in xylene and coverslips mounted with
Permount (Fisher Scientific).
BrdU staining
Staining for BrdU incorporation was performed as previously described (see Chapter 3). Pregnant
females were injected with 10 microliters per gram body weight of BrdU/FdU solution (3 mg/ml
BrdU; 0.3 mg/ml FdU in PBS) one hour prior to sacrifice. Embryos were then recovered and
processed either for frozen or paraffin sections. Paraffin embedded sections were analyzed for the
incorporation of BrdU as described while frozen sections were treated similarly except that
deparaffinization and rehydration steps were not required.
Results
Derivation of Rb-deficient ROSA-26 ES cells
17 females were ovariectomized and 56 blastocysts recovered from them. From these 56
blastocysts, 16 independent ES cell clones were established. Of these 16, 3 clones were
determined to be Rb-/- and contain the ROSA-26 transgene. All three were also male. Two of
these lines (ES2 and ES4) were used to create chimeric animals. Both lines allowed creation of
good chimeras and analysis of these chimeras showed that they were phenotypically
indistinguishable. In addition to these two lines, a Rb+/-;ROSA-26 positive male ES cell line
(ES6) was also successfully used to create chimeras. Test breeding of these chimeras showed that
they were capable of passing the ES cell genome through the germline with high frequency. Also,
a line of wild-type male ES cells carrying the ROSA-26 transgene was used to create chimeric
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animals. This cell line (BS 1) was derived and characterized with Shane Shih in the process of
similar experiments he was performing to study Nf-1 gene function (Jacks et al., 1994).
Analysis of Chimeric Embryos
Examination of X-gal stained frozen sections from embryos (both control and wild-type chimeras)
confirmed that Rb-deficient cells could contribute to most cell lineages. One limitation to the
analysis is that the ROSA-26 transgene does not appear to be expressed in enucleated red blood
cells when examined with these methods, despite the fact that previous FACS analysis had
suggested that it was expressed ubiquitously through all stages of hematopoietic development.
Examination of livers from days 12.5 to 14.5 showed that Rb-deficient (X-gal staining) fetal
hepatocytes, stromal fibroblasts, and erythroid progenitors were present and appeared normal.
One obvious difference between Rb-DKO and wild-type ES cell derived chimeras was that the
fact that Rb-DKO chimeras exhibited highly elevated levels of megakaryocytes in their fetal livers
(Figure 6-2). The vast majority of these megakaryocytes stained positive for X-gal indicating that
Rb-deficiency in the liver may cause a cell autonomous defect at least at one level. Livers from
these chimeras have also been utilized in a collaboration with Kay Macleod to successfully rescue
the hematopoietic systems of lethally-irradiated adult animals. Analysis of these rescued animals
is ongoing.
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Figure 6-2
Analysis of 13.5 day fetal liver
(Top) Hematoxylin and eosin stained section of a fetal liver from a Rb-DKO chimera showing the
presence of megakaryocytes (arrows).
(Bottom) X-gal stained section of another Rb-DKO chimera fetal liver illustrating that
megakaryocytes are X-gal positive.
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One other obvious Rb-associated defect to analyze in the context of these chimeras was
neurogenesis. As discussed previously, Rb-deficient embryos have a high degree of ectopic
proliferation (measured by BrdU incorporation) associated with cell death in the central and
peripheral nervous system. X-gal staining analysis of Rb-deficient chimeric embryos clearly
shows the presence of normal appearing Rb-deficient cells in all parts of the central and peripheral
nervous system (Figure 6-3 and data not shown). Cell staining in the forebrain and midbrain
showed X-gal staining throughout the cytoplasm of the cell, while staining in the hindbrain, spinal
cord, dorsal root ganglion, and trigeminal ganglion was localized to specific sites in the cytoplasm.
This localization difference was also seen in chimeras derived from wild-type ES cells.
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Analysis of Rb-DKO fetal chimera central nervous system
X-gal stained sections of forebrain (top), midbrain (middle), and hindbrain (bottom) clearly
showing the presence of Rb-deficient cells.
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Several litters of chimeric animals were exposed to BrdU for one hour prior to their isolation. In
order to assess whether Rb-deficient neurons are still proliferating abnormally in the context of a
chimeras a collaborative effort between Kay Macleod and I to more fully characterize the
differences between Rb-deficient neurons in chimeras and germline Rb-deficient animals is
ongoing. This analysis will focus on the analysis of cell proliferation, apoptosis, and examination
of expression of potential Rb targets. Preliminary analysis has revealed that neurons in the
chimeras exhibit a cell autonomous defect in that in situ hybridization analysis reveals highly
elevated levels of Cyclin E mRNA expression. Expression analysis of other relevant genes is
ongoing.
Analysis of Adult Chimeric Tissues
Staining patterns of representative adult tissues are discussed below.
Adrenal
As noted by the relatively high contribution of Rb-deficient cells (as measured by the GPI assay),
Rb-deficient cells contributed significantly to both the cortex and the medulla. Staining in the
cortex was of a speckled nature, while staining in the medulla was more punctate. Significantly,
the pheochromocytomas present in Rb-DKO chimeras appear to be exclusively comprised of Rb-
deficient cells. Areas of medulla which appear normal have contribution of both X-gal positive
and negative cells. These date indicate that Rb-deficiency is necessary, but not sufficient, for the
induction of pheochromocytomas.
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Adrenal X-gal staining in adult Rb-DKO chimeras
(Top) Hematoxylin and eosin stained section of adrenal gland showing normal cortex (C), normal
medullary tissue (n), and adrenal medullary hyperplasia (arrows).
(Bottom) X-gal staining of the same adrenal gland shown above (note that these are not adjacent
sections). Areas of adrenal medullary hyperplasia are composed of all X-gal positive (and thus
Rb-deficient cells) while normal medullary tissue is a mixture of X-gal positive and negative cells.
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Cerebellum
Analysis of Rb-DKO chimeras showed that X-gal positive staining was mainly restricted to
cells of the Purkinje cell lineage. No X-gal positive cells could be found in the granular cell
layer. X-gal positive Purkinje cells always appeared to be enlarged and some were
ectopically placed, while X-gal negative cells always appeared to be normal in terms of
placement and size. These data illustrate that the Purkinje cell defect in Rb-DKO chimeras
is probably due to a cell autonomous defect caused by Rb-deficiency (Figure 6-5E and F).
Choroid plexus epithelium
Rb-DKO chimeras exhibited high levels of contribution to choroid plexus epithelium. X-
gal positive cells displayed strong staining uniformly through the cell (Figure 6-5A and B).
Liver
Staining of hepatocytes showed contribution to this lineage. Staining was uniform
throughout the cytoplasm, but not present in the nucleus (Figure 6-6D).
Lung
Strong contribution of Rb-DKO cells was noted in the bronchial epithelium with staining
uniform throughout the cytoplasm of the cell. X-gal positive cells were also noted in the
alveolar sacs, although staining was less intense relative to the bronchial epithelium (Figure
6-6A). Interestingly, lung tissues stained via the whole mount or vibratome method stained
positive with X-gal but those processed for frozen sections did not.
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Retina
Very low contribution of Rb-deficient cells was noted in the retina. Rare X-gal positive
ganglion cells were present (Figure 6-6C). Analysis of retinas isolated from chimeras
derived from wild-type ES cells is ongoing.
Lens
Because of the disorganized lens structure associated with cataracts, it was difficult to
identify individual cells staining positive for X-gal. However, obvious positive activity
was observed in cellular debris in the lens (Figure 6-5C).
Cartilage
Both cartilage in the tracheae and in other parts of the body showed good levels of Rb-
deficient (X-gal positive) cells (Figure 6-6E).
Skeletal muscle
Strong positive staining of skeletal muscle was noted with staining present throughout the
cytoplasm of individual muscle fibers (Figure 6-6B). Again, like the lung tissue, staining
worked for the whole mount/vibratome method but not with frozen sections.
Cerebrum
Staining of individual cells in the cerebrum was noted (Figure 6-5D).
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Kidney
Staining of kidney tubules was evident (data not shown).
Prostate
Strong staining of prostate epithelium was noted when the whole mount method of staining was
used (data not shown).
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Figure 6-5
Representative X-gal staining of tissues from chimeras derived from ES2 and ES4 injected
blastocysts
A and B. Choroid plexus epithelium (100X). Note the strong staining throughout the cytoplasm.
C. Chimeric lens. A obvious cataract (C) is present. Positive staining is seen in the cellular debris
within the lens capsule.
D. Cerebrum. Staining of cells within the cerebrum of a 4 month old chimeric animal.
E and F. Staining of cerebellum of chimera. Low power view in E (40X) and high power view in
F (100X). Granular cell layer (g), molecular layer (m), and Purkinje cell layer (p) are noted. Note
in F that several large Purkinje cells including an ectopically placed one (arrow) are Rb-deficient.
The lack of staining in the granular layer can not be ascribed to a phenotype associated with Rb-
deficiency as no staining is seen in granular cells from control mice.
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Representative X-gal staining of tissues from chimeras derived from ES2 and ES4 injected
blastocysts
A. High power view (100X) of lung. Note the obvious presence of large numbers of positively
staining cells in the bronchial epithelium (surrounding the lumen of the large bronchiole). An
arrow notes an Rb-deficient cell in the alveolar spaces.
B. Skeletal muscle (10OX)
C. Retina (100X). Positively staining cells in the ganglion layer are present.
D. Liver (10OX)
E. Tracheae (40X)
F. Testis (100X)
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Discussion
The development of the ROSA chimera system for the analysis of chimeric tissues has allowed us
to begin to address the issues raised by the initial chimeric analysis (see Chapter 5) in more detail.
The ability to mark individual cells within the fetal liver and the nervous system of the chimeras
should go a long way towards understanding the cell autonomous defects seen in both tissues in
Rb-deficient embryos.
Cell autonomous phenotypes in adult chimeras
The use of these ES cells has allowed us to address whether some of the effects previously noted
in the chimeric adults were due to cell autonomous effects of Rb-deficiency. In the case of the
Purkinje cell defect, the analysis supports the conclusion that Rb-deficiency is associated with the
Purkinje cell defect as all abnormal Purkinje cells noted did stain positive for X-gal. In addition,
the analysis of adrenal medullary hyperplasia shows that this pathology is associated with Rb-
deficiency.
Non-cell autonomous phenotypes
The work presented here also reinforces the concept that both the hematopoietic and neurological
defects associated with Rb-deficiency can be rescued in the context of wild-type cells in the
developing chimera. Interestingly, in the case of the developing nervous system discussed above,
Rb-deficient neurons in chimeras still have altered states of gene expression but are present in
significant numbers without the highly elevated levels of neuronal cell death seen in embryos
homozygous for a germline mutation in the gene. Understanding the basis for this difference
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between Rb-deficient cells in the constitutionally homozygous mutant embryos and the chimeras
will be one of the greatest challenges to emerge from this work.
Other uses of chimeras
The characterization of chimeras derived from these cells has allowed us to extend our previous
observations (see Chapter 5). Perhaps more importantly, it has allowed us to further develop the
chimera system as one which can used to test models of Rb function as well as derived and
identify unique reagents to perform in vitro experiments.
One of the best examples of such work is a collaboration with Hong Yang, a graduate student in
the laboratory of David Livingston at the Dana Farber Cancer Institute. Based on earlier reported
work that expression of a wild-type human RB gene can rescue the embryonic lethality seen in Rb-
deficient mice, Hong has taken the Rb-deficient cell lines described above (ES2 and ES4) and
electroporated different versions of a human RB cDNA minigene (expressed behind a human RB
promoter) into them. Clones which demonstrate expression of the introduced RB gene are then
used to create chimeric animals. These chimeras are then analyzed for the defects seen in Rb-
DKO chimeras (cataracts, pituitary tumors, adrenal medullary hyperplasia, etc.). This system
allows an examination of the functions of different domains in pRB in a physiologically relevant
setting.
In addition analysis of Rb-deficient cells in the context of the chimeras, these animals have
provided valuable reagents for study of Rb function in tissue culture. One example of this is work
being performed by Mark Day (Univ. of Michigan) and Gerald Cunha (UCSF). Initial analysis
showed that Rb-deficient cells were capable of contributing to the prostate epithelium of adult
chimeras (data not shown). Animals I provided were used as a source for Rb-deficient prostate
epithelial cells which can be grown in vitro and used to examine the role of Rb in the control of
prostate growth and differentiation. Along these same lines, I have provided mice to Oliver
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Bogler, a post-doctoral fellow in Webster Cavenee's lab from which Rb-deficient astrocytes have
been isolated and will be characterized.
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CHAPTER 7
Generation of ES Cells Deficient for Both Rb and p53
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In order to further evaluate the role of Rb and p53 in tumorigenesis, ES cells deficient in both Rb
and p53 were derived. The generation of chimeras from these ES cells is ongoing and will
continue after I graduate.
The generation of these ES cells was considerably more challenging than the derivation of other
ES cell lines due to several factors. The most straightforward manner to isolate these ES cells is to
generate them from Rb+/-;p53-/- crosses. The most limiting factor was that Rb+/-;p53-/- animals
are difficult to generate and maintain. As discussed in Chapter 3, Rb+/-;p53-/- animals die in the
first six months of life from the affects of several tumors. Those animals which do breed are often
adversely affected by the presence of these tumors, diminishing their reproductive performance.
In addition, females which do breed and are used for the ES cell generation procedure often are not
in good enough physical shape to survive the necessary surgical procedures.
Despite the difficulties outlined, I was able to generate one ES cell line which was deficient for
both Rb and p53. Unfortunately, this cell line did not carry the ROSA-26 transgene and
furthermore did not carry the agouti allele, which necessitates Southern blot analysis to identify
chimeric progeny. Chimera generation from this cell line has been initiated.
In an attempt to bypass the difficulties associated with the generation of ES cell lines in the manner
described in Chapter 4, I also tried to generate Rb-/-;p53-/- ROSA-26 containing ES cells through
manipulation of cells in culture. Cell lines ES2 and ES4 (both Rb-deficient and carrying the
ROSA-26 transgene) were electroporated with the targeting vector p53 Hygro KO. This vector is
similar to the one described in Appendix A which used to create p53-deficient mice except that it
contains a hygromycin resistance gene in place of a neomycin resistance gene. This was necessary
because the ES2 cells were already resistant to G418 and another selectable marker was needed to
identify successfully electroporated clones. These electroporated cells were then selected in media
containing hygromycin and gancyclovir and subsequently analyzed to identify clones with a
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homologously targeted p53 allele. These successfully targeted clones were then subjected to
selection in high concentrations of hygromycin to attempt to induce gene conversion of the
remaining p53 wild-type allele to the mutated allele. This would presumably double the
concentration of the hygromycin resistance gene in the cells and allow for survival in higher
hygromycin concentrations. Such protocols have been used to induce gene conversion with
neomycin resistance genes, but have not been reported for hygromycin. Preliminary experiments
done on the p53 heterozygously targeted cells described above have failed to yield clones with the
desired gene conversion event. Nevertheless, these cells should be valuable in generating Rb-/-
;p53-/- ROSA-26 containing ES cells either by further examining the possibility of inducing gene
conversion with increased concentrations of hygromycin or by retargeting the remaining wild-type
allele of p53 with a puromycin resistance gene based vector.
Materials and Methods
Most methods used in the isolation of ES cells deficient for both Rb and p53 are identical to those
described above. Those not previously described follow.
Electroporation of Rb-I- ES cells with p53 hvrro targeting vector
ES cells were electroporated as described previously. The p53 targeting vector was prepared
similarly to that described in Appendix A except that the hygromycin resistance gene was
substituted for the neomycin resistance gene. 36 hours after the electroporation, cells were
exposed to hygromycin (0.125 ug/ml) and gancyclovir (2 micromolar) for 7 days. Forty-eight
hours after selection was stopped, individual colonies were picked and trypsinized and expanded
on ES cell feeders. When colonies had grown to sufficient numbers, a portion were frozen while
the remainder were used to isolate DNA to screen for homologous recombinants. Clones were
screened for homologous recombinants in the same manner as described in Appendix A.
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Selection in presence of higher hygromycin concentrations
The two clones identified as having a homologous recombination event in the p53 allele were
plated on 10 cm gelatinized plates (1.0 x 104 cells were plated on each plate). After 36 hours
individual plates were exposed to ES media with the following concentrations of hygromycin (in
ug/ml): 0, 0.5, 1.0, 1.5, and 2.0. Selection conditions were maintained for 7 days after which
individual clones were isolated and Southern blot analysis done as described above. In some
cases, p53 PCR analysis was performed to assess the genotype of ES cell clones.
Results
Of 17 females which survived the ovariectomization procedure, 45 blastocysts were recovered and
5 ES cell lines derived from them. The one Rb-/-;p53-/- ES cell derived (2-17 #1) was used to
generate chimeric animals as described above. The analysis of offspring derived from blastocyst
injections with these ES cells is more complicated than others, due to the fact that the ES cells are
homozygous for the C57B1/6 agouti locus and do not carry the ROSA-26 transgene. In the first
round of analysis of the potential of these ES cells to generate chimeric animals, 20 blastocysts
were injected and implanted (along with 10 uninjected carrier blastocysts). 10 animals were born
as a result and were examined for chimerism by Southern blot for the presence of the Rb-mutant
allele. None of the 10 were found to be chimeric. Further rounds of injections are ongoing.
Initial retargeting of ES2 ES cells
One hundred seventy clones were isolated from the electroporation of ES2 cells with the p53
hygro KO vector. Southern blot screening revealed that two of the first 16 clones analyzed
contained the desired homologous recombination event. These clones were labeled 2-19 #17 and
2-19 #18.
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Selection of clones in increased hygromycin concentrations
The number of colonies remaining on each plate after selection is shown below. Ten thousand
cells were initially plated on each plate.
Table 7-1. Selection of ES cells in increased hyvromvci,, concentrations
Clone 2-19 #17
Hygromycin concentration
0 mg/ml
0
0.5
1.0
1.5
2.0
# Colonies
422
450
398
216
149
25
Clone 2-19 #18
Hygromycin concentration
0 mg/ml
0
0.5
1.0
1.5
2.0
# Colonies
484
508
452
396
230
24
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Southern blot and PCR analysis revealed that none of the colonies examined (including all 48
which survived the 2.0 ug/ml selection had undergone the desired gene conversion.
Discussion
In order to better understand the cooperative effects between Rb and p53 mutations in murine
carcinogenesis, I have derived ES cells deficient in both genes. These cells are now being used to
generate chimeric animals for analysis. Several potential experiments can be performed with these
cells to enhance our understanding of the functions of both genes. One obvious line of inquiry is
to examine adult chimeric animals for tumorigenesis in the tissues where Rb+/-;p53-/- exhibit
tumors or pathological abnormalities (pineal gland, islet cells of the pancreas, bronchial epithelium,
retina).
I have also made progress towards the generation of a cell line which is deficient for both Rb and
p53 and carries the ROSA-26 transgene (Friedrich and Soriano, 1991). As described in the results
section of this chapter, Rb-deficient ROSA-26 containing cells have been generated which are
heterozygous for a p53 targeted mutation. Initial attempts to generate p53-deficient cells from
these clones by growing them in the presence of increased concentrations of hygromycin have
been unsuccessful. Several reports of generating ES cells deficient for a particular gene have been
described for selecting for gene conversion events resulting in doubling the number of genomic
copies of the neomycin resistance gene (Mortensen et al., 1992), but none so far for the
hygromycin resistance gene. This could be due to the different activities of the two antibiotics.
Selection of cells in the presence of even higher amounts of hygromycin may allow for the
isolation of the desired cells. An even more efficient way to generate these cells may be to
electroporate the p53 heterozygous cells with a p53 targeting vector carrying a puromycin
resistance gene.
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Once Rb-/-;p53-/- ROSA-26 containing ES cells have been generated they can be used to analyze
contribution to tissues on a cellular basis. A comparison of the contribution of these cells to
tissues relative to Rb-deficient ROSA-26 cells alone may yield important insights into how Rb-
deficient cells are eliminated by p53-dependent apoptosis in different tissues.
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CHAPTER 8
Summary And Implications
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As discussed in Chapter 2, a great deal is known about how pRB acts in tissue culture. In
addition, many studies have implicated loss of function mutations in RB with the development of
human cancer. Despite this large collection of data, until recently relatively little was known about
the normal role of Rb in development. In Chapter 2, the development of techniques which made
the creation of mice with germline mutations in Rb possible was reviewed. This has allowed
several researchers, including myself, to begin to address the physiological role of Rb (Clarke et
al., 1992; Jacks et al., 1992; Lee et al., 1992).
The role of Rb in development
The creation of Rb-deficient mouse strains unexpectedly revealed that Rb was not necessary for
murine development up to day 13.5 of gestation. This was surprising based on the fact that Rb
appears to be an important regulator of cell cycle control in almost all cells examined. In addition,
higher vertebrates have evolved a complex regulatory network to control the activity of the Rb
protein through its phosphorylation status (see Figure 2-3). In the case of the INK4/Cyclin D/cdk4
or 6 network, it appears that the only important target relative to cell cycle control may be the Rb
protein (Guan et al., 1994; Hirai et al., 1995; Lukas et al., 1994; Lukas et al., 1995; Medema et al.,
1995). How then do mice completely deficient for Rb function progress to such an advanced
developmental state? While answering this question has not been the main focus of this work, data
presented in Appendices C and E address this question. It appears, at least at some level, that the
related Rb-family proteins p107 and p130 may play a role in allowing Rb-deficient embryos to
progress to 13.5 days of development. The generation of animals deficient for both Rb and p1 0 7
(Appendix C) as well as animals deficient for both Rb and p130 (G. Mulligan and Tyler Jacks,
unpublished) has shown that they fail in development earlier than Rb-deficient animals alone,
while animals deficient for either p107 or p130 fail to show any significant developmental
abnormalities (Cobrinik et al., 1996). A rigorous assessment of the molecular basis for this
observation will need to be performed to prove there is functional compensation during
development for loss of Rb-function.
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Another related question would be how well animals with an impaired ability to inactivate pRb
progress through development. Perhaps the constitutive expression of members of the INK4
family members or the creation of mice deficient in all three cyclin D genes would block
development early in gestation. Such experiments may reveal that while the lack of Rb function is
not compatible with late stages of development, the ability to properly inactivate pRb is required at
a very early stage.
While the analysis of Rb-deficient mice reveals developmental requirements for Rb in
hematopoiesis and neurogenesis, mutations in the genes whose products have been shown to
regulate pRB suggest that pRB control is important for the normal development of other tissues.
As previously discussed, D type cyclins and the INK4 family of kinase inhibitors (which
specifically inhibit the actions of D type cyclin-associated cdks) appear to regulate the cell cycle
exclusively through their control of pRB (or perhaps pRB-family protein) phosphorylation status.
Thus, any defects noted in mice with targeted mutations in these genes may reflect a
developmental requirement for proper pRB regulation. The phenotypes of mice deficient for cyclin
Dl were reviewed in Chapter 2. Briefly, Cyclin DI-deficient mice fail to thrive neonatally and
exhibit defects in retinal differentiation and mammary development (Sicinsky et al., 1995). The
creation of mice deficient for the INK4 protein pl 6MTS 1 has also been reported (Serrano et al.,
1996). These mice are developmentally normal but are susceptible to the development of
sarcomas and lymphomas.
In addition to these mutations in the afferent pathway, mice with targeted gene disruptions in
effectors downstream of pRB activity are beginning to be created and analyzed. The first example
of such is the creation of mice deficient for the E2F-1 gene (Field et al., 1996; Yamasaki et al.,
1996). Since E2F-1 activity is thought to be regulated by its binding to pRB (and not by
association with p107 or p130) defects noted in these mice may suggest additional roles for Rb in
development. The analysis of these mice revealed that loss of E2F-1 resulted in tissue atrophy in
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some cases. Such a phenotype would be expected based on the idea that E2F-1 was an oncogene.
However, the analysis also revealed that E2F-1 had properties consistent with it acting as a tumor
suppressor gene in some tissues. Perhaps this should change how we view the relevance of the
E2F interaction with pRB. The interpretation of the interaction has mainly been that pRB simply
inhibited the activity of E2F until pRB was phosphorylated. The release of free E2F would then
drive cells into the cell cycle. This data along with several other reports (Weintraub et al., 1995;
Weintraub et al., 1992) suggests that E2F facilitates pRB-associated promoter repression. Thus,
the interaction between pRB and E2F-1 has regulatory significance for both members of the
complex. Whether this model is also operative with other E2F:pRB family member interactions
remains to be determined.
The availability of mouse strains with mutations in many of the relevant regulatory and effector
genes of the pRB, p107, and p130 pathways should allow significant insight into these and other
questions in the future. The generation of mice with mutations in other INK4, cyclin, and E2F
genes will undoubtedly follow.
The role of Rb in tumor suppression
The major focus of my work has been on using the Rb-deficient mice to gain a better
understanding of the role of Rb in tumor suppression. The tumor predisposition of Rb
heterozygous mice and children constitutionally heterozygous for an RB mutation, while different
(discussed below), is in both cases relatively limited. This despite the fact that, at least in humans,
RB mutations have been observed in many sporadically occurring tumors and alterations in either
Rb (reviewed in Chapter 2) or the Rb regulatory pathway (p 16, Cyclin D, cdk4) have been
estimated to occur in 80-90% of human tumors (Ed Harlow, personal communication). Why are
constitutionally heterozygous mice only predisposed to pituitary and thyroid tumors and humans
only retinoblastoma and osteosarcoma?
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One possible explanation for this could have simply been that in most tissues a very small window
of time exists during which loss of the wild type allele of Rb would initiate the process of
tumorigenesis. Loss of Rb function during any other time would not result in a growth advantage
for cells in those tissues. To address this question, we created chimeric mice whose adult tissues
were composed of significant numbers of Rb-deficient cells (Chapter 5). While these animals
lived only to the age of 5 months, they did not exhibit widespread tumorigenesis. The only
noticeable neoplasia observed besides intermediate lobe pituitary tumors was in the adrenal
medulla, where hyperplastic growths histologically similar to pheochromocytomas were seen.
This implies that a small temporal frame in which loss of Rb function would induce tumorigenesis
could not explain the limited tumor spectrum in constitutionally heterozygous mice.
Another explanation for the limited tumorigenesis seen in Rb heterozygous mice was that an
accumulation of other mutations was necessary to uncover a carcinogenic predisposition of Rb-
deficient tissues. The work presented in Chapter 4 shows this to be the case in some instances.
The observed cooperativity between Rb and p53 mutations in murine tumorigenesis and the
mechanism of suppression of tumors of Rb-deficient cells by p53 has very important implications
in human tumors. This is reinforced by the effectiveness of treatment strategies for Rb-deficient
tumors. Retinoblastomas, which retain wild-type p53 activity (S. Friend, personal
communication), are among the most highly treatable malignancy known (Dryja, 1989). Survival
rates of this tumor range up to 95% (S. Mukai, personal communication). Unfortunately,
retinoblastoma may be the exception rather than the rule when it comes to the treatment of Rb
deficient tumors. Almost every other tumor type in humans which has been associated with Rb
deficiency also has been associated with p53 deficiency (see Chapter 4). It may be that p53-
deficiency is a necessary corequisite for tumorigenesis in Rb-deficient cells in the majority of
tissues. As p53 deficiency has been associated with a poor prognosis in terms of response to
treatment in many human tumors (Bardeesy et al., 1994; Horio et al., 1993; Lowe et al., 1994a;
Lowe et al., 1994b; Thorlacius et al., 1993), it may explain why many of the sporadic cancers
associated with Rb deficiency (for example pancreatic, breast, and lung) respond very poorly to
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treatment for example see. The fact that genetic alterations compromising the Rb pathway have
been estimated to occur in 80-90% of human tumors (Ed Harlow, personal communication) and
p53-deficiency has been implicated in over 50% of human tumors (Greenblatt et al., 1994)
reinforces the importance of understanding the cooperative tumorigenesis observed in more detail.
One could envision one day that a highly effective treatment strategy for Rb-deficient tumors
would be to reintroduce p53 function (after p53 functions are better understood) since Rb-
deficiency has been shown to result in p53-dependent apoptosis in several contexts.
A question which stems from the observation of cooperative tumorigenesis between Rb and p53
and the suggestion that Rb-deficiency can result in p53-dependent apoptosis in some tissues is
what is p53 sensing that causes it to induce apoptosis. Several observations must be considered
when assessing this question. One is that Rb-deficiency alone is clearly not the signal for the
apoptotic induction. Many cell types in the Rb-deficient embryos and in the Rb-DKO chimeras
are not susceptible to apoptosis (although this observation in the chimeras is complicated by
potential non-cell autonomous effects from the presence of wild-type cells). In addition, work in
the Rb-DKO chimeras clearly shows that some of the defects seen in Rb-deficient embryos can be
rescued by the presence of wild-type cells. Finally, not all forms of apoptosis associated with Rb
-deficiency are dependent on p53. Examples of this include p53-independent apoptosis in 16.5
day lens fiber cells expressing E7 and the fact that the cell death in the dorsal root ganglia of Rb-
deficient embryos is still observed in embryos deficient for both Rb and p53 (Macleod et al.,
1996). Interestingly, death in the central nervous system of Rb-deficient embryos is p53-
dependent (Macleod et al., 1996).
Work on several Rb-deficient cell types suggests that most, if not all Rb-deficient cells, have
intrinsic alterations in their cell cycle machinery that can be observed under specific circumstances.
For example, Rb-deficient fibroblasts grown in tissue culture and neurons in Rb-deficient embryos
and Rb-DKO chimeras express constitutively high levels of cyclin E and p21 (Herrera et al., 1996
and Chapter 6). Furthermore, fibroblasts induced to differentiate into myotubes by the
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introduction of myoD can be stimulated to reenter the cell cycle by exposure to high levels of
serum (Novitch et al., 1996; Schneider et al., 1994). This phenomenon is not seen in wild-type
fibroblasts and suggests that some component of the cell cycle machinery involved in maintaining
or inducing terminal differentiation is abnormal.
A model which can be invoked to explain the fact that Rb-deficiency does not lead to apoptosis in
more cell types despite the fact that most may be intrinsically abnormal is that a second signal
must be present (or absent). One of the best candidates for such a signal would be a survival
factor secreted into the cellular environment. The corequirement for the absence of a survival
factor with Rb-deficiency for apoptotic induction could explain why apoptosis in several Rb-
deficient embryonic cell types appears to inhibited when these cells are present with wild-type cells
in the Rb-DKO chimeras. Such a factor could underlie the observed non-cell autonomous
phenotypes seen in Rb-deficient embryos.
Other reflections on this work
What other important (more general) observations have come out of the research described here?
One aspect reinforced by my work can simply be stated that a mouse is not a human being. While
that may sound relatively obvious, too often those of us in the mouse "knock-out" field lose track
of that point. Because of the incredibly conserved nature of signaling pathways throughout
phylogeny, many of us expected that just because the signaling pathways were conserved they
were effecting the same endpoint in all organisms. While some murine models of tumor
suppressor gene mutations and other gene mutations have similar phenotypes to their human
counterparts (for example Apc (Dove et al., 1994; Moser et al., 1990) and p53 (see Appendix A)),
many others do not. Rb-deficient mice do not develop retinoblastoma. p16-deficient mice do not
develop melanoma (Serrano et al., 1996). Nf-1 heterozygous mice are not susceptible to
neurofibromatosis (Jacks et al., 1994). This is the case with many other gene knockouts (see
Table 2-1). Perhaps some aspects of the artificially controlled laboratory environment are part of
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the explanation, but they are unlikely to explain everything. Understanding these species-specific
differences will be important in improving the use of these mice to model the human condition
associated with deficiencies in these genes and may even enable us to gain further insight into the
molecular roles of these genes in cell growth control.
Finally, this work has pointed out another obvious observation overlooked by many in the mouse
field which is that cells within an organism are in most cases not isolated entities. Perhaps because
molecular biology is so reductionist in its nature, many of us expect that when we create mice
deficient for a particular gene that we will find a very clean, easily studied phenotype in these mice.
In the case of Rb this is clearly not the case. The work presented in Chapter 5 and 6 clearly
illustrates that many aspects of the Rb-deficient phenotype result from non-cell autonomous
defects or at least can be rescued by the presence of wild type cells in the context of a chimera.
Specific cells may have paracrine, autocrine, and endocrine functions and a defect in a particular
cell type may create several secondary defects. Future work on the Rb-deficient mice and the Rb-
DKO chimeras will undoubtedly shed light on the relevant cellular interactions and secreted
factors. This will have important implications in better understanding development and even
tumorigenesis in general.
173
Literature Cited
Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P,
Shows T and Pelletier J. (1994). Anaplastic Wilms' tumour, a subtype displaying poor prognosis,
harbors p53 gene mutations. Nat Genet. 7: 91-97.
Clarke AR, Maandag ER, van Roon M, van der Lugt NMT, van der Valk M, Hooper ML, Berns
A and te Riele H. (1992). Requirement for a functional Rb-1 gene in murine development. Nature.
359: 328-330.
Cobrinik D, Lee M-H, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D,
Weinberg RA and Jacks T. (1996). Shared role of the pRB-related p130 and p 107 proteins in limb
development. Genes Dev. in press.
Dove WF, Luongo C, Connelly CS, Gould KA, Shoemaker AR, Moser AR and R.L. Gardner.
(1994). The adenomatous polyposis coli gene of the mouse in development and neoplasia. Cold
Spring Harb Symp Quant Biol. 59: 501-508.
Dryja TP. (1989). Genetics of retinoblastoma. Curr Opin Pediatrics. 1: 413-420.
Field S, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, Orkin SH and Greenberg
ME. (1996). E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 85:
549-561.
Greenblatt MS, Bennett WP, Hollstein M and Harris CC. (1994). Mutations in the p53 tumor
suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG and Xiong Y.
(1994). Growth suppression by p18, a p 16INK4/MTS 1- and p 14INK4B/MTS2-related CDK6
inhibitor, correlates with wild-type Rb function. Genes Dev. 8: 2939-2952.
Herrera RE, Sah VP, Williams BO, Weinberg RA and Jacks T. (1996). Altered cell cycle kinetics
and gene expression in Rb-deficient fibroblasts. Mol Cell Biol. 16 (5): 2402-2406.
Hirai H, Roussel MF, Kato J-Y, Ashmun RA and Sherr CJ. (1995). Novel INK4 proteins, p19
and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell
Biol. 15: 2672-2681.
Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K,
Nakamura Y, Ueda R and al. e. (1993). Prognostic significance of p53 mutations and 3p deletions
in primary resected non-small lung cancer. Cancer Res. 53: 1-4.
Jacks T, Fazeli A, Schmidt E, Bronson R, Goodell M and Weinberg R. (1992). Effects of an Rb
mutation in the mouse. Nature. 359: 295-300.
Jacks T, Shih TS, Schmitt EM, Bronson RD, Bernards A and Weinberg RA. (1994).
Tumourigenic and developmental consequences of a targeted Nfl mutation in the mouse. Nat
Genet. 7: 353-361.
174
Lee EY-HP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, Herrup K and Lee W-H. (1992). Mice
deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature. 359:
288-295.
Lowe SW, Bodis S, Bardeesy N, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T,
Pelletier J and Housman DE. (1994a). Apoptosis and the prognostic significance of p53 mutation.
Cold Spring Harb Symp Quant Biol. 59: 419-426.
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and
Jacks T. (1994b). p53 status and the efficacy of cancer therapy in vivo. Science. 266: 807-810.
Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Durr P, Strauss M and Bartek
J. (1994). DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to
relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol. 125: 625-638.
Lukas J, Parry D, Aagard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J. (1995).
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature. 375:
503-506.
Macleod K, Hu Y, and Jacks T. (1996). Loss of Rb activity activates both p53-dependent and
independent cell death pathways in the developing mouse nervous system. EMBO J. in press.
Medema RH, Herrera RE, Lam F and Weinberg RA. (1995). Growth suppression by p16INK4
requires functional retinoblastoma protein. Proc Natl Acad Sci USA. 92: 6289-6293.
Moser AR, Pitot HC and Dove WF. (1990). A dominant mutation that predisposes to multiple
intestinal neoplasia in the mouse. Science. 247: 322-324.
Novitch BG, Mulligan GJ, Jacks T and Lassar AB. (1996). Skeletal muscle cells lacking the
retinoblastoma protein display defects in muscle gene expression and accumulate in S phase.
submitted.
Schneider JW, Gu W, Zhu L, Mahdavi V and Nadal-Ginard B. (1994). Reversal of terminal
differentiation mediated by p107 in Rb-/- muscle cells. Science. 264: 1467-1471.
Serrano M, Lee H-W, Chin L, Cordon-Cardi C, Beach D and DePinho RA. (1996). Role of the
INK4a locus in tumor suppression and cell mortality. Cell. 85: 27-37.
Sicinsky P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge
SJ and Weinberg RA. (1995). Cyclin D1 provides a link between development and oncogenesis in
the retina and breast. Cell. 82: 621-630.
Thorlacius S, Borresen AL and Eyfjord JE. (1993). Somatic p53 mutations in human breast
carcinomas in an Icelandic population: a prognostic factor. Cancer Res. 53: 1637-1641.
Weintraub SJ, Chow KNB, Luo RX, Zhang SH, He S and Dean DC. (1995). Mechanism of
active transcriptional repression by the retinoblastoma protein. Nature. 375: 812-815.
Weintraub SJ, Prater CA and Dean DC. (1992). Retinoblastoma protein switches the E2F site
from positive to negative element. Nature. 358: 259-261.
175
Yamasaki L, Bronson RT, Jacks T, Dyson N and Harlow E. (1996). Tumor induction and tissue
atrophy in mice lacking E2F-1. Cell. 85: 537-548.
176
APPENDIX A
Analysis of the Effects of p53-Deficiency on Murine Tumorigenesis and Development
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Notes of Attribution
The murine strains described in this work were created by Tyler Jacks, with assistance from
Earlene Schmitt and Schlomit Halachmi, while he was a post-doctoral fellow in the Weinberg
laboratory. Lee Remington and I performed all the necropsies of affected p53-mutant animals.
Lee performed the majority of the Southern blot analysis, while I analyzed all the resulting
pathology slides with Rod Bronson at Tufts University. The initial analysis of exencephaly
(incidence and pathology) in this strain was performed by Valerie (Tan) Sah, an undergraduate
whose research I supervised, and myself. Laura Attardi and George Mulligan later analyzed the
expression of p53 and the levels of apoptosis in the p53-deficient embryos.
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The p53 tumor suppressor gene is one of the most frequently mutated genes identified in human
tumors (Greenblatt et al., 1994; Harris and Hollstein, 1993; Levine, 1992). In order to establish
systems to study its function, several groups created strains deficient in p53. Analysis of these
strains by all four groups resulted in similar conclusions (Donehower et al., 1992; Jacks et al.,
1994; Purdie et al., 1994; Tsukada et al., 1994). The majority of animals homozygous for the
mutation die in the first six months of life due to the development of one or more aggressive
tumors; primarily T-cell lymphomas or sarcomas. Mice heterozygous for the mutation begin to
die around one year of age and develop a wide spectrum of tumor types, with an enrichment for
sarcoma-type tumors. Thus, the heterozygotes serve as a good model for Li-Fraumeni syndrome
(Malkin, 1993; Malkin et al., 1990). This human disorder is characterized by susceptibility to
several tumor types relatively early in life in patients who carry a germline mutation in one p53
allele.
In addition to its effects on tumorigenesis in adult mice, we have found a small, but significant,
percentage of p53-deficient female embryos do not survive until adulthood. These mice die
shortly after birth from exencephaly, a result of defective neural tube closure in the developing
midbrain. Interestingly, this phenotype is entirely female specific. The reports of both the tumor
studies and the exencephaly are included below.
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Tumor spectrum analysis in p53-mutant mice
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Background: The p53 tumor suppressor gene is
mutated in a large percentage of human malignancies,
including tumors of the colon, breast, lung and brain.
Individuals who inherit -ne mutant allele of p53 are
susceptible to a wide range of tumor types. The gene
encodes a transcripional regulator that may function
in the cellular response to DNA damage. The con-
struction of mouse strains carrying germline mutations
of p53 facilitates analysis of the function of p53 in
normal cells and tumorigenesis.
Results: In order to study the effects of p53 mutation
in vito, we have constructed a mouse strain carrying
a germline disruption of the gene. This mutation
removes approximately 40 % of the coding capacity of
p53 and completely eliminates synthesis of p53
protein. As observed previously for a different
germline mutation of p53, animals homozygous for
this p53 deletion mutation are viable but highly pre-
disposed to malignancy. Heterozygous animals also
have an increased cancer risk, although the distribu-
tion of tumor types in these animals differs from that
in homozygous mutants. In most cases, tumorigenesis
in heterozygous animals is accompanied by loss of
the wild-type p53 allele.
Conclusion: We reaffirm that p53 function is not
required for normal mouse development and
conclude that p5.3 status can strongly influence tumor
latency and tissue distribution.
Current Biology 1994, 4:1-7
Background
The p53 tumor suppressor gene appears to be a critical
regulator of normal cell proliferation. This is indicated
by the fact that mutant alleles of this gene are found in
a majority of human tumors, involving a wide range of
tumor types [1]. In addition to the frequent somatic
mutation of p53 in sporadic cancer, germline mutation
of one allele of this gene in humans causes an inborn
predisposition to cancer known as Li-Fraumeni
syndrome [2]. Individuals with Li-Fraumeni syndrome
are highly prone to the development of sarcomas and a
variety of other tumor types, including carcinomas of
the breast and brain [31.
Although the precise mechanism(s) by which p53
normally suppresses tumor formation is not known,
recent experiments have implicated the gene in con-
trolling cell-cycle arrest in response to damage to the
genome resulting from radiation [4,51 and gene amplifi-
cation [6,71. Moreover, following certain stimuli, p53
function is required for some cells to undergo pro-
grammed cell death (apoptosis) [8,91. The p53 gene
encodes a DNA-binding protein [10] that can have both
positive and negative effects on transcription [11-161.
Recently, Donehower et al. [171 have utilized
the technique of gene targeting in murine embryonic
stem (ES) cells to construct a mouse strain carrying
a germline mutation in the p53 gene. These authors
reported the surprising observation that mice
homozygous for this mutation are viable. Thus, despite
its clear importance in suppressing the transformation
of a number of cell types, p53 is not essential for
normal development of the mouse. However, the
presumed role of p53 in tumor- suppression was
supported by the observation that homozygous mutant
animals were highly prone to malignancy in the first
months after birth [171. These authors also reported
tumors in a small number of animals heterozygous for
the p53 mutation. Thus, as is the case with humans
suffering from Li-Fraumeni syndrome, a germline
mutation of p53 in the mouse can lead to increased
cancer susceptibility.
In an effort to confirm and extend the observations of
Donehower et al. [171, we have constructed a mouse
strain carrying a p53 mutant allele that is different from
the one described by them. This mutation, which
deletes approximately 40 % of the p53 coding region,
completely blocks production of p53 protein.
Consistent with the earlier report [171, homozygosity for
this p53 deletion mutation is compatible with normal
murine development. We have also studied the kin-
etics and tissue distribution of tumor formation in
animals homozygous and heterozygous for this p53
mutation. The data demonstrate that the heterozygous
tumor phenotype closely resembles that seen in
Li-Fraumeni syndrome and differs from that observed
in the homozygous mutant animals. The tissue dis-
tribution of tumors in heterozygous mice may reflect
the somatic mutation rate in different tissues and cell
types.
Correspondence to: Tyler Jacks.
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Results
p53 gene targeting
One allele of the p53 gene was disrupted in D3 ES cells
using the targeting vector p53KO shown in Figure 1.
The neomycin resistance gene (neo) in this vector is
flanked by fragments of p53 totaling 8 kilobases (kb);
neo replaces approximately 40 % of the p53 coding
sequences, beginning within exon 2 (upstream of the
initiator codon AUG) and extending into intron
6. The HSV-TK gene follows the p53 sequences to
allow negative selection using the protocol of Mansour
Fig. 1. p53 gene targeting. (a) Scheme for targeting one allele of
the murine p53 gene in ES cells. Homologous recombination
between the p53KO targeting vector and one allele of the
endogenous p53 gene results in the replacement of p53 coding
sequences between exons 2 and 7 with the neo gene expression
cassette and the formation of the p53A mutant allele. ES cell
clones were screened by Southern blotting of genomic DNA
digested with EcoRI (R) plus Stul (S) and hybridized to probe
derived from p53 exon 1 (A), which is not present in p53KO.
The structure of the mutant allele in putative heterozygous ES-
cell clones was confirmed using a 3' cDNA probe (B), covering
exons 7-10. Details of the construction of p53KO are described
in Materials and methods. (b) Genotypic analysis of offspring
from a p53 heterozygous cross. Tail DNA was isolated from
offspring at weaning and examined by Southern blotting as
described above using probe A. This probe hybridizes to an 8.0
kb R-S fragment from the wild-type allele (wt) and a 6.5 kb R-S
fragment from the p53A allele (mut). Animals 2 and 6 are
p53A'A, animal 7 is p53 1+ , and animals 1, 3 ,4, and 5 are
p53+ . Molecular weight standards are shown (lane 1 Kb), along
with their sizes (in kb) at right.
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Fig. 2. Immunoprecipitation of p53 protein. Fibroblasts isolated
from wild-type (+/+), heterozygous (+/-), and homozygous
mutant (-/-) embryos were labeled with a [355] methionine and
[35S] cysteine, and whole cell lysates precipitated with negatiie
control (C) or two p53-specific antisera: pAb248 (2) and
PAb421 (4). Position of molecular size markers are shown (in
kD) on the right and the expected position of p53 protein on the
left. Note the absence of a specific signal from -/- cells and that
the signal from the +/- cells is reducedcompared with +/+ cells.
et al. [181. p53KO was introduced into D3 cells by elec-
troporation and, following selection in G418 and
gancyclovir (GANC), cell clones were screened by
Southern blotting of their DNA.
A probe derived from exon 1 of p53 (and not present
in the p53KO targeting vector) hybridizes to an EcoRI
to StuI fragment of approximately 8 kb from the wild-
type p53 allele, whereas the mutant allele created by
homologous recombination between p53KO and the
endogenous p53 gene yields a 6.5 kb fragment (Fig. 1).
Of 200 G418/GANC-resistant ES cell clones screened, 8
were found to be heterozygous for the p53 mutation
(data not shown). The calculated enrichment from the
HSV-TK counterselection [181 was six-fold, indicating an
overall targeting efficiency of 1/150 per neo-resistant
clone. Because this mutation results in the deletion of a
significant fraction of the p53 coding sequence, -vwe
have designated this allele p53A.
p53-mutant mice
Injection of three independent heterozygous ES cell
clones into wild-type C57BL/6 blastocysts produced
male chimeras that were able to transmit the p5.3
mutation upon breeding to C57BL/6 females. Male and
female heterozygous mice were then intercrossed to
determine the viability of homozygous mutant animals.
Of the first 422 offspring of heterozygous crosses, 120
were p53"~*, 232 were p53+' A and 70 were p53 I. A
representative Southern blot of tail DNA from one litter
of mice is shown in Figure 1.
Throughout their first few weeks, the gross appearance
of the p53/AI animals was normal, and they were
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Fig. 3. Effects of p536 mutation on survival. Viability of 34 wild-
type animals (white circles), 100 heterozygotes (blue circles),
and 49 homozygous mutants (red circles) was monitored for a
total of 500 days. Points represent animals that had died or had
to be sacrificed owing to ill health. The single wild-type animal
that died during this period had developed a tumor. Tumors
were also observed in 17 of 24 heterozygotes and 41 of 49
homozygotes examined by necropsy (see text).
fertile. Thus, the homozygous mutation of p53 is com-
patible with normal embryonic and postnatal
development. These results are consistent with the
earlier report of Donehower et al. [17] describing a
different germline mutation of p53 . In our experi-
ments, the yield of p5 3 'A offspring from heterozygous
crosses has been only 16.6 % (70/422), rather than the
expected 25 %. This may be the result of the death of a
fraction of homozygotes either during embryogenesis
or after birth but before weaning.
Analysis of p53 protein
The effect of the p536 mutation on the synthesis of p53
protein was examined using fibroblasts isolated from
pi53 , p53+/ , and p53IA embryos. Early passage cells
were labeled with [35] methionine and [35S] cysteine,
and whole-cell lysates were precipitated with two p53-
specific monoclonal antibodies. The antibodies PAb421
and PAb248, which recognize epitopes in the amino
and carboxyl termini of the protein, respectively [191,
precipitate full-length p53 from wild-type and heterozy-
gous cells, whereas neither antibody detects a specific
protein product in homozygous mutant fibroblasts (Fig.
2). Thus, the p536 mutation eliminates the production
of full-length p53, and the mutant allele does not
appear to yield any truncated proteins that accumulate
in cells. In addition, we have consistently observed that
the steady-state level of p53 protein in heterozygous
fibroblasts is approximately half of that in wild-type
cells (Fig. 2).
p53 /A6 mice as a model for Li-Fraumeni syndrome
In humans, inheritance of one mutant allele of p53
causes a broad-based cancer predisposition known as
Li-Fraumeni syndrome [2). The predominant tumor
types in humans who are heterozygous for a p53
mutation are sarcomas and carcinomas of the breast
and brain [31. We have closely monitored p53' A
animals for signs of malignancy. As shown in Figure 3.
heterozygosity for the p5 3A mutation does not affect
viability until the mice are approximately nine months
of age. By 17 months, 28 %/0 (28/100) of the heterozv-
gous animals had died or had to be sacrificed because
of ill health. Necropsy revealed obvious tumors in 1- of
24 of these animals.
Figure 4 shows the distribution of tumors observed in
heterozygous animals. The most common tumor types
were sarcoma (including fibrosarcoma, osteosarcoma,
rhabdomyosarcoma, hemangiosarcoma, anaplastic
sarcoma and lyomyosarcoma) in 57 % (25/44) and
lymphomas in 25 0% (11/44) of animals. We have also
observed one brain ependymoma, one hair matrix
tumor, five lung adenocarcinomas, and two hepatomas
in this group of heterozygous animals. Pathological
sections of a typical osteosarcoma, a rhabdomyosar-
coma, and a hair matrix tumor are shown in Figure 5.
SOsteosarcoma
O Brain
O Lung adenocarcinoma
[] Hair matrix tumor
l] Hepatoma
* Lyomyosarcoma
0 Lymphoma
U Rhabdomyosarcoma
[ Fibrosarcoma
L Anaplastic sarcoma
U Hemangiosarcoma
U Teratoma
Fig. 4. Tumor distribution in hetero-
zygous and homozygous mutant
animals. Pie charts show the relative
frequency of tumor types observed
in p53/A and p53A', mice.
Frequencies determined from 44 total
tumors in heterozygotes and 56 total
tumors in homozygotes. Note that the
sarcoma is the most common tumor
type in heterozygotes, whereas
lymphomas are most common in
homozygotes.
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We conclude that the tumor spectrum observed in p53
heterozygous mice is similar (although not identical) to
that seen in humans with Li-Fraumeni syndrome.
Loss of heterozygosity
The vast majority of p53 mutations in sporadic cancers
in humans are base substitutions that cause missense
changes in the coding region of the gene [1]. Many of
the resulting mutant p53 proteins have increased half-
lives and are thought to interfere with the function of
wild-type p53 protein expressed in the same cell 1201.
In addition to their apparent role in eliminating residual
wild-type p53 activity in the cell, such mutant p53
proteins may act positively by contributing to cell pro-
liferation even in the absence of any wild-type p53
protein [21,221. Therefore, it was of interest to examine
the p53 status in the tumors of p53'+/ animals. In par-
ticular, we wished to determine if the wild-type allele
of p53 was simply lost during tumorigenesis or whether
it had acquired an 'activating' mutation resembling
those present in many human tumor DNAs.
The p53 status of tumor DNA was analyzed using
Southern blotting (Fig. 6) or the polymerase chain
reaction (PCR; data not shown). In 9/12 tumors tested,
the wild-type allele of p53 was either completely
absent or clearly under-represented. Most of the tumor
DNA samples did show a residual signal from the
wild-type allele (Fig. 6), which we assume results
from contamination of the tumor preparation with
surrounding normal tissue.
These data indicate that p53 function is eliminated
during the development of most, if not all, tumors in
the p53+/ animals. Furthermore, the loss of the wild-
type allele typically occurred via a chromosomal
mechanism (that is, large deletion, mitotic recombina-
tion or chromosomal nondisjunction) rather than by
point mutation. In the minority of tumors that did not
show loss of the wild-type p53 allele, the gene was
either not mutated or had sustained a point mutation or
other subtle lesion that would not have been detected
by our methods. We conclude that the creation of a
point-mutated allele of p53 is not a prerequisite for
tumorigenesis in these animals.
Accelerated tumorigenesis in p53A/A mice
Although initially healthy, mice that are homozygous
for the p53A mutation are highly predisposed to malig-
nancy. As shown in Figure 3, homozygotes have a
greatly accelerated rate of tumorigenesis compared
with heterozygous or wild-type mice. Of the first 49
homozygotes screened, 46 died by six months of age.
By nine months, all animals had died or had to be sac-
rificed. Necropsy revealed obvious tumors in 41 of the
49 animals. Six mice were discovered to have two
distinct tumors, often a lymphoma with either a
sarcoma or a teratoma.
Whereas mice heterozygous for the p53A mutation
were most prone to developing sarcoma, the predomi-
nant tumor type in the p53/A animals was lymphoma
at 71% (44/56), usually affecting the thymus (Fig. 4). A
section through a representative thymic lymphoma is
shown in Figure 5(a). Homozygous mutant animals also
developed other tumor types, including osteosarcoma,
rhabdomyosarcoma, hemangiosarcoma and teratoma.
In order to determine the cell type of origin of the
thymic tumors, we screened cells isolated from four
tumor samples by flow cytometry using a number of
T-cell-specific markers. All four tumors stained posi-
tively for both CD4 and CD8 (data not shown),
indicating that they arose from the transformation of
relatively immature thymocytes [23]. We have success-
fully adapted CD4/CD8 double-positive cells isolated
from several of the tnymic lymphomas to growth in
tissue culture, which will facilitate further analysis.
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Fig. 5. Histopathology of representa-
tive tumors. (a) Thymic lymphoma
from a p53a/A animal with tumor cells
surrounding a blood vessel (BV).
Arrows delineate the border of the
tumor and normal lung (NL), which
may contain infiltrating tumor cells.
(b) Hair matrix tumor from a p53+/A
animal consisting of regions of
transformed basal cells (B) and
(above) exfoliating squamous
cells, ghost cells, and keratin. (c)
Rhabdomyosarcoma isolated from a
heterozygous animal showing tumor
giant cells (filled arrows) and a char-
acteristic strap cell (unfilled arrow).
(d) Osteosarcoma from a p53' / ^
animal. Tumor consists of both
fibroblastic (F) and osteoblastic (0)
regions; a characteristic bone spicule
is indicated (arrow). Magnification:
panels (a) and (c), 300X; panels (b)
and (d), 75X.
I
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Fig. 6. Loss of heterozygosity. Southern blot analysis of DNA
isolated from tumors of p53 4/A mice. DNA was digested with
EcoRI and Stul and hybridized with probe B shown in Figure 1.
Tail DNA (T) from a heterozygous animal shows three bands,
which are derived from the wild-type p53 allele (wt), the p53^A
allele (mut) and the p53 pseudogene (y). Of the six tumor
samples shown, five show a greatly reduced signal from the
wild-type allele, consistent with its loss during tumorigenesis.
One tumor (H) has retained the germline pattern. H, hepatoma;
L, lymphoma; S, anaplastic sarcoma; He, hemangiosarcoma; 0,
osteosarcoma; F, fibrosarcoma.
Discussion
The method of gene targeting in mouse ES cells [24]
has allowed the construction of a large number of
novel mouse strains that can be used to study diverse
areas of biology, including development, immunology,
human genetic disease and cancer. Here, we have
described the properties of a mouse strain carrying a
targeted deletion mutation in the p53 tumor suppressor
gene. Given the importance of p53 mutations in
sporadic and familial forms of cancer, this strain and
analogous strains constructed by others represent a
valuable resource for cancer research.
Donehower et al. [171 first reported the unexpected
observation that mice homozygous for a particular p53
mutation were viable. This mutation replaces a part of
p53 intron 4 and the 5' portion of exon 5 with a neo
expression cassette [171. We have constructed a second
mutant allele of p53, one that clearly blocks production
of p53 protein, and we find that animals homozygous
for this mutation also survive gestation normally.
Therefore, although p53 is mutated in a large fraction
of human malignancies [11, the function of this gene is
dispensable for normal development, at least in the
mouse. Homozygous mutant animals are, however,
highly predisposed to cancer. All 49 homozygotes
followed in this study died by nine months of age, and
(with the exception of eight animals on which
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necropsy could not be performed) all had obvious
tumors.
The absence of a developmental defect in p53-deficient
animals coupled with their greatly increased cancer risk
suggests that p53 might function specifically as a sup-
pressor of tumorigenesis rather than as a general
cell-cycle regulator. Consistent with this view, we and
others have recently shown that p53 is required for the
normal cellular response to DNA damage, either G1
growth arrest in fibroblasts [51 or apoptosis in thymo-
cL.tes [8,91. The failure of p53-deficient cells to undergo
proper cell-cycle arrest or programmed cell death
following DNA damage could result in an increased
mutation rate or the inappropriate survival of damaged
cells [251. p53 is also required for apoptosis in cells
expressing the adenovirus E1A oncogene ([261 and S.
Lowe, T.J., D. Housman and H.E. Ruley, manuscript
submitted). Thus, in addition to acting to limit the
mutation rate (including the rate of oncogenic
mutations), p53 may also function to eliminate cells
that have already undergone oncogenic mutations.
Accordingly, cells lacking p53 function would be
expected to be more readily transformed as a result of
the abrogation of this death program.
As reported here, the most common tumor observed in
p53-deficient mice is thymic lymphoma, and in all
cases examined the tumor cells were found to express
the surface antigens present on immature thymocytes.
Given the requirement for p53 function in radiation-
induced apoptosis in this cell type [8,91, the high
frequency of thymic lymphoma may result from the
failure to eliminate cells that have suffered some form
of DNA damage. One potential source of DNA damage
during T-cell development is the rearrangement process
involving the T-cell receptor (TCR) genes. The state of
the TCR genes has not yet been examined in these
tumors.
In addition, we have found that mice heterozygous for
the p53A mutation are predisposed to cancer. The
tumor phenotype of these animals differs from that of
homozygotes, both with respect to latency and distribu-
tion of tumor types. The longer tumor latency observed
in heterozvgous mice could be explained by the
requirement for heterozygous cells to mutate the wild-
type p53 allele at some point during tumorigenesis.
Indeed, three quarters of the tumors from p53"'
animals examined here showed loss of the wild-type
p53 allele. This result indicates not only that elimina-
tion of p53 function is selected for during
tumorigenesis, but also that the acquisition of a poten-
tially activating point mutation in the remaining p5.3
allele is infrequent in this setting. These data are com-
patible with models in which point-mutated alleles of
p53 act predominantly to inhibit the function of wild-
type p53 protein.
Heterozygous animals also differ from homozygotes in
the spectrum of tumors to which they are predisposed.,
with sarcomas being the most common tumor type
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observed in heterozygotes rather than the lymphomas
of the homozygotes. Given the requirement to mutate
the wild-type p53 allele in heterozygotes, an important
factor in determining the tumor spectrum in these
animals may be the frequency of this mutational event
in different tissues. In particular, the relatively slow
elimination of the wild-type p53 allele would be
expected to limit the frequency of thymic lymphoma in
heterozygotes, as the number of immature thymocytes
drops dramatically following thymic involution at
several weeks of age.
The value of animals carrying a permline p53 mutation
extends beyond the analy::s of their particular tumor
phenotypes. The animals described here have been
extremely useful as a source of mutant cells with which
to study p53 function in vitro [5,7,9,27). Also, p53-
mutant mice can be bred to other cancer-prone mouse
strains (for example, other tumor suppressor gene
mutants [28-30] or oncogene transgenics [311) in order
to examine the possible cooperative effects ot p53
deficiency and other oncogenic mutations. These
animals represent an important tool in the continuing
analysis of the role of the p53 tumor suppressor gene
in controlling malignant transformation.
Conclusions
The generation and characterization of p53-deficient
mouse strains has provided important insights into the
role of this gene in growth control and neoplasia. The
surprising dispensability of p53 function for embryonic
development demonstrates that p53 is not required for
normal cell growth or differentiation. However, p53
function is clearly important to the suppression of
tumorigenesis, as heterozygous and homozygous
mutant animals are highly cancer prone. In addition,
p53 status (wild-type, heterozygous or homozygous
mutant) is an important determinant of the latency and
tissue distribution of tumors.
Materials and methods
Gene targeting
p53KO was constructed by cloning fragments of the murine
p-53 gene (isolated from strain BALB/c) [321 into the
targeting vector pPNT [331. The neo gene in p53KO is
flanked by a 3.5 kb fragment extending from the BamHI
site in intron 1 to the NcoI in exon 2 and a 5 kb fragment
extending from the BamHI in intron 6 to the EcoRI down-
stream of exon 11 132]. Electroporation of p53KO into D3 ES
cells 1341, subsequent drug selection, and Southern blot
analysis were performed as described [281. The Southern
blot probe A (Fig. 1) consists of an EcoRI to Bsmnl fragment
of p53 genomic DNA including exon 1: probe B is a SactI
to Kpitt fragment of p53 cDNA which includes exons 7
through 10.
Heterozygous ES cells (derived from strain 129/SV) were
injected into C57BL/6 blastocysts essentially as described in
[351. Extensively chimeric males were screened for germline
contribution of the mutant cells by breeding to C57BL/6
females. Genotypic analysis was performed by Southern
blotting (see above) or PCR. The wild-type p53 allele was
amplified using PCR primers directed against exon 6 (W5':
5'-ACAGCGTGGTGGTACCTTAT-3') and exon 7 (W3': 5'-
TATACTCAGAGCCGGCCT-3'), whereas the p53" allele was
amplified using a primer directed against neo (M5': 5'-
CTATCAGGACATAGCGTTGG-3') and W3'. Homozygous
offspring were generated initially from heterozygous inter-
crosses and subsequently from homozygous intercrosses. All
of these animals are on a 129/SV x C57BL/6 mixed genetic
background.
p53 protein analysis
Immunoprecipitation of p53 protein was performed as
described in [71 using early passage fibroblasts from wild-
type, heterozygous and homozygous mutant embryos,
prepared as described in [361. Antibody PAb421 was
purchased from Oncogene Science. Control antiserum
(M73, adenovirus E1A) and PAb248 were generously
provided by E. Harlow.
Tumor analysis
Animals that died or w ere sacrificed were subjected to
complete necropsy. Tumor samples were surgically
removed and fixed in Bouin's solution. Specimens were
processed for histology, embedded in paraffin, sectioned at
6 ,. and stained with hemotoxylin and eosin. Loss of hbet-
erozygosity analysis was performed on DNA isolated from
fresh tumor samples using either Southern blotting or PCR
as described above.
Tumor cells isolated from thymic lymphomas were stained
with phycoerythrin-conjugated anti-CD4 and fluoroscemin
isothyocyanate-conjugated anti-CD8 antibodies (anti-L3T-i
and anti-Lyt2, Becton Dickinson) and analyzed using a
FACStar Plus fluorescence-activated cell sorter (Becton
Dickinson).
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A subset of p53-deficient
embryos exhibit exencephaly
Valerie P. Sah" ,3, Laura D. Attardi', George J. Mulligan', Bart O. Williams',
Roderick T. Bronson2 & Tyler Jacks'
Defects in neural tube formation are among the most common malformations leading to
infant mortality. Although numerous genetic loci appear to contribute to the defects
observed in humans and in animal model systems, few of the genes involved have been
characterized at the molecular level. Mice lacking the p53 tumour suppressor gene are
predisposed to tumours, but the viability of these animals indicates that p53 function is
not essential for embryonic development. Here, we demonstrate that a fraction of p53-
deficient embryos in fact do not develop normally. These animals display defects in
neural tube closure resulting in an overgrowth of neural tissue in the region of the mid-
brain, a condition known as exencephaly.
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The p53 tumour suppressor gene is frequently mutated
in a wide range of human cancers'. Recent evidence
suggests that the gene is required for G 1 growth arrest
following DNA damage' ,3 or the induction of apoptosis4
", depending on the cell type. Interestingly, mice lacking
p53 are viable, although they are prone to developing a
variety of tumours within four to six months of age"-".
The viability of animals lacking p53 has been taken to
indicate that p53 plays no role in normal mouse
development.
Malformations of the developing neural tube are
common congenital defects, with frequencies worldwide
that vary from one to nine per 1,000 total births'6.
Anencephaly, a lethal condition in which the brain tissue
is exposed, and spina bifida, a condition involving
regionalized disruption of spinal nerve pathways, are the
most prevalent forms of neural tube defects (NTD)" 7.
The aetiology of these defects is not well defined, but
genetic and environmental factors are known to influence
NTD in human populations and mouse model systems.
Although these and other studies strongly suggest that
different inherited factors contribute to NTD, the identity
of such loci remains unclear.
Mouse models of NTD resemble to varying degrees the
human condition with respect to location and pathology
of the defect, female preference, partial penetrance and
environmental sensitivity'"7, s. Several mouse mutants
exhibit exencephaly, a defect related to anencephaly, in
which the brain protrudes above the skull. In the Splotch
and curly tail mutants, both exencephaly and spina bifida
are observed. The spina bifida observed in 15-20% of
curly tail (ct) mutant embryos" appears to involve a
specific proliferative defect in the gut endoderm and
notocord 20. Although the molecular basis for the ct
mutation remains uncharacterized, a recent study has
mapped the gene to mouse chromosome 4 and identified
several modifier loci' 6. Despite such evidence that neural
tube defects involve multifactorial inheritance, the
mechanistic processes disrupted by these or other genetic
lesions remain obscure. It is likely that the defects in a
variety of systems may lead to abnormalities in the
complex process of neurulation
Mice lacking the p53 tumour suppressor gene are
indistinguishable from their wild type littermates except
for their dramatically early onset of tumour
formation"''3 . It has been noted, however, that the
frequency of recovery of these homozygous mutant
animals is slightly less than anticipated'3. We describe
here a developmental analysis demonstrating that a
variable percentage of p53-deficient animals exhibits
mid-brain exencephaly, a neural tube defect that is
incompatible with post-natal survival.
Phenotype of p53-deficient embryos
Crosses between mice heterozygous for a targeted
mutation in exon 5 of p53 have yielded 23% homozygous
mutant offspring (close to the expected mendelian ratio
of 25%), leading to the conclusion that p53 function is
not necessary for mouse developmentl 2.However, in our
analysis of animals produced from heterozygous
intercrosses of mice carrying the p53A mutation on a
mixed (129/sv x C57BL/6) genetic background, the
frequency of homozygous mutants (p53- '-) recovered at
weaning was 20%, slightly less than the anticipated value
(Table 1). The reduced yield of p53-'- animals from such
crosses was more apparent on the inbred 129/sv genetic
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Table 1 p53 genotypes of adult and embryonic mice
Mouse background Heterozygous-heterozygous crosses
p53 *1 p53÷*- p53-1- p53-4-
Adults
Mixed 176 (30.2%) 290 (49.7%) 117(20.1%) N/A
129/sv 35 (24.3%) 84 (58.3%) 25 (17.4%) N/A
Embryosb
Mixed 42 (28.8%) 70 (48.0%) 31(21.2%) 3 (2.1%)
129/sv 7 (21.9%) 19(59.4%) 4 (12.5%) 2 (6.2%)
Heterozygous-homozygous crosses
Embryosc
Mixed - 215(56.3%) 153 (40.1%) 14 (3.7%)
129/sv - 49 (47.1%) 47 (45.2%) 8 (7.7%)
aExencephaly. b13.5 gestation days. c12.5-18.5 gestation days. Offspring of crosses
between p53 *- were weaned and genotyped at three weeks of age. The numbers of
animals recovered of each genotype on a mixed or 120/sv inbred background are
indicated. Day 13.5 embryos were also analyzed and the occurrence of mutants exhibiting
exencephaly is indicated. For each category percentages of the total number of specimens
analysed are indicated in parentheses. The lower portion of the table summarizes the
analysis of embryos from crosses of p53 -'- with p53 '- animals.
background, where just 17% of the offspring were of this
genotype (Table 1). These data suggest that a fraction of
the p53-deficient animals either do not survive gestation
or die sometime after birth prior to weaning. In order to
address whether some p53-deficient embryos developed
abnormally, we examined litters from heterozygous
intercrosses at day 13.5 of gestation. Of 34 p53-deficient
embryos recovered at this stage from the mixed genetic
background, 3 (8.8%) displayed abnormal head and
brain morphology. Moreover, 14 of 167 (8.4%) p53-' -
embryos derived from heterozygous-homozygous crosses
on the mixed genetic background had this appearance
(Table 1). This defect was characterized by an overgrowth
of neural tissue, usually confined to the region of the
fore- and mid-brain, but occasionally also affecting the
hind-brain (Fig. la). The neural overgrowth precluded
normal formation of the cranium in this region and
therefore the brain protruded above the skull, a condition
termed exencephaly.
The percentage of exencephalic embryos was higher
on the 129/sv inbred genetic background, where 10 of 61
p53-'- embryos (16%) derived from either heterozygous-
heterozygous or heterozygous-homozygous crosses
exhibited this phenotype consistent with the lower yield
of liveborn p53-1- animals on the inbred background
(Table 1). None of 402 p53-'" or p53+• embryos examined
from the two genetic backgrounds were exencephalic,
nor has exencephaly ever been observed in over 1,000
embryos derived from heterozygous intercrosses of mice
with mutations in Rb or Nfl on these genetic
backgrounds2 "'22. Furthermore, this developmental
phenotype was due to the absence of p53 function rather
than a mutation in some closely linked gene, since we
observed exencephaly in two independent lines of p53-
mutant mice derived from different targeted embryonic
stem cell clones".
Exencephaly results from the failure of neural tube
closure followed by outward expansion of neural tissue
via the eversion of the neural plate. As shown in Fig. Ic
and d, the exencephalic p53-'- embryos clearly displayed
the persistent opening of the neural tube in the region of
the fore- and mid-brain. Histological sections of the p53
'- exencephalic embryos were characterized by absence of
bilateral symmetry on the two sides of the forebrain (Fig.
2a,c,e ). The surface of the cerebrum was covered by
ependymal cells, as if the ventricles were turned inside
out. Numerous random invaginations of this surface
layer deep into the distorted cerebrum resulted in the
formation of many small pseudo-ventricles and rosettes
of ependymal cells (Fig. 2e). Except for this particular
neurological defect, these exencephalic embryos were
otherwise histologically normal (Fig. 2a), and they were
Fig. 1 Whole mount view of p53-- exencephalic embryos and
littermate controls. a, Lateral view of 13.5 day exencephalic
p53- - embryo. Note that the skull is open caudally. b, Littermate
of animal shown in (a). The skull covers the brain completely.
Note the well-defined lateral ventricle. p53+*, p53 ÷'- and non-
exencephalic p53-- embryos were indistinguishable visually.
c, Ventral view of a 13.5 day exencephalic p53-4- embryo in
which the cerebrum is exposed and the two hemispheres are
asymmetric. d, Dorsal view of embryo in c with exposed mid-
and hind-brain. e, Lateral view of 18.5 day exencephalic
p53"'- embryo. f, Normal littermate of animal shown in e.
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Fig. 3 Sex determination of exencephalic p531- embryos. DNA samples from
control male (M) and female (F) adult mice, embryos of normal appearance, and
p53-'- exencephalic embryos were subjected to PCR analysis for sex determination.
The presence of Y chromosomal DNA in males produced a 610 bp fragment with
primers directed against the Zfy gene23. All five exencephalic embryos shown and
22/22 additional exencephalic embryos lacked the Zfy band and were, therefore,
female. Primers directed against the autosomal Nfl gene 22 were included as a
control for the presence for DNA. Sizes (in base pairs) of
standards (123 bp) are shown at left.
targeted mutation in the p53 gene (L. Donehower et al.
pers. comm.). Thus, the absence of p53 function during
development in the mouse can lead to a dramatic, and
ultimately fatal, embryological abnormality. This
phenotype is consistent with the high-level expression
of p53 we and others have seen during early
embryogenesis, both in the developing brain and other
tissues26' 27. Additionally, the discovery of a function
for p53 in mouse embryogenesis underscores the fact
that tumour suppressor genes are important in normal
development as well as tumorigenesis. For example,
homozygous inactivation of the Rb2 1' 28'29, Wt 30 and
Nfl 22"., tumour suppressor genes all lead to embryonic
lethality associated with specific developmental
abnormalities.
The developmental phenotype ofp53 mutants exhibits
partial penetrance, which varies depending on the genetic
background. This finding implies the presence of
modifying genes and thus suggests that the process of
neural tube closure is governed by a variety of gene
products. This is consistent with studies of other mouse
molecular weight
model systems, such as the Curly tail
or Splotch mutants, which show
variable penetrance and expressivity,
depending on a combination of
genetic and environmental factors32.
The polygenic nature of neural tube
closure is consistent with the fact
that it is a complex morphological
process involving changes in cell
shape, migration and proliferation,
and a subtle perturbation in any of
these could produce the observed
phenotype. It is also striking that the
phenotype we observe is completely
female-specific. Exencephaly more
frequently affects female embryos
than male embryos both in humans
and model systems". The reason for
this sex-specificity remains elusive,
although it may have a specific genetic
basis that is related to the expression
of genes which act in a completely
female-specific manner.
It is possible that in wild-type
embryos, p53 functions only under rare circumstances of
improper neural tube closure (8-16% of cases) to bring
about some compensatory developmental mechanism.
Alternatively, p53 maybe essential for the normal pattern
of neural tube closure, and the survival of most p53-
deficient embryos may reflect the existence of an
alternative mechanism which is effective in only 80-90%
of cases. Support for the latter possibility comes from
studies of the SELH/Bc mouse strain, which also exhibits
exencephaly at approximately 17% frequency". All
embryos of this strain fail to execute a particular aspect of
neural tube closure, but in most cases an alternative
pattern is adopted which is apparently equally effective".
Preliminary studies indicate, however, that there is no
such obvious difference between the patterns of neural
tube closure in wild type and p53-deficient embryos.
Precisely how lack ofp53 function affects proper neural
tube closure is unknown. Based on its known role in
other contexts several models can be proposed. For
example, p53 has been shown to have critical roles both
in mediating G1 arrest in response to DNA-damaging
Fig. 4 Whole-mount TUNEL analysis of
p53-1- embryos and littermate controls.
a, Anterior view of 8-9 dayp53 +'- embryo
stained to detect cell death. Note
punctate nuclear staining along forebrain
neural folds. b, Posterior view of 8-9
dayp53 -4- embryo stained to detect cell
death. As in thep53 +'-embryos, nuclear
staining is along hindbrain neural folds.
c,d, Negative control reactions: 8-9 day
embryos stained in same way as other
samples, but without TdT in the assay.
Note the absence of specific stainina.
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Fig. 3 Sex determination of exencephalic p53-'- embryos. DNA samples from
control male (M) and female (F) adult mice, embryos of normal appearance, and
p53-1- exencephalic embryos were subjected to PCR analysis for sex determination.
The presence of Y chromosomal DNA in males produced a 610 bp fragment with
primers directed against the Zfy gene23.All five exencephalic embryos shown and
22/22 additional exencephalic embryos lacked the Zfy band and were, therefore,
female. Primers directed against the autosomal Nfl gene22 were included as a
control for the presence for DNA. Sizes (in base pairs) of molecular weight
standards (123 bp) are shown at left.
targeted mutation in the p53 gene (L. Donehower et al.
pers. comm.). Thus, the absence of p53 function during
development in the mouse can lead to a dramatic, and
ultimately fatal, embryological abnormality. This
phenotype is consistent with the high-level expression
of p53 we and others have seen during early
embryogenesis, both in the developing brain and other
tissues26' 27 . Additionally, the discovery of a function
for p53 in mouse embryogenesis underscores the fact
that tumour suppressor genes are important in normal
development as well as tumorigenesis. For example,
homozygous inactivation of the Rb 21' 28'29 , Wtl 30 and
Nfl22'31 tumour suppressor genes all lead to embryonic
lethality associated with specific developmental
abnormalities.
The developmental phenotype ofp53 mutants exhibits
partial penetrance, which varies depending on the genetic
background. This finding implies the presence of
modifying genes and thus suggests that the process of
neural tube closure is governed by a variety of gene
products. This is consistent with studies of other mouse
model systems, such as the Curly tail
or Splotch mutants, which show
variable penetrance and expressivity,
depending on a combination of
genetic and environmental factors32.
The polygenic nature of neural tube
closure is consistent with the fact
that it is a complex morphological
process involving changes in cell
shape, migration and proliferation,
and a subtle perturbation in any of
these could produce the observed
phenotype. It is also striking that the
phenotype we observe is completely
female-specific. Exencephaly more
frequently affects female embryos
than male embryos both in humans
and model systems"7. The reason for
this sex-specificity remains elusive,
although it may have a specific genetic
basis that is related to the expression
of genes which act in a completely
female-specific manner.
It is possible that in wild-type
embryos, p53 functions only under rare circumstances of
improper neural tube closure (8-16% of cases) to bring
about some compensatory developmental mechanism.
Alternatively, p53 may be essential for the normal pattern
of neural tube closure, and the survival of most p53-
deficient embryos may reflect the existence of an
alternative mechanism which is effective in only 80-90%
of cases. Support for the latter possibility comes from
studies of the SELH/Bc mouse strain, which also exhibits
exencephaly at approximately 17% frequency". All
embryos of this strain fail to execute a particular aspect of
neural tube closure, but in most cases an alternative
pattern is adopted which is apparently equally effective".
Preliminary studies indicate, however, that there is no
such obvious difference between the patterns of neural
tube closure in wild type and p53-deficient embryos.
Precisely how lack of p53 function affects proper neural
tube closure is unknown. Based on its known role in
other contexts several models can be proposed. For
example, p53 has been shown to have critical roles both
in mediating GI arrest in response to DNA-damaging
Fig. 4 Whole-mount TUNEL analysis of
p53"- embryos and littermate controls.
a, Antenor view or -9 aayps '- embryo
stained to detect cell death. Note
punctate nuclear staining along forebrain
neural folds. b, Posterior view of 8-9
day p53 - - embryo stained to detect cell
death. As in thep53 '/-embryos, nuclear
staining is along hindbrain neural folds.
c,d, Negative control reactions: 8-9 day
embryos stained in same way as other
samples, but without TdT in the assay.
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agents 2,3 and in mediating apoptosis in response to
DNA-damaging agents and/or oncoprotein
expression 4-'0 . In addition, p53 can act as a sequence-
specific transcriptional activator or a repressor"3
depending on the context. During neural tube closure,
p53 could potentially have a role in mediating cell
cycle arrest either to limit cell proliferation or to
prepare cells for a differentiation event important for
closure. Indeed, incorrect regulation of cell cycling is
thought to be the central cause of spina bifida in ct
mutants 20. Alternatively, p53 deficiency could have a
subtle effect on programmed cell death, which ;s not
detectable in our assays. Finally, p53 may simply
regulate certain genes that are critical for neural tube
closure. In fact, one known difference between wild-
type and p53 mutant embryos is the levels of the
mRNA encoding the p21 cyclin-dependent kinase
inhibitor3 . p21 mRNA is elevated in the brain of p53
mutant embryos, and this could potentially be
significant in the induction of exencephaly.
The identification of p53 as a novel player in the
process of neural tube closure is also important because
few factors involved in this process have been defined
at the molecular level. Despite the fact that numerous
mouse mutants have been characterized, few gene
products have been identified. Only the Pax3 and Gli3
transcription factors have been identified as the affected
genes in the Splotch (Sp) and Extra-toes (xt) mutants,
respectively3637. Characterizing the role of p53 in neural
tube closure should, therefore, augment our molecular
understanding of neural tube closure. Determining the
mechanism for the development of the defect will prove
useful for designing therapy for neural tube disorders in
humans. In addition, an elucidation of the function of
p53 in neural tube closure may lead to a better
understanding of the role of this gene in tumour
suppression.
Methods
Embryo analysis. p53"- female mice were mated with either
p53"- or p53-'- males. Midday of the day on which the vaginal plug
was detected was considered to be day 0.5 post-coitum (p.c.).
Pregnant females were sacrificed from 12.5 to 18.5 days p.c. and
embryos surgically removed for analysis. Embryos were fixed in
10% buffered formalin, dehydrated in graded solutions of ethanol,
embedded in paraffin, sectioned at 6 lm, and stained with
hematoxylin and eosin.
PCR analysis. Mouse embryos were harvested at between 12.5 and
18.5 days of gestation. Yolk sac DNA was obtained and used for p53
genotyping"' and sex determination for each embryo. Two sets of
primers (one specific for the Zfy gene23 , another for the Nfl gene22)
were used together in each of the PCR reactions for sex
determination. DNA samples were taken through 30 cycles of
amplification (30 s at 92 "C; I min at 55 "C; I min at 72 'C) in an
MJ PTC-100 machine. Amplification products were visualized on
a 2% agarose electrophoresis gel stained with ethidium bromide.
The Zfyprimers were fon' ard 5'-AAGATAAGCTTACATAATCA-
CATGGA-3', and reverse 5'-CCTATGAAATCCTTTGCTGCACA-
TGT-3' (generously provided by David Page); the Nfl primers
were: forward 5'-GGTATTGAATTGAAGCAC-3' and reverse 5'-
TTCAATACCTGCCCAAGG-3' (ref. 22). Forp53 genotypes, DNA
was obtained from tail preparations of 21-day-old mice and
genotyped for p53 status as described for the p53A mutation'.
Whole mount TUNEL assay. The TUNEL assay was performed as
described, with some modifications3 s: 8.0-9.0 day embryos were
fixed in 10% buffered formalin and then transferred to 70%
ethanol. Embryos were rehydrated and then treated for I h in a 4:1
solution of methanol:30% H,0,, followed by 3 washes with PBT
(PBS with 0.1% Tween-20). Embryos were incubated 5 min in 15
Vgg ml-' proteinase K and then two times 5 min I 2 mg ml-' glycine.
Embryos were fixed again in 4% paraformaldehyde, 0.2%
glutaraldehyde in PBS for 1 hour and washed 3 times in PBT. The
TdT reaction was done for 1 hour at 37 'C in a 50 ,ul reaction
containing IX TdT buffer, 10-15 U TdT (Gibco-BRL) and 20 ghM
digoxigenin-11-dUTP (Boehringer-Mannheim). The reactions
were stopped by doing 4 washes in 300 mM NaCI, 30 mM Na
Citrate, 0.1% Tween, over a 30 min period. The embryos were
blocked in 10% fetal calf serum in PBT for 1 h. Anti-digoxigenin
Fab fragment-HRP conjugate (Boehringer-Mannheim I was
preabsorbed for 1 h with 1% fetal calf serum and 0.3% mouse or
chick embryo powder in PBT. Embryos were incubated I h in
preabsorbed antibody in PBT, at a concentration of 0.1-0.5 U
antibody ml-'. Embryos were washed 4 times in PBS and developed
in HRP substrates (Peroxidase substrate kit, Vector Laboratories)
until visible staining was detected. Embryos were then washed in
PBS and photographed.
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Characterization of Rb-Deficient Fibroblast Growth
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Notes of attribution
The data presented in this appendix represents work done by myself and Valerie (Tan) Sah, an
undergraduate student whose research I supervised. Portions of this data were included in the
following publication. A copy of this publication is included at the end of this appendix.
Herrera RH, Sah VP, Williams BO, Makela T, Weinberg RA, and Jacks T. (1996) Altered cell
cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol
Cell Biol. 16(5): 2402-2406
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As discussed in Chapter 1, many of our insights into the function of pRB have come from studies
performed on tumor derived cell lines. An inherent problem in such analysis is the fact that such
tumor cell lines have undoubtedly acquired many mutations during both the initial process of
tumor formation and the subsequent adaptation for growth in vitro. Thus, while tumor cell lines
differing in the status of Rb (for example SAOS-2 and U2OS) have been utilized in side by side
comparisons to assess Rb function ( for example see (Gu et al., 1993)), the effect of other
unknown genetic lesions on the specific function being studied is unclear. To help develop an in
vitro system to overcome these problems, Valerie Tan, an undergraduate whose work I
supervised, and myself characterized the growth of murine embryonic fibroblasts (MEFs)
obtained from Rb-deficient embryos. Our work was included in a report of work done primarily
by Ralph Herrera, a post-doctoral fellow in the laboratory of Robert Weinberg, which has been
recently published in Molecular and Cellular Biology and is included at the end of this appendix.
Materials and Methods
Preparation of Murine Embryonic Fibroblasts
All cells used for the analysis described were derived from embryos purebred for the 129/Sv
genetic background. Rb heterozygous females mated to Rb heterozygous males were sacrificed
12.5 days post-coitus and the embryos dissected from the uterus. Each embryo was separated and
the yolk sac removed for eventual determination of Rb genotype via PCR (see Chapter 3). The
head and internal organs were then dissected away from the remainder of the embryo. The
remainder of the embryo was then rinsed in PBS and then placed in trypsin where it was minced
with two sterile razor blades into a small aggregates of cells. These were then placed at 37 degrees
for 30-45 minutes at which time 5 milliliters of fibroblast media (10% fetal calf serum, Pen/strep,
in DME) were added. The resulting solution was then resuspended in a pipette 10 times and then
added to 25 mls of fibroblast media in a T-75 flask. After growth to confluency, the cells were
trypsinized from the T-75 flask by placing at 37 degrees for 10 minutes and then spun down. The
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cell pellet was resuspended in fibroblast media and equal parts were added to two T-175 flasks
containing 50 mls of fibroblast media. Upon growth to confluency in the T- 175 flasks, the MEFs
were trypsinized from the flask, spun down, and resuspended in freezing media. Each flask
yielded approximately 20 vials of MEFs frozen at a concentration of approximately 2.5 X 106
cells.
Examination of growth kinetics of MEFs
This analysis was adapted from previously described protocols (Kastan et al., 1991). Early
passage MEFs were grown at least one passage after thawing before experiments were performed.
1.5 X 106 cells were plated on a 10 cm plate and grown for 24-36 hours. The following procedure
was then used to examine the cell cycle kinetics of the MEFs.
BROMODEOXYURIDINE / PROPIDIUM IODIDE ASSAY
1. Prepare BrdU solution: 20 ml DME mix + 201l BrdU/Fdu (3 mg/ml BrdU and 0.3 mg/ml
FdU); 0.45 g filter into bottle.
2. Starting with 2 x 106 cells/plate, aspirate medium.
3. Pulse with 8 ml BrdU solution, and incubate for 4 hours at 370 C.
4. Aspirate off BrdU, and add 1ml trypsin/plate, incubating for iminute at 370C.
5. Quench reaction with 5 ml DME mix/plate; scrape with rubber policeman and transfer into
15 ml falcon tubes.
6. Count cells in hemacytometer.
7. Spin down in Sorvall RT6000 at 1400rpm at 40 C.
8. Aspirate, and wash 2 times with 3ml IFA/tube.
9. Fix cells with 70% MeOH at -200 C for 5 minutes. Add 2 ml MeOH/1 x 106 cells.
10. Spin for 10 minutes; aspirate.
11. Add 1 ml 0.1N HC1/0.7% Triton X 100 and incubate over ice for 10 minutes.
12. Add 2 ml PBSA; vortex and spin 10 minutes; aspirate and vortex pellet.
13. Add 0.5 ml dH20 and then 16 k1 0.1N HC1. Heat at 97-1000 C in water bath for 10 minutes.
14. Immediately transfer to ice bath on shaker for 10 minutes.
15. Add 1.5 ml IFA/0.5% Tween 20; spin, aspirate and vortex pellet.
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16. Wash once with 2 ml IFA/0.5% Tween 20; spin and aspirate.
17. Add 100 gl BrdU-FITC (1:5 dilution in IFA) and incubate over ice and in the dark for 30
minutes.
18. Wash cells 1 time with 1 ml IFA/0.5% Tween 20; spin and aspirate.
19. Add 1 ml IFA/0.5% Tween 20 + lg1t RNase A, and incubate in 370 C water bath for 15
minutes.
20. Add 10 gl 50 mg/ml propidium iodide and incubate on ice and in the dark overnight.
21. After the incubation, run the cells on a fluorescence activated cell sorter (FACS).
Concomitant with the BrdU/PI analysis, doubling times were calculated for these cell lines. 3.0 x
105 cells were plated onto several different 6 well wells. Then, every 24 hours, two wells was
trypsinized and the total cell number recorded. Doubling times calculated in this manner were
used with the data from the BrdU/PI FACS analysis to calculate the number of hours the average
cell in the population of MEFs spent in each phase of the cell cycle. In addition, cells were
analyzed for physical size by plotting forward versus side scatter on the FACS machine.
Results
Cell Size Determination
The FACS analysis of these MEF populations revealed that Rb-deficient cells had a diameter
approximately 85% of their wild-type counterparts and this calculated to a reduction in volume of
about 40%. A representative FACS analysis of this determination is shown in Figure B-1 on the
following page.
198
Figure B-I
Relative Size of Rb +/+ and Rb -/- MEFs.
The graph below shows an example of forward versus side scatter FACs analysis of Rb +/+ and
Rb -1- MEFs.
4M
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Cell Cycle Kinetics
The results of the experiments on cell cycle kinetics are summarized in the tables below.
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Table B-
Summary of Cell cycle kinetics experiments
Data are shown +/- standard deviation. For Rb +/+ cells data from 14 independent experiments representing 6 independent cell lines was
used. For Rb -/- cells data from 16 independent experiments representing 7 independent cell lines was used.
Doubling Time
(Hours)
26.60 +/- 9.1
% GO/G1 GO/G1 Time % S
(hours)
65.5 +/- 6.9 17.4 +/- 6.3 18.7 +/- 7.1
S Time
(Hours)
4.9 +/- 2.2
% G2/M G2/M Time
(Hours)
15.6 +/- 4.9 4.2 +/- 2.2
45.7 +/- 7.8 12.1 +/- 2.8 31.2 +/- 7.8 8.2 +/- 2.0Rb -/- 26.54 +/- 7.8
MEF
Genotype
Rb +/+
22.2 +/- 9.4 6.0 +/- 3.2
Discussion
The data presented in this appendix suggest that although the tissue from which Rb-deficient
MEFs are derived (embryonic body wall) appears normal, the MEFs themselves exhibit intrinsic
differences from wild-type MEFs. Examination of normal cell cycle kinetics from exponentially
growing cell populations revealed a shortening of Gl phase in the Rb-deficient cells with a
concomitant compensatory lengthening of S phase. This difference is also associated with a
decrease in the cell size. Perhaps some defect associated with a disruption in restriction point
modulation causes the cells to prematurely enter S phase before the necessary metabolites have
been built up to ensure a normal progression through S phase. The cell may compensate for this
by increasing the length of S phase to allow the necessary metabolite levels to build up.
The decreased cell size probably also is due to the premature entry into S phase. Other examples
of alterations which cause a decrease in cell size include fibroblasts in which cyclin E is ectopically
expressed (Ohtsubo and Roberts, 1993). This similarity between the cyclin E-overexpressing
cells and the Rb-deficient cells was examined further by Ralph Herrera, who showed that the
general regulation of cyclin E levels was significantly altered in Rb-deficient MEFs.
In perhaps the most important observation associated with the analysis of the MEFs, Ralph
Herrera showed that some aspects of restriction point regulation in Rb-deficient MEFs were
altered. While the restriction point as defined by sensitivity to serum withdrawal is not
significantly altered, Rb-deficient MEFs are not sensitive to low levels of cycloheximide as are
their wild-type counterparts. The differences of Rb-deficient MEFs in responding to these two
assays to measure the restriction point are not clear at this time.
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Fibroblasts prepared from retinoblastoma (Rb) gene-negatiie mouse embrvos exhibit a shorter G, phase of
the growth cycle and smaller size than wild-type cells. In addition, the mutant cells are no longer inhibited by
low levels of cycloheximide at any point in G, but do remain sensitive to serum withdrawal until late in (;,.
Certain cell cycle-regulated genes showed no temporal or quantitative differences in expression. In contrast,
cyclin E expression in Rb-deficient cells is deregulated in tio ways. Cyclin E mRNA is generall, derepressed
in mutant cells and reaches peak levels about 6 h earlier in (;, than in wild-type cells. Moreover, cyclin E
protein levels are higher in the Rb- - cells than would be predicted from the levels of its mRNA. Thus, the
selective growth advantage conferred by Rh gene deletion during tumorigenesis may be explained in part by
changes in the regulation of cyclin E. In addition, the mechanisms defining the restriction point of late G, may
consist of at least two molecular events. one cycloheximide sensiti'e and pRb dependent and the other serum
sensitive and pRb independent.
The rctinoblastoma (Rh) tumor suppressor gene i,, iacti-
sated in a wide range of human tumors. Its encoded protein
pRb. has been implicated in cell cycle regulation and is knoM% n
to regulate members of the E2F family of tran,,crption factors.
These factors. in turn. control the expression ott a ariets ot
genes expressed in the G, and S phases of the cell cycle (34).
Therefore. loss of Rb function might be expected to result in
deregulated gene expression and abnormal cell cicle progres.-
sion.
pRb has been shown to be phosphor-lated at a particular
stage of the cell cycle (2. 4. 6, 11). This phosphor.lation occurs
late in G, and is responsible for the inactisation of pRb. This
event is thought to be critical for passage into S phase. There-
fore, a characterization of the mediators of pRb phosphor la-
tion and of the consequences of this event is central to ani
understanding of the molecular details of cellular progression
through G, and into S.
Recently it has been shown that cyclin-dependent kinases
(CDKs). in concert with their regulatory cvclin subunits. can
phosphorylate pRb ()10. 14. 16). The cvclin CDKs of particular
interest are cyclin E CDK2 and cclin D.CDK4.6. These mol-
ecules are active in G,. the time of pRb phosphor'lation. and
indeed have been shown to phosphorvylate pRb in vitro and in
transfection studies. In addition, these regulatory proteins are
essential for transit through G,. and their premature activation
leads to an accelerated G, (28. 31). Thus. cvclin CDKs are
prime candidates for the pRb kinases.
Also occurring late in G, is the mammalian restriction (R)
point (29). The R point was defined by Pardee (29) as the
position in G, beyond which cells are committed to continue
into S phase. Three criteria are used to define this point. After
the R point, cells (i) no longer need serum to continue into S.
(ii) are no longer sensitive to inhibition by transforming growth
factor 13 and (iii) are no longer sensitive to low levels of the
'Corresponding author Phone. (h17) 253-0-262. Fa\ (617) 253-
9863.
pr( tein ,,inthesis mnhibitoi c0clohe\lmiIde. 'Threfore1. ['hc iind
the, R ,point. eell, are no longer responsi\c to inhi•btors si,":a,,
.and no longler n1eed s,1 mulator siogna l, for progression Int, S
The precise role,, of pRh in controlling cell proliter,.lion
has\c been ditficult to define. since experiments designed to
tandisze pRh function usually hase beer' conducted swith t::mor
cells that have suffered a number ot ,.ther mutations in addi-
tion to) alteration of Rh. These other hanges complicate anal-
sis oft the role of pRb Itself. To circumient this problemi. w\\
hase anallzed fibroblasts prepared from Rh-deficient nlmouse
,mnbrios: these cells are geneticalls matched with those pre-
pared from ssild-tipe embros with the exception of the known
mutation in Rh itself (15).
I V\TERI .LS AND \ETHOI)S
(ell cle analses, It r -. ic prin ariiibroll I',isolite!'d iron• /
\P nienst' t•. ll• e\'• ic n.i ,,crc ,ar d oi (d i c lbr% n~, c ', ,.i i ,i]ti llk.i
p.'.•,tc iaufthi. ot ined i mt. ti c01 i m.,te emb,.l s-k (. c-, sct D, i.u tkd s,
bromeox.'o \uriamtte-proplauum idthde ,tid ni,. ,in e ittt i)h K t' ,i
f Mt Scatn or cell :%clc or -tiee ,nait-ý.-. ! i-or itilth midmnc ne01(1 i,,0nn
\expcrient-n. tLeils were stared in .crum-iree [Dt)uheei nm"letdl • I L alc timtCo
tor .-4 h hetore bhe•n rcmtirnulated vwith L", -cerum Ior the indilced lime'
'I thsmidine labeing w%,o tor 31 mmn behtre hwse and counting
Immunoblot analise , and kinase assas,. Immunoblot irlndhs. L cre pci
tirnlted h .tandard procedure, 11 Antbihodilc,, to c\hin protetn- wcrc it ,i
ra.bit polclon.ai .erum Speciticil, ot the antibodie-, wa , confirmed I ' detecctll
ti rctomhbilniti cNhclin protein ancrd lmigration in sodium dodecul .ullrtae.-po.ac-
rLlammldet geltectrophoresst Kln•se asayl,t were performed as descrihcd pat. lt-
i•"ul (221. using equal amounts ti protein tor each mmunoprccipitanon -\nit-
hiodi•, Ito CDK2 were iromt Santa Cruz Biotechnology Quantitication iii the
kmaiN as,%% wa, hb denuitometrie scanning
RNA analyses. R\.\ purification and Northern (R--\) analises were per-
tormed hs -,tandard procedure,, ( ) The probes were derned from cD\ V, t 1 th
respectiie genes Quantification was hb denstometric scanning.
RESULTS AND DISCUSSION
Microscopic examination and flow cytometric analysis re-
vealed that the diameter of the Rh cells was approximatelk
85"; of that of the wild-type cells (Fig. IA). The calculated
401I) smaller solume of the Rb cells suggested a shorter
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ýersus side-scatter Il( c\tometrtc analsis Slue is plottcd in th \ .i\ .xiw J..
number is plotted on the t ais Cures trom mutant and vl!d-lspec ,;
indicated (Bi F.-ACScan analisl, it ai-.nchronouslK grrowingm utant and s• .
t.pe cell labeled Aith brimo deouridine-propidium iodide to detcmi al :'n
percentagek ot cell in each cell cicle phase Ihe ,(;G, (;, G . and ph11.l•-s
labeled. (C) Summar, of FACScan analyses. %ith standard delatlon, ItIm ,
total ot 14 and lh experiments trom Rh" and Rh cells. respecticlxcL I
obserned compensator mncrease in S seen in the mutant cells has alsot bcen ot• 1,,
in fibroblasts oerexpressing c.chn E (2s). tD) I'Hlthymidine incorporation
mutant and wild-t.,pe cell% labeled at diflerent times alter release into (
readdition of serum to stared cell• Data are derined trom an cxpclnicin'
pertormed in triplicate, standard deviations are indicated bh error bars imii.m ,
results\ were obtained trom cell derned from at least Il) dilerent Rh 1n1
Rh embrios (E) Thymidine incorporation ol mutant and uild-i\pce ,:
labeled after grovth in reduced concentrations of serum Cells Arc gr•An I•
da~,s, at the serum concentrations indicated and then labeled \itth I[:lthI\ d,.
The t axis is expressed as the percent incorporation ol, cells grow n t In" L ' ,1:
Data sho.n \&ere derised from an experiment pertormed in triplc.tilcate sm.;
de, lations are inmdcated b, error bars
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growth cycle. Therefore. we determined the length of the cel
cycle phases by flow cytometry of asynchronously growing cells
As shown in Fig. IB and C, while the percentages of Rb and
wild-type cells in G, were comparable, there was a 20% reduc-
tion in the number of mutant cells in G, and a concomitant
increase of 12% of those in S. Since the percentage of cells in
each cell cycle phase reflects the time required for each cell
type to transit that phase, we concluded that pRb influences
the timing of G, and that its absence leads to an abbreviated
G, and reduced cell size. However, because of a lengthened S
phase, the overall doubling time of the pRb-deficient cells wa,
comparable to that of their wild-type counterparts (not
shown).
T'o confirm these altered cell cycle kinetics. mutant and
wild-type cells were starved of serum and then released from
Go by the readdition of serum. S-phase entry was monitored b,,
measuring incorporation of [HJthymidine into DNA. \Mutant
cells synchronized in this fashion exhibited a G, phase that is
3 to 4 h shorter than that of their ,wild-type counterparts L Fig.
ID). reinforcing the results from flow ctonmetrx Together.
these observations prox ide direct e ,idence indica tinn that pRh
indeed is an important regulator of cell ckcle prograrc,,n.
It was otf interest to determine if the mitogenic elffct, of
serum worked in part through inactj,.ttanon ot pRh. hecrct, re.
we determined if the Rb cells had obtained sonie Ie el ot
scrum independence for growth. Rh and RIh cells ~'erc
grown in various concentrations of serum for 3 dax,i hcture
being pulse-labeled with I'HJthmididne. As showh n in Fig. IE.
the two cell types exhibit very similar degrees of labeling at all
concentrations ot serum used. This result ,uggests tha t while
serum stimulation of growth ma, work in part bh mnacttlation
of pRb. other molecular events are required for cells to pro-
ceed through the cell cycle.
As described above, the critical checkpoint of (G, has been
termed the R point by Pardee (29). The R-point transition andL
the onset of pRb phosphor-lation and inactn-ation occur at
similar times in mid,late G,. suggesting a connection between
these two processes. Therefore. it was of interest to determine
whether R-point control was maintained in the Rh cells.
Mutant and wild-type cells were growth arrested hb serum
starvation and then allowed to reenter the cell ccle bh reid-
dition of serum. At various points thereafter, either serum \~as
removed (Fig. 2A) or cvcloheximide was added to the cells to
a final concentration of 50 ng ml (Fig. 2B). The R point., as
defined by escape from serum dependence. was found to occur
at similar times relative to the onset of S phase in both cell
types (Fig. 2A). Because the Rb cells progress through G,
more rapidly than wild-type cells and enter S phase 3 to 4 h
earlier following serum addition (Fig. ID). the R point is
similarly shifted by this amount of time relatie to controls
(Fig. 2A). Importantly. the Rb - cells remain dependent on
serum factors up to the R-point transition (Fig. IE). In striking
contrast, the cycloheximide R point appeared to be largely if
not completely absent in the Rb - cells (Fig. 2B): thus. Rb
cells escaped cycloheximide inhibition rapidly after serum re-
stimulation. These results indicated that the R-point transition
depends on at least two distinct, separable molecular pro-
cesses, one cvcloheximide sensitive and pRb dependent and
the other serum sensitive and pRb independent.
A shorter G, and smaller size have also been obserxed in
cells that overexpress several of the G, cclin genes (28. 31-
33). For this reason, we determined the levels of cyclin proteins,
at various points of the cell cycle in the Rb and wild-type
cells by immunoblotting. The expression of G, cclins was
variably affected b% the absence of pRb (Fig. 3A). C'clin DI
levels were slightly elevated (approximatel. two- to fourfold) in
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the Rh cells at different points in G,. In contrast. c\cln I
protein lexels were xastl\ increased in the pRb-deticient cell,
regardless of their position in G or G,. Quantitation oll aut-
tadiograms indicated that the mutant cells contain apprtxt-
matelh 10 times more cvclin E protein (data not shown). In
addition, the slight induction of cvchn E protein levels occur-
ring in wild-type cells late in G, was observed earlier in the
Rb cells (Fig. 3A: compare 18- and 24-h time point,, ll
wild-type cells with 6- and 12-h time points in mutant celI).
Cyclin A protein levels were slightly elevated in the mutants
early in G, as well as in G,. These observed increases could be
a consequence of the premature and highly elevated exprc,,es-
sion of cyclin E in the pRb-deficient fibroblasts or a direct
regulation of cyclin A expression by pRb.
We next addressed whether the increased levels of the cxcln
E and A proteins present in the mutant cells also led tat a
corresponding increase in CDK2 kinase activity. Accordingl\
CDK2 complexes were immunoprecipitated from wild-t'pe
and pRb-deficient cells and used to phosphorylate histonc Ill
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FIG 3 (A) Immunoblot analyjs of protein Ihsates piepared after the readdition lI erum to htdlarcd ecel'ls lot, cotalllin total protcin Ilsates from cells smIIuliie
with serum tor the indicated tlmes. Cs•rlrn proteins ere detecied b- pol\clioni rahtbbitr tinbodi,  Protein amounrs ,ere nlorrnall7edd b\ spectrophotomretric method'
tnid PPonccau S staining ot the nitrocellulose tilters B) IHisione Ill kina,c .ictlis t ol anti-('DK2 immunopreeipitales prepa.red after the radditlion of serum to si.itr c
cellI for the indicated times I(') Ouaniiic,itlon of the anti-CDK2 ImrmunopLrecpliable histone ic I kinase acti•I.\
in % itro. Figures 3B and C show that immunoprecipitates from
the Rbh cells displa, higher HI kinase acti\ ities throughout
G,. In addition, the peak of kinase acti itV occurs earlier in the
mutant cells, and this difference is comparable to their short-
ening of G,. It should be noted that the kinasc Lactlfties were
measured by using CDK2 antibodies in the immunoprecipita-
tions. Therefore. both cvclin A and cvclin E could have con-
tributed to increased CDK2 activity. In addition. as in wild-
tope cells. Rb cells undergo a serum-dependent activation
of CDK2 function, despite constitutise high levels of cclin E
protein. Indeed. this pRb-independent kinasc actilvation ma,
account for the observed serum dependence ot the Rb cell,,
(Fig. IE and 2A).
We next performed Northern blot analsts of RNA prepared
at various times after the readdition of serum to determine it
the dramatic increase in cyclin E protein leiels in the Rh
cells was due to differences in le-vels of cclin E mRNA. E%-
pression of the cyclin E gene has been shown to be normall,
induced in late G, several hours before entrance into S phase
(8. 11. 20. 21 ). As shown in Fig. 4A and C. peak levels of cchnlin
E mRNA expression were seen 6 h earlier in the mutant cells.
This difference is comparable to the overall shortening of G,
,,een in the Rb cells. In addition, cvclin E mRNA levels
were elevated in all parts of G, in the mutant cells. However.
as in the CDK2 kinase activity profile (Fig. 3), an induction tof
cxclin E mRNA occurs in the Rb cells, suggesting that the
cvclin E gene is under complex transcriptional control. only a
part of which is responsive to pRb inactivation.
Work of others has demonstrated that the ectopic expres-
sion of cvclin E causes a substantially shortened G, phase of
the cell cycle, smaller cells, and a longer S phase (28. 32. 33).
These observations suggest that the entrance into the late
phase of G, is controlled by the availability of cyclin E mRNA
and protein and can be advanced by prematurely elevated
protein levels. The pRb-deficient cells show a phenotype strik-
ingly similar to that of these cyclin E-overproducing cells, in-
cluding elevated cyclin E protein levels at all points of the cell
cycle. It is interesting that elevated levels of cvclin E have
recentlv been observed in several human tumors (17. 18).
Transcriptional up-regulation of the TK and cyclin A genes.
which normally follows cvclin E induction, was also accelerated
in the Rb cells (Fig. 4A and data not shown). Whether this
is a direct result of the absence ot Rh function or an indirect
effect of the overexpression of cvclin E is unclear.
In contrast to the changes in gene epression obserned in
mid late G,. transcription of' the immediate-eark gente c-/(N
and transcription of two delaed-earl genes. c-mn( ,iand lthc
cich n D I gene. showed identical patterns (Fig. 4A rand B) Ih'l
tinding suggests that pRh does not ewxrt an% direct control ott
gene expression earl in G, and thus contra,,sts lth tresults lI
others implying pRb-mediated control of c-los and the cxclhn
)1I gene and E2F-mediated control ot c-Mc (13. 19. 24. 35
36). Theretore. the ir;fluence of pRb on the timetable of (
progression appears to be limited largel.\ to its effects on the
timing of the induction of cyclin E mRNA and subsequentl•
occurring processes. This suggests, in turn. that the G, phase oI
the cell c\cle is dilided into two periods demarcated by the
mid late (;. \eent of cclin E mRNA induction.
:VA descrlhed abo\e. the peak le\els of c clin E mRNA are
about twvofold higher in the Rb-deficient cells but the le\els of
protein are about 10 times higher. This disparity suggests that
pRb maý also influence posttranscriptional control mecha-
nisms goecrning cclin E expression. The nature of these,
mechanisms and their regulation by pRb are unknown at thi,,
time.
The detailed mechanisms underlying the negative regulation
of cyclin E expression bý pRb are not resealed b\ the present
work. One possibilit\ is suggested bi the obser\ation (Il()a) that
the cvclin E gene promoter contains a number of E2F sites. the
activity of which may be inhibited by pRb. Independent ot
mechanism, the observed ability of pRb to antagonize cyclin E
expression would seem to stand in opposition to earlier studies
demonstrating that cyclin E operates to antagonize pRb func-
tion (14). In this earlier work. ectopic expression of cyclin E
was found to cause the hyperphosphorvlation of pRb and its
functional inactivation. The two sets of observations can be
reconciled by the existence of a self-reinforcing, positive feed-
back loop that is established in late G . in which cyclin E
participates in the functional inactivation of pRb while the
resulting inactivated pRb permits the ongoing expression of
cyclin E. We note that a positive feedback loop has also been
proposed to describe the control of late G, transit in the yeast
Saccharonmyces cerevwsiae and fruit flies (5, 7. 9, 25-27).
Unexplained by the present work is the disparity between
the reduced G, phase of the pRb-deficient fibroblasts in cul-
ture and the relatively normal development of Rb embryos
up until day 13 of gestation (15). particularly in light of the
presumed importance of G, in various growth control and
206
Vol. 10. 1996
Rb +/+
0 3 6 9 12 in 1R 91 24
Li
Rb -/-
0 3 6 9 12 15 18 21 24
Cycln E
nyc
Cycln Dl
STK
GAPDH
S 2 . 4 5 6 7
8 Rb -/- Rb +/-
0 15 30 60 120 240 0 15 30 6o 120 24
fos
1 2 3 4 5 6 7 9 1 1 2 1
10 11 12 I 1: ; I 1! 16 17
V -4
ii h Tih. clic Jhidc -nhnham :.. , 10 \NoI)H
\ hi l i •- \ thin : Inrt ,alt- IJ C J \ \ Iurl L _ u •l m < k) 'H I T I I L ,
\nthorn h\ inmh
diffcrentllationi mcchanism,,n . In ldcition. the reli0atilc n trn- l
trancriptional induction ol the cell ccicc-regulited i.Cne, c-f i,
C-mfl . and the c\clin D gone othbcirNed ini pRb-deic'cnt htlhro-
hblsts 'uggests that these gene mat he regulated hb other
non-pRbh protmins.
El idence from a \arieti o1 sourccs indicatc, that the R point
repre,,ents a cell c'cle landmark that is of central import-ancc in
cell crowkth control (29). Indeed. It has been ,ho n that tran,-
tormed cells are more resistant to c\hcloheimnide thanL arc their
nontran;formed counterpart (3. .' 30) ý ct other reult,,
Incdicate that the pRb control mechanisrns are diurupted hb at
N ariet, of a in man, and possibly all tIrpcs of tumor Cells
(37) BI at least one operational detinition--cclohetimide
inhibition-R-point control appears to be absent in Rb
mouse embrvo fibroblasts. This obsern ation, together , ith the
obhsencred contemporaneity ot pRb phosphorxlation and the
R-point transition. suggests that pRb may mediate control of
this important gro Vtli-regulating checkpoint
\C KN O\WLE DG( \I E VTS
i c tihank K KIc\ oniari ind - PAardce for the Ik .ID\ - P Sictner
and \1 Elclr, for thoe ,lclin E cD\A. J Pines nd I iltunt Tm for icllin
. .n tihrum. J Rohert i,, r o in Li antin c um fr I rl o\ for I ,l I n7S0-7
\ {,131 . \ [ \•: U k\. \I•:
JN'i
J 1 ' WC
'1" IN0` '1:1d te (1ý-- lk e o
' Foundow iiil \mriru I hi Hk H <I
"01o Inc \11cr1C ,n ( ICnCI J iut: i \ \i ) II I L li, I \ l
( harittblc IFr',t I - • aind ]hc \anton1iI (amccI InI nttIc •, \ \\
I ) R -. \ , ain \m c ic.i:n ( ,C i r So icit\ Rc.C a1.1i Pii c --0 : 1
Ian A[-,,,nt Inseuc.] ato\ !t the f ojM,,',,d I u1'hc', \led1,..:] I-: 111,_
RFFEREN( I, '
kusubel. F. \.. R Brent. R F kington, D1). 1) Moore. J. (. idman. I
'rnith, and K. Struhl ed.i. IM'i ( 1n1:1t p iitl i I I .'
,r e .n e P b uh ,,t n L \ , o . t , I n , i n d J k h n \ % \ i: & b ' ,n 1 •L \ . ,
Buchkoni ch, K.. L A Duf., and E. farh• ,•".I 1 Ihi c i'. in
l pno,,pni ,i~i~cd during --,pcii. ph i,c, i 1i1C Che '%.c ( 1•5'
( ampis. J., E. E. \ledrano. G \iorreo, and -. B. Pardee 1 P2 Rtct
P int corintrol ot cn11 ,routh h\ ,ibilc pie ilc cid nc ,r ii.
,dihit, in -,intorrmcd ,..l, Proc \,t l d -\c 1.i I S\ 79:40' -.iii
S(hen. P. 1L. P. Sui.l, J. 'i. She". J. N. 'Xang. and \N II. I ' -
P h- iph, in n t i cnhe r i mi.i- c r p rn u ! l .
t  
.h .
d. C'c iJ lld Jh lc:i enrnlion ( c! 58.1 l ,M-i
S rou. F. R.. and X. Ii inkelenberi. i041 \ potnt 1 , , , .
,( _n e [ \ A fn d \ -' C C I ! !" ,"pr ej ;:l n '
1,e l ,,.k ( ci 65:x-5
De ( aprio. J.1. \.. .\\ Ludio". I). L'ynch. N. I-urukaa. I t,rithn. If
Plnica-Iormns, ( %I. Huani. and I). M. .Loi ngston. '. I- -
iI 1;
I*·c~--"~-(rar~--r~----- ·--
•L
r.
~e~(l""s"~·""p""p"""~
111- HRRLR \ I F \1
( ELL (C) ( U: Rl - M LA I i\1()\ MHIf Rf. II \013L \s U( )\ 5PRO I F 1
the retinohlaktoma suscepubhiitl% genre h.is poperties of ,i ct1l cxcle regula-
tors element. Cell 58:108)5-ll95
. Dirick, L., and K. Nasmyth. 1991 Posiise feedback in the actisation of G I
csclins in yeast. Nature (London) 351:754-757.
I Dulic. V.. E, Lees., and S. I. Reed. 1992. Association of human csclin E %ith
a periodic G I-S phase protein kinase. Science 257:1958-1961.
9. Duronio. R. J., and P. H. O'Farrelf. 1994. Developmental control of a GI-S
transcrptional program in Drosophila. Deseiopment 120:1503-15153.
I0. Ewen. M1. E., H. K. Sluss, C. J. Sherr. H. Matsushime. J. Kato, and D. M.
Livingston. 1993. Functional interactions of the retinohlastoma protein ith
mammalian D-rtpe ciclhns. Cell 73:4?,7--47
Ilia Geng, Y., E. N. Eaton. \M. Pic6n, J. M. Roberts, A. S. Lundberg. . (Gilford.
C. Sardet, and R. A. Weinberg. Regulation oL cychn E transccnptionon h 2F,
and relnoblastoma protein Oncogen, min pres,
I Geng. I.. and R. A. Weinherg. 1993 Transforming groth factor beta etfects
on c\prcsion ,it G I cclhnand cchlin-dependent protein kmases Proc \a•i
\cad Sec L SA90:10315-10319
12 Herrera. R. E.. and P. E. Shaw. It'9 L\ shadokiing proside, a ninpif
lmeinls to qu.ntil\ nucleic acid transferrCd to h\bridi/ation cmeml•bralne
\ucIlei Acids, Rcs 17:,1(M2.
1 Hiebert. S. W.. 1L. Lipp, and J. R. Nesins. 19N9• LI -- deppndent 15.n-
actilanon o tt hc humanM \l( promote is mediaLted bt the I.2T lau'll P1,
Natl, \caid ci LS \ 86:3594-•' 9-
4 Hinds. P. W4.. S. \littnacht. 1. Dulic. k. rnold. S. 1. Reed. and R. L.
Heinhergi. '12 Regulaiiin of rictinoblaiomna prlhcin uII ,n- ,\ C .'i'i1
\[prcfssll oI l iuiaill. ii \ Icni ,',:si Ce'•ll 70:09
' )' 1
-1 I l i i
Jacks. T.. %. Faneli. E. 1I. Schmitt. R. 1. Bronson. \1. \. (,oodell. and H. \.
Yleinherg. 19Q2 LiLcit ,i an RRh mutation in lithe ousc Lure l I,
359:29 "-
, ato. ... IH. H latsushime.. S4. Hliebert. \I. E. E ien. and ( . .J. ,herr..'
D)IucLt hIihdII ' It0.n I) to1 the lWte cInoblasihtmI e dn:: , 'RN 1 :R")
pR1 phosplholl.lin) bI\ the .chn l)J.Lpen.lden KamCe 1(k- ( 1'.1.. l. D ,
,: lI -,24
keomarsi. ik. .. L (L.ear%. G. ohinar. E. Lees. 11. .1. minuvrt. and \. B.
Pardee. 14 . •t i [sn 1:i pote•lail.l progi)noisi. k1htt 1. I , ! u.''L -'
(tncec Rei 54:3si- s5
I' keonlomar,. K.. and 4. B. Pardee. ('3 Rcdunduitt .I.:m11 '.\;'. e.SS
Znce amlpliicantiin bliieasit cainceicclls hProl N 0,\ oi , L L 1\ ,90:
112-111i
i Kim. S. .1. H. ID. Lee. P. D1). Robbins. K. Busam. M1. ..spirn. and I. B.
Roberts. 11Ai Regulation ol iitnsiaormnn greiosth ati. hia eI e l \pe'-
,ioti b, the product of the retn obl t-ma-suscp til'h( \ 1k. Pl. o , i
\a..J 1SCI ( 88:.S\ 115• i'0
li Koff. \1.. 1. Ohtsuki. K. Polak. J. 1M. Roberts, and .J. la•asague. '
\c.i.ell\ rCeuLtil oil (il 1 Il nllalllll ll •aan • inhibitiont .\Chnli .- epell-
dent kinmise hl TGrh-beia Science 260:53f1-53'i
21 Lem, D. J.. V. Dulic. and S. I. Reed. 1991. Isolation of three no\el human
csclhns bs rescue ot GI cclin (CIn) function in n east. Cell 66:11 '-121•1)
22. fIakelj. T. P.. J. D. Parin, J. Kim. L. J. Huber. P. A. Sharp. and R. 4.
lHeinberg. 1995. A kina,e-deficient transcription factor THII-tH is funticltnal
in basal and actuated transcription. Proc. Nail Scad Scl I'SA 92:51t4-
5178
23 Nledrano. E. E.. and A. B. Pardee. I1580 Presalent deficienc. in lumui cell,
of csclohcimide-induced cicle arrest Proc Natl. A.\ad Sci ISA 77:4123-
412f
24 Muller. 1H.. J. Lukas. A. Schneider. P. H'arthoe. j. Bartek. 1. Eilers. and \1.
Strauss. 1994 C4clini DI etpression it rcgul.ted h\ the rcelnobl.isioma pir~-
in Proc \ili. -\c.id Sci LS.\ 91:2945-2Q14(
2 \lurra). 4.. and 1'. Hunt. 1OI, Ihe cell c\cle \\ t flFeman. (,, \c
\2, asm.th. K.. and L. Dirick. 11I'l he ,It c o ,l I 14 anid `\k i m i01the .a- 1 t
(of GI c'.clin in \icast (ell 66:9'I5- (113
2- Ogas. J.. B. J. -ndrews. and 1. Herskowitz. L111 lnr.iin. t.p ional · 'ao
i, C.I 1. ( L\2 a-' d al pilutale nc\%IGI civch'h (el i(t 52.1, i\ '% 1 , 1 pow i,
re' ul.aor (it 61-.spcculi ircnscripiioln (Cli 66:1l(l -'1(1>
2 ()htsuho. 1M.. and .J. . Roiherts. -1L.3 ( \,.dcpnndelnJ riClr, ulaton1 0 (i,
t mmlllltlh i (lbrl'i,'s lan' cee 259:1, i( -12
S Pardee. %. H. 9 -) (1il -11s 11 1,' C1•l.Lon t .l P" it t l .
246:"•11 ' ,(i
: Pardee. %. B.. and 1... .ni ames. N., s i, 2 1 ' ' .
"Im;-icl k enc BIk,•K A,. P , N , , 2 s- \ ' 2" ,.... ..-
* Quelle. 1). F.. R. %. ,shmun. S V. shurtlefl..1. '1 Kali. I) l.ir-,i.i. 1% . I
Roussel. and C. .1J. herr. <1) ()\e t . -i-,, .n ,to 1) t .. .
Resniliks. D.. 1l. (o(ien. If. iulnard. and '. I. Reed. '
N . i ') ;,n t0 ranis iln ! ls .1 Of I" ' iH 1)' (d I is inf ,
,k,.cv' \Il, (:elf Iil 14:l~ i '0-
Resnilzk%. D.. and S. 1. Reed. !,,1 l; i 1nt ,ie' 1<, ash s 1 , ,, I
' u,..,n , the , -lI- n o.m! ,I, \t , ( Ui [hol 15:4a .
Rilei. 1).J.. E. N, .Lee. and %%. II. Ltee. ,L.i. I ' ". il i'lan .sim !
0'!.. lMa, t .1 l(tlm1 ...pp( \!.t R n (Is Hah I: 11:
Rohbbins. P. 1,..1. 1. Hloruit/. and R. C. lulligan. :((i \I ,ll\. iCai ,
i n0 t manhl1l C-Io pr.'-to hii ih. l kt lol I t p lddl'. \Lhlk
' L ,nd1 ,n l .3 4 6: "0 - ) F ii- t .w 'm 3 5 1 :4 1':, )
I halmeler. K.. H. Snoszik. R. Mlertl. E. L.. Sinnacker..and 11. I.ipp. I ,
S9i t •her l I Fn \|l( Plrilomn ! D( k:s.llt1\ - :--- I
li inherg. R. V. "A14 1 I h, R1, m ,i'n ,wjo i J k c,",1 ( : Io 81: '
208
Vol . 10. 199h
Literature Cited
Additional references can be found on the previous page.
Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavl V and Nadal-Ginard B. (1993).
Interaction of myogenic factors and the retinblastoma protein mediates muscle cell commitment
and differentiation. Cell. 72: 309-324.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW. (1991). Participation of
p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
Ohtsubo M and Roberts J. (1993). Cyclin-dependent regulation of GI in mammalian fibroblasts.
Science. 259: 1908-1912.
209
APPENDIX C
Phenotypes of Mice Carrying Targeted Mutations
in Both Rb and p107
The work described in this appendix has been accepted for publication in Genes and Development.
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Notes of attribution
The p107 gene disruption and the analysis described was performed by Myung-Ho Lee, a post-
doctoral fellow in the laboratories of Ed Harlow and Nick Dyson, in collaboration with Tyler
Jacks. The analysis of the phenotypes in mice carrying mutations in both genes were performed
jointly by myself and Myung-Ho Lee, with assistance from George Mulligan.
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As briefly described in Chapter 1, Rb is a one of a three member gene family which also includes
p107 and p130 (reviewed in 9 Cobrinik, 1996). To assess whether pl07 and p130 play essential
roles in murine development or can act as tumor suppressor genes in some capacity, several
investigators working in collaboration created mice with targeted inactivated mutations in both
genes. pl30-deficient mice were created by David Cobrinik, Greg Hannon, David Beach, Robert
Weinberg, and Tyler Jacks and found to have no detectable phenotype. pl07-deficient mice were
created by Myung-Ho Lee, Nick Dyson, Ed Harlow, and Tyler Jacks and were similarly found to
have no detectable phenotype.
To examine whether Rb, pl07, and p130 had overlapping functions in murine development,
several people began to cross the strains and analyze all the combinations of animals deficient for
two of three genes. My contribution to this was to collaborate with Myung-Ho Lee to analyze the
phenotypes associated with mice deficient for both the p107 and Rb genes. Our analysis indicated
mice carrying mutations in both Rb and p107 did indeed show synergistic defects. Rb+/-;pl07-/-
mice are severely runted and most die neonatally. Those that do survive exhibit severe multifocal
retinal dysplasia and surviving females exhibit vaginal atresia. Rb-/-;p107-/- embryos fail a full 1-
2 days earlier than Rb-/- embryos and display earlier defects in liver and nervous system
development. The report of this analysis follows.
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Targeted Disruption of p107: Functional Overlap Between p107 and Rb
Myung-Ho Leel,6 , Bart O. Williams2 , Georg-, Mulligan2,3, Shizuo Mukai4 ,
Roderick T. Bronson 5, Nicholas Dyson 1, Ed Harlow1, and Tyler Jacks 2 ,3,7
1Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts 02129
3Howard Hughes Medical Institute, 2Center for Cancer Research and Department of Biology,
Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
4Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School,
Boston, Massachusetts 02114
5Department of Pathology, Tufts University Schools of Medicine and Veterinary, Medicine,
Boston, Massachusetts 02111
Running Title: Targeted disruption of p107
Key Words: p107; Rb; gene targeting; apoptosis; retinal dysplasia; liver
6Present address: The Pulmonary Center, Department of Medicine, Boston University School of
Medicine, Boston, Massachusetts 02118
7Corresponding author.
213
Abstract
To explore the physiological role of pl07, a member of retinoblastoma gene (Rb) family, we
disrupted the mouse gene by homologous recombination in embryonic stem cells. p107
homozygous mutant mice were viable, fertile, and displayed no obvious abnormalities. To
investigate possible functional overlap between p107 and Rb, mice with mutations at both loci
were generated. Rb+/l-;pl07-1- mice have a pronounced growth retardation and increased
mortality rate during the first 3 weeks after birth. The Rb+/-;pl07-/ pups that survive to
adulthood did not show any altered tumor predisposition when compared to Rb+ /- mice but
developed multiple dysplastic lesions of the retina. Embryos homozygous for both Rb and p107
died at approximately 11.5 days of gestation, two days earlier than embryos homozygous for Rb
alone. Histological examination revealed accelerated apoptosis in the liver and the central nervous
system of Rb-l-;pl07-1- embryos relative to Rb-1/ embryos. These results provide the first in vivo
evidence that p107 and Rb have overlapping functions in some tissues of the developing and adult
mouse, particularly with respect to apoptosis but not tumorigenesis.
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Introduction
The retinoblastoma gene (RB) is a prototype of the tumor suppressor genes. In humans, mutation
of the RB is frequently found in tumors, and the inactivation of both copies of the gene appears to
be the rate-limiting event in the genesis of retinoblastoma (Cavenee et al., 1983; Dryja et al., 1984;
Friend et al., 1986; Lee et al., 1987). In addition, mutation of genes that function in the regulation
of the retinoblastoma protein (pRB) also occurs frequently in human tumors, suggesting that the
deregulation of the normal pathway in which pRB functions is a common and important event in
many types of tumorigenesis (Friend et al., 1986; Fung et al., 1987; Harbour et al., 1988; Lee et
al., 1988; TAng et al., 1988; Yokota et al., 1988; Horowitz et al., 1989 and 1990; Toguchida et al.,
1989). Inactivation of Rb by gene targeting in the mouse has revealed that pRB is required for
normal development. Embryos homozygous for mutant Rb die between 13.5 and 15.5 days of
gestation with extensive apoptotic cell death in the liver, central nervous system, and ocular lens as
well as inefficient definitive erythropoiesis (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992;
Morgenbesser et al., 1994). Adult mice heterozygous for the Rb mutation do not develop
retinoblastoma but are highly predisposed to intermediate lobe pituitary tumors and medullary
carcinoma of the thyroid (Jacks et al., 1992). Analysis of chimeric Rb- /- mouse embryos suggests
that Rb'-1 retinoblasts may undergo cell death instead of proliferating (Maandag et al., 1994).
However, retinoblastoma has been induced in the mouse by the targeted expression of SV40 large
T (Windle et al., 1990; Al-Ubaidi et al., 1992), or human papillomavirus type 16 (HPV-16) E7
and E6 (Howes et al., 1994), both of which inactivate Rb family proteins and p53. This raises the
possibility that mutations in other members of the Rb family and p53 are further required for
induction of retinoblastoma in the mouse.
The p107 and p130 genes encode proteins with related structures and similar biochemical
properties to pRB. Much of the sequence similarity among pRB, p107, and p130 resides in the
domains that mediate interaction with viral oncoproteins. The transforming regions of adenovirus
E1A, SV40 large T antigen and HPV-16 E7 proteins target these Rb family proteins. The Rb
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gene family is expressed in most cell types, and like pRB, the overexpression of either p107 or
p130 has been shown to arrest cells in G1 phase of the cell cycle (Zhu et al, 1993; Claudio et al.,
1994). All three proteins have been shown to associate with the transcription factor E2F in vivo
and to repress E2F-dependent transcription when overexpressed. The co-expression of E2F genes
reverses the cell cycle arrest caused by pRB (Zhu et al., 1993; Qin et al., 1995), p107 (Zhu et al.,
1995) or p130 (Vairo et al., 1995). Thus, like pRB, p107 and p130 may also be negative
regulators of cell proliferation, acting at least in part through regulation of the E2F transcription
factor.
Despite the extensive similarities among pRB, p107, and p130, there are several indications that
these proteins have distinct properties. pRB, p107, and p130 appear to bind to different subsets of
E2F and at different phases of the cell cycle. p107 interacts preferentially with E2F-4 in cycling
cells (Ginsberg et al., 1994; Beijersbergen et al., 1994a), whereas pRB interacts with E2F-1, E2F-
2, and E2F-3 (Lees et al., 1993) and p130 with E2F-4 (Vairo et al., 1995) and E2F-5 (Hijmans,
1995). Cyclin A/cdk2 or cyclin E/cdk2 are found in most p107/E2F and p130/E2F complexes but
not in pRB/E2F complexes (Cao et al., 1992; Ewen et al., 1992). Furthermore, p130/E2F
complexes are detected in cells in Go, whereas the pRB/E2F and p107/E2F complexes appear later
in G1 and persist in S phase cells (Shirodkar et al., 1992; Cobrinik et al., 1993; Schwarz et al.,
1993). Possible functional differences between p107 and Rb are further supported by in vitro data
showing that ectopic expression of pl07 suppresses proliferation of the human cervical carcinoma
cell line C33A, whereas overexpression of Rb does not (Zhu et al., 1993). A role for p107 in
embryonic development is also suggested by its distinctive expression pattern in the heart, which
differs from that of Rb. The p107 gene is expressed at high levels in the heart during embryonic
development, and transcript levels then decrease significantly at birth, whereas the Rb gene is
expressed steadily at low levels during the same period (Kim et al, 1994).
Despite considerable in vitro evidence for the involvement of p107 in growth control and
development, there is no proof supporting such a function in vivo. Importantly, it is uncertain
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whetherpl07 can act as tumor suppressor gene, because no specific mutation ofpl07 has been
reported in tumors to date. To address whether p107 is involved in growth control and
development in vivo and to investigate the functional relationship between p107 and pRB, we have
created p107 mutant mice by gene targeting and generated Rb and p107 double mutant mice. We
have determined that while deficiency for p 107 does not induce obvious abnormalities in mice or
the cell cycle profile in cultured cells, it alters the phenotype of the Rb mutation, particularly with
respect to apoptosis and retinal pathogenesis.
Results
p107 gene targeting
The p107 gene was inactivated in murine embryonic stem (ES) cells by homologous
recombination as shown in Fig. 1. A targeting vector (Fig. lA) was constructed in which a
fragment containing a 95 bp 3' region of exon 1 and a 2.3 kb region of the downstream intron was
replaced by a PGK-neo expression cassette, containing the neomycin resistance gene driven by the
phosphoglycerate kinase promoter, in the anti-sense orientation relative to the coding region of
p107. A herpes simplex virus thymidine kinase gene expression cassette (PGK-tk) was also
placed adjacent to the 5' end of the homology to allow the use of both positive and negative
selection (Mansour et al., 1988). Homologous recombination was predicted to produce a mutant
allele capable of synthesizing only the first 22 amino acids of the wild-type p107 sequence.
D3 ES cells (Gossler et al., 1986) were electroporated with the linearized construct, and individual
clones resistant to both G418 and gancyclovir were isolated and expanded for screening by
Southern analysis of genomic DNA. Of 50 doubly resistant colonies screened, 12 had
incorporated the predicted mutation in the p107 gene by homologous recombination, as judged by
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genomic Southern blot using a 5' probe that lies outside the region of homology with the targeting
vector as well as a 3' probe (Fig. IB).
Following injection into C57BL/6 blastocysts, two of the properly targeted ES cell clones
produced chimeras which transmitted the p107 mutation through the germline. As expected, half
of the agouti offspring of such chimeras were heterozygous for the mutant p107 allele based on
Southern blot analysis of tail DNA. To determine whether mice homozygous for the disrupted
p107 gene were viable, heterozygotes were interbred and their progeny were genotyped. Southern
analysis of tail DNA (see Fig. 1C) showed the expected Mendelian distribution of genotypes: of
130 animals screened, 33 were wild-type, 68 were heterozygous, and 29 were homozygous for
the mutant allele. Thus, p107 is a nonessential gene in the mouse.
p107 homozygous mutant mice do not produce detectable p 107 protein and mRNA
To confirm that the p107 gene had been fully inactivated, the level of p 107 protein was examined
in extracts of embryonic fibroblasts derived from wild-type and p107 mutant mice. Extracts were
immunoprecipitated with a mixture of anti-pl07 monoclonal antibodies (SD9 and SD15), and the
immunoprecipitates were analyzed by western blot with an anti-pl07 monoclonal antibody (SD9)
which recognizes an epitope in the "spacer" region of p107. As shown in Figure 2A, extracts
from the homozygous mutant embryonic fibroblasts do not contain any detectable p107 protein,
whereas the level of p107 protein in heterozygous mutants was approximately 50% of wild-type.
Similarly, western blot analysis of extracts made from whole embryos (E18) probed with the SD9
monoclonal antibody detected no p107 protein (data not shown.). Lack of p107 in the mutant mice
was further confirmed by analysis of RNA. Northern blotting of poly(A)+ RNA from wild-type
and p107 mutant whole embryos (E18) demonstrated that p107-1- mice lack normal p107 mRNA
(Fig. 2B).
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We also examined the possibility of compensatory up-regulation of pRB and p130 protein in the
absence of p107. Western blot analysis of total proteins isolated from wild-type and mutant
embryos with antibodies specific to pRB or p130 indicated that relative to wild-type, no significant
difference was observed in the amount of pRB and p130 in whole mutant embryos (E18) (Fig.
2C), or separately in their liver, heart, lung, and brain (data not shown).
p107 mutant mice are viable and fertile
p107+ /- and p107-1- mice have not displayed any increased morbidity or mortality up to 24
months of age. Routine comparative gross and histological surveys of internal organs of 4- to 12-
month old homozygous mutant animals did not reveal any developmental or pathological
abnormalities. The development of T- and B-cells in the thymus and spleen of mutant mice were
also normal compared to wild-type, as determined by the expression pattern of CD4/CD8 and
IgG/IgM, respectively (data not shown). Additionally, the loss of p 107 did not impair fertility, as
litter sizes from homozygous breeding pairs were similar to those of wild-type mice. Mutant mice
generated on an inbred 129/Sv genetic background also did not show any abnormal phenotype up
to 10 months of age. However, upon careful examination of p107-/- embryos, we have observed
subtle thickening of the bones of the forelimbs (D. Cobrinik et al., manuscript in preparation).
pl07-deficient embryonic fibroblasts
p107 has been implicated in cell cycle control, because it forms complexes with E2F and
cdk2/cyclin A or cdk2/cyclin E in G1/S phase. To assess directly the affects of p107 deficiency on
cell cycle regulation, we examined the cell cycle features of p 107-deficient embryonic fibroblasts
(passage 4 to 6) derived from 12.5 days embryos. The pl07-deficient cells did not show
significant differences from wild-type cells in cell cycle profile as determined by flow cytometric
analysis of BrdU/propidium iodide-labeled cells, growth curves, length of G 1 phase after serum
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release, or serum dependency (data not shown). These data do not support an obligatory role for
p107 in cell cycle regulation, at least in this cell type.
Rb+l-:D107+/- mice
We tested the possibility that p107 and pRB might perform partially overlapping functions by
crossing the pl07-homozygous mutant mice to mice carrying the RbX3 t mutation (Jacks et al.,
1992). The initial cross of pl07-' to Rb+ /' mice yielded Rb+l/-;pl07+ /- offspring with the
expected frequency of 50%, and the phenotype of these animals was indistinguishable from that of
their Rb+/l littermates. Rb+/-;pl07+/- animals died from tumors in the intermediate lobe of the
pituitary as seen in the Rb+l- mice at approximately one year of age. PCR analysis of 7 pituitary
tumors from these mice indicated that the wild-type allele of Rb was absent while the wild-type
allele of pl07 was retained (data not shown.). Thus, there appears to be no selective advantage to
loss of pl07 function during tumor development in this tissue.
Retarded growth of Rb+/-:p107-/- mice
To investigate the effect of p107 deficiency on the Rb+l- phenotypes, Rb+/-;pl07-/- mice were
generated. To generate Rb+/-;pl07-/- mice, Rb+l/-;pl07+/- mice were intercrossed or crossed to
pl07-1- mice. As assessed at 3 - 4 weeks of age, the number of Rb+/l;pl07- /- animals obtained
was markedly lower than expected (Table 1A and IB). Litters contained pups of approximately
uniform size at birth, but after several days, some runted pups were evident. Genotyping showed
that the runted pups were consistently Rb+1/;pl07 "- - , and they were born at somewhat lower than
the expected frequency. Of 81 pups genotyped at one week of age from Rb+/-;pl07+ /- by p107-
/- crosses, 15 (19%) were Rb+/-;pl07-/-, which is significantly fewer than expected frequency of
25%. These mice were severely growth retarded for several weeks, averaging approximately 50%
of the weight of their littermates (Fig. 3A). The average body weight of 1 week old
Rb+l-;pl07-/- mice was 3.2 + 0.4 g (n= 8), whereas that of Rb+/-;pl07+ /- mice was 6.2 ± 0.3 g
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(n= 6), which is comparable to the other mutant genotypes and wild-type. At 2 weeks of age, a
similar difference persisted: 4.5 ± 1.2 g (n= 10) for Rb+/';pl07-/- compared to 11.0 ± 0.6 g (n=
8) for Rb+l-;pl07+ /-. Approximately 25% of these Rb+l-;pl07-1- mice survived beyond three
weeks of age. Most of these surviving animals gained weight slowly, reaching 70 - 90% of
normal weight after 3 months. A representative growth curve for Rb+/';pl07-/" mice is shown in
Figure 3B. Most of the male Rb+/';pl07-/' animals were fertile (Table IC and 1D) and
apparently normal up to 12 months of age. However, approximately 75% of female Rb+/l-;pl07-
/" mice had vaginal atresia (Fig. 3C). Although the vaginal opening was not present in the affected
females, the remainder of the reproductive tract appeared normal (not shown). Between 4 - 6
months of age, the affected female mice accumulated fluid in the uterus and died. Surviving Rb+/l
;p107-4- mice subsequently succumbed to pituitary tumors associated with their Rb+l/ status after
12 months. Thus, at least out to one year of age, there is no obvious additional tumor phenotype
associated with this mutant combination.
Retinal dysplasia in Rb+-:;pl07-/- mice
Although retinoblastoma does not develop in Rb+l- mice or chimeric mice constructed with Rb-/-
ES cells (Williams et al., 1994; Maandag et al., 1994), this tumor is observed upon retinal
expression of viral oncogenes that bind and inactivate all three members of the pRB family.
Therefore, we carefully examined the retinas of surviving Rb+/- ;p107-1- animals at the age of 4 - 6
months by indirect stereoscopic ophthalmoscopy. Retinal lesions were detected in all 12 Rb+l/-
;p107"/- mice examined, and 11 out of the 12 were affected in both eyes. Typically, each eye
exhibited 5 to 7 individual lesions consisting of small white bodies, usually in clusters (Figure
4A). No retinal abnormalities were detected in any of 8 p107-1/ mice examined or in greater than
20 Rb+l - mice examined (data not shown). Histological analysis of eyes from Rb+/';pl07-/ "
mice confirmed the presence of retinal lesions, which were characterized as severe retinal dysplasia
or disruption of the normal photoreceptor architecture (Figs. 4B to 4E). Histological analysis of
retinas taken from 4 day old Rb+/-;pl07-/ - neonates also showed the presence of subtle, yet
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significant disruptions of the photoreceptor layer of the retina (Figs. 4F and 4G), which could
represent precursors to retinal dysplasia.
Early death of Rb-/-:pl07-/- embryos
pRB is required for normal mouse development (Lee et al., 1992, Jacks et al., 1992, Clarke et al,
1992). Rb-/- embryos die between 13.5 - 15.5 days of gestation, with excessive apoptotic cell
death and inefficient erythroid differentiation. In order to examine the developmental
consequences of inactivation of both Rb and p107, Rb+/-;pl07-1- males were crossed to Rb+ /-
;p107+/- females to produce double mutant embryos at an expected frequency of 12.5%.
Embryos were recovered at different days of gestation, examined morphologically and genotyped.
As shown in Figure 5, in contrast to Rb-" - embryos, the double mutant embryos died significantly
earlier than 13.5 days of gestation. Analysis of E11.5 embryos revealed that of the 19 Rb-l-;pl07"
/- embryos examined, 9 were dead and 2 were noticeably smaller than their littermates.
Histological analysis of the surviving embryos revealed an abnormally high frequency of pyknotic
nuclei (characteristic of apoptosis) in the central nervous system (CNS) (Fig. 6B). This is in
contrast to embryos deficient for pRB alone in which apoptosis in the CNS is not apparent to this
extent until E13.5 (Lee et al., 1992, Jacks et al., 1992, Clarke et al, 1992). At E12.5, seven out of
eight Rb-l-;p107-1- embryos detected at this stage were dead or in various stages of resorption.
Detailed histological analysis of the viable embryo revealed abnormally high levels of apoptosis in
the liver as indicated by the presence of pyknotic nuclei (Fig. 6D) and in the CNS (data not
shown). Rb-1- embryos did not show this degree of apoptosis in the liver at this developmental
stage (Fig. 6C). The apoptotic cell death in the liver of double mutants was not evident at E11.5.
These data indicate that the p107 deficiency enhances the induction of apoptosis associated with
loss of pRB in the liver and CNS.
Analysis of E10.5 embryos showed that of 10 double mutant embryos recovered, 2 were dead and
2 were noticeably smaller than the majority of their control littermates. However, histological
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analysis of the viable embryos did not reveal any obvious pathology at this developmental stage.
In an effort to elucidate the cause of early death of Rb-l-;pl07-1 - embryos, histological analysis of
yolk sacs from viable double mutant embryos at 11.5 days of gestation was performed.
Compared to Rb+/l-;pl07-1- embryos, there was a significant decrease in the number of
erythrocytes in the yolk sac blood vessels as well as disorganization of the endothelial linings of
the vessels. However, Rb-/" mice also frequently showed a similar defect at the same gestational
age (data not shown; Clarke et al., 1992). Therefore, it remains unclear why the Rb-l-;pl07 -/-
embryos fail earlier in gestation than Rb-1- embryos.
Muscle formation of Rb--;:pl07-I- embryos
The expression of viral oncoproteins that bind to pRB, p107, and p130 induces pleiotropic effects,
including the inhibition of myogenic differentiation (Webster et al., 1988; Endo 1992; Maione et
al., 1992) and induction of DNA synthesis in the nuclei of differentiated myotubes (Endo 1992).
Although aberrant cell cycle re-entry has been reported in Rb-1 - myotubes (Schneider et al., 1994),
most aspects of skeletal muscle differentiation are observed in pRB-deficient embryos (Clarke et
al., 1992; Jacks et al., 1992; Lee et al., 1992) and cells (Schneider et al., 1994). In light of the
partially overlapping developmental functions of the Rb gene family (this study and D. Cobrinik et
al., manuscript in preparation), as well as previous suggestions of functional redundancy between
pRB and p107 in muscle development (Gu et al., 1993; Schneider et al., 1994), we examined
Rb-l-;pl07-"- embryos for the presence of skeletal muscle. Histological analysis of double mutant
and control embryos at E12.5 revealed myofibers in the body wall and primordial tongue in all
embryos (data not shown). In addition, immunohistochemical analysis with an antibody specific
for sarcomeric actin showed comparable staining in the body wall of Rb-l-;pl07-1- (Fig. 6F) and
control embryos (Fig. 6E). This indicates that at this stage in development, both myogenic
commitment and differentiation can occur normally in the absence of both pRB and p107.
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Discussion
pRB, p107, and p130 comprise a family of proteins sharing common structural organization and a
significant degree of sequence similarity. Evidence from many different experimental systems has
suggested that this family of proteins has critical functions in the control of cell proliferation and
differentiation. In the present study, we have addressed the biological role of p107 and its
functional relationship with Rb. Using gene targeting in ES cells, we have generated p107-
deficient mice. Unexpectedly, these mice are viable, healthy, and fertile. The oldest p107-1- mice
are now greater than 2 years of age, and to date, no tumor phenotype is evident. Furthermore, the
analysis of embryonic fibroblasts derived from p107-deficient embryos did not reveal any
detectable differences in cell cycle characteristics relative to wild-type cells.
These findings are surprising in light of the extensive literature describing studies carried out in
tissue culture cells indicating that p107 may function in control of the cell cycle progression, in the
regulation of cell proliferation and cell differentiation (See for example, Cobrinik et al., 1993;
Schwarz et al., 1993; Zhu et al., 1993; Beijersbergen et al., 1994a; Beijersbergen et al., 1994b; Gu
et al., 1994; Kim et al., 1994; Schneider, et al., 1994; Hoang et al., 1995). The absence of overt
abnormalities in pl07-deficient cells or pl07-deficient mice would on the surface appear to
contradict these previous findings. It may be that p107 function is not essential in these processes
and that the earlier results derive from ectopic p107 overexpression. However, it is also possible
that p107 is normally involved in cell cycle progression and differentiation, but that in its absence,
other proteins, including other members of the Rb gene family can functionally compensate for its
absence.
The data presented in this paper shows that p107 and Rb have overlapping function in some
tissues at specific stages of development. Embryos deficient for pRB die between 13.5 and 15.5
days of gestation. In contrast, Rb-/-;pl07-/- embryos died beginning at 10.5 days of gestation with
none surviving beyond 12.5 days. Thus, a requirement for p107 function in mid-gestation
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development is revealed in the context of pRB deficiency. The early death of the double mutant
embryos was accompanied by accelerated apoptotic cell death in the liver and central nervous
system compared to Rb mutant embryos alone. It is noteworthy that mice deficient for p130 or
both p107 and p130 did not show embryonic lethality or obvious abnormality in apoptotic cell
death (D. Cobrinik et al., manuscript in preparation); however, p107 and p130 share overlapping
functions in other cell types and at other stages of development.
The functional overlap between p107 and Rb could occur at several different levels. At one
extreme, the enhanced phenotypes of the Rb/pl07 double mutnat mice might be due to true
biochemical redundancy. Here, the redundancy might arise from naturally shared activities or
might be fostered by the loss of a closely related family member. At the other extreme, functional
overlap might arise from the combination of partially crippled pathways that when brought
together in the double mutants greatly magnifies the phenotype in the affected cell. Whichever the
case, the novel phenotypes described here will provide the needed materials to decipher the
overlapping activities of these important regulators of proliferation.
Since Rb-'l-;pl07-/- embryos showed an altered phenotype, we investigated whether loss of p107
affected the tumor phenotype of Rb+l- mice. Rb+l/-;pl07-1- mice showed severe growth
retardation but did not display any additional tumor phenotype beyond the pituitary tumors caused
by Rb heterozygosity. However, Rb+-';pl07-/- mice developed focal lesions in the retina with
degeneration of the photoreceptor layer and retinal dysplasia. Such lesions are not present in Rb+l/-
or p107-1 mice. Moreover, lesions of this type were not found in chimeric mice partly composed
of Rb -1- cells (Maandag et al., 1994). Although the frequency and focal nature of these lesions
suggests that they result from the inactivation of the remaining wild-type Rb allele, this has not yet
been demonstrated experimentally. The defect in the photoreceptor layer is reminiscent of the
degeneration of the retina due to photoreceptor cell death in transgenic mice following the
expression of the HPV-16 E7 oncogene exclusively in photoreceptor cells and pineal gland
(Howes et al., 1994). However, as the E7 protein can bind to pRB, p107, and p130, it was unclear
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from these studies whether the cell proliferation and apoptosis caused by E7 expression resulted
from the inactivation of all three proteins or from inactivation of specific family members. In the
present study, retinal lesions were not found in p130-1', Rb+1-;p130-1-, p107+ /- ;p130-1-, and
p107-l-;p130+ /- mice (unpublished data), suggesting that degeneration of the retinal layer may be
a specific consequence of the inactivation of Rb and pl07. These data suggest that the entire
photoreceptor layer would be affected in Rb-l-;pl07-/- mice. However, such an analysis is
precluded by the fact that double mutant embryos die prior to retinal differentiation. The
production of chimeric mice using ES cells mutant for both Rb and p107 may address this
question.
Although mutation of the p107 gene is unlikely to be a rate-limiting or initiating event for tumor
formation, the appearance of the retinal lesions in Rb+/- ;p107-/- mice suggests that there may be
specific settings in which mutation ofpl07 may promote tumor progression. By analogy with the
cooperative effects of HPV-16 E6 and E7 in tumorigenesis in the retina (Howes et al., 1994), one
might expect that germline mutation of p53 along with Rb and p107 might lead to frank
retinoblastoma. Further studies are needed to identify additional genetic backgrounds in which
loss of p107 function might contribute to tumorigenesis.
Taken together these observations are consistent with the notion that p107 and pRB can serve
related functions in growth control and/or differentiation in some developmental contexts but not in
the inhibition of tumor formation, save perhaps for the retina. Since p107 and pRB both interact
with E2F but associate with different subsets of E2F polypeptides (Beijersbergen et al., 1994;
Ginsberg et al., 1994), it is possible that their roles in the regulation of E2F may explain both the
specific and related functions. Alternatively, other growth control and differentiation pathways
normally regulated by these proteins may contribute to the mutant phenotypes. Further
characterization of the biochemical basis of the observed defects should help elucidate the relevant
pathways.
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Materials and methods
Isolation of genomic p107 clones
A mouse genomic library constructed from the liver DNA of the strain 129/Sv (Stratagene) was
screened using a fragment of the mouse p107 cDNA as a probe. A 350-nucleotide fragment from
the 5' end region containing the ATG translation initiation codon was prepared by PCR and was
radiolabeled by random primer labeling techniques (Pharmacia). Filters were washed under high
stringency (0.5 x SSC, 0.1% SDS at 65"C). Several clones were isolated, and a lambda clone with
a 15 kb genomic insert was identified as containing exon 1 by Southern blot analysis and
sequencing. The insert was subcloned into pBluescript SK (Stratagene) and extensively mapped
with restriction enzymes.
Construction of the targeting vector
The targeting vector was derived from the pPNT vector, which contains the thymidine kinase gene
and the neomycin resistance gene (Tybulewicz et al., 1991). The 4.0 kb Pstl mouse genomic
fragment and 3.0 kb HindII-NotI (derived from a cloning site of pBluescript SK) fragment
surrounding the first exon of the mouse p107 gene (which encodes amino acids 1 - 52) were
cloned into pPNT surrounding the neomycin resistance gene. The unique Not1 site in the
construct was used to linearize the plasmid prior to electroporation into ES cells.
ES cell culture, transfection. and selection
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The D3 ES cell line (passage 5), derived from strain 129/Sv, was grown on feeder layers of g-
irradiated (1500 rad for 30 min) embryonic fibroblasts in Dulbecco's modified Eagle's medium
supplemented with 15% heat-inactivated fetal calf serum (Hyclone), 0.1 mM nonessential amino
acids, 0.1 mM 2-mercaptoethanol, and 1000 units/ml mouse leukemia inhibitory factor (ESGRO;
GIBCO BRL). Cells (8 x 106) were electroporated in 0.8 ml of medium with 40 mg of linearized
targeting vector DNA at 400 V/250 mF in a Bio-Rad Gene Pulser, and were plated on feeder cells.
Selection with 300 mg/ml G418 (GIBCO BRL) and 2 mM gancyclovir was started 48 hr later.
Three hundred doubly resistant colonies were selected for screening by Southern analysis.
Southern blot analysis to identify targeted clones
Individual ES cell clones were lysed in 20 mM Tris-HC1, pH 7.5, 150 mM NaC1, 5 mM EDTA,
0.5% SDS, and 0.25 mg/ml proteinase K overnight at 37"C. Samples were extracted with phenol-
chloroform, and genomic DNA was isolated by ethanol precipitation. Genomic DNA (10 mg)
from each clone was digested with Hpal and Sphl, resolved by electrophoresis on 0.9% agarose
gels, and transferred to nylon membrane (Hybond-N+; Amersham). Prehybridization was carried
out in 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 1% bovine serum albumin (BSA), and
7% SDS at 65*C. Hybridization was performed with the 32p-labeled probe in 0.2 M sodium
phosphate, pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS, 15% formamide, and 100 mg/ml salmon
sperm DNA at 65°C. The 5' hybridization probe was a 950 bp Rsal fragment derived from 1.5 kb
Hpal-EcoR1 fragment of p107 genomic DNA, which contained sequences not included in the
targeting vector. A 500 bp HaeIII fragment derived from a 1 kb EcoR1-Sphl fragment was used
as the 3' probe. Filters were washed three times in washing buffer (40 mM sodium phosphate, pH
7.2, 1 mM EDTA, and 1% SDS ) at 65"C, and exposed to film.
Generation and breeding of chimeric mice
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Blastocysts were isolated from C57BL/6 mice at day 3.5 of pregnancy, and 12 ES cells were
injected into the blastocoel cavity. The blastocysts were implanted into the uterine horns of
pseudopregnant CD1 recipient females. Chimeric offspring were identified by agouti contribution
to the coat color due to the ES cells and were crossed to C57BL/6 females. Germ-line
transmission of the mutant allele was assessed by Southern blot analysis of tail biopsies of agouti
progeny.
PCR analysis of 1l07 genotype
DNA from tail biopsies or yolk sacs was isolated as described for the Southern blot analysis
above. A 330 bp PCR fragment specific for the p107 mutation allele was amplified using primers
3' to the disrupted region (p107 com = 5'-TCGCTGGCAGTCTGAGTCAG-3') and within the
integrated neo construct (pl07 neo = 5'-ACGAGACTAGTGAGACGTGC-3'). A 280 bp PCR
fragment specific for the wild-type p107 allele was amplified using the same pl0 7 com primer
used above and a primer corresponding to the region deleted in the mutant allele (pl07wt = 5'-
TGTCCTGAGCATGAACAGAC-3'). DNA samples were amplified in 20 ml reaction in buffer
containing 60 mM Tris-HC1, pH 9.0, 15 mM (NH 4 )2S04, 3.5 mM MgC12, 1mM of each dNTP,
1 unit Taq polymerase (Promega), and 1 mM of each primer. Samples were amplified for 30
cycles for 1 min at 94°C, 1 min at 60°C, and 1 min at 72TC. PCR products were resolved by
electrophoresis on 1.5% agarose gels and visualized by ethidium bromide staining. Primers for
PCR analysis of Rb genotype and reaction conditions for amplification have been described
previously (Jacks et al., 1992).
Northern and western blot analyses
For northern blot analysis, total RNA was isolated from embryos by guanidinium thiocyanate-
phenol-chloroform extraction (Chomczynski and Sacchhi, 1987) and enriched for poly(A)+ RNA
using oligo(dT) cellulose. Samples (4 mg) were resolved by electrophoresis on 1% agarose gels
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containing formaldehyde, transferred to nylon membrane (Hybond-N+; Amersham), hybridized
to a 4.8 kb mouse full-length p107 cDNA probe in the presence of 30% formamide, with other
conditions as described above for Southern blotting. To prepare cell lysates, cells were extracted
with lysis buffer (50 mM HEPES buffer, pH 7.0, 250 mM NaCl, 0.1% Nonidet P-40, 5 mM
EDTA, 1 mM phenylmethylsulfony fluoride, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 0.5 mM
DTT, and 0.5 mM sodium fluoride), and centrifuged for 10,000 x g for 10 min. Embryos were
frozen and pulverized in liquid nitrogen before extraction. Protein concentration was measured
with a Coomassie blue dye binding assay (Bio-Rad). To immunoprecipitate p107 in lysates, the
supernatants were incubated with a mixture of monoclonal anti-pl07 antibodies (SD9 and SD15)
at 4"C for 1 hour. For western blot analysis, the immunoprecipitates or cell lysates were denatured
in SDS loading buffer and separated by SDS-polyacrylamide gel electrophoresis, and transferred
to Immobilon-P membranes (Millipore). Membranes were incubated with anti-pl07 antibody
(SD9) or monoclonal anti-pRB antibody (3C8, Kanji), or polyclonal anti-p 130 antibody (C-20,
Santa Cruz), and then subsequently incubated with a goat anti-rabbit or anti-mouse horseradish
peroxidase-labeled antibody (Amersham). Antigen-antibody complexes were detected by
enhanced chemiluminescence (ECL, Amersham).
Retinal examination by indirect ophthalmoscopy and fundus photography
Pupils were dilated by topically applying eye drops consisting of 2.5% phenylephrine-HCI and
0.4% tropicamide (Phen/Trop, Mass Eye and Ear Infirmary Formulary, diluted 1:1 with sterile
BSS) to the cornea of each eye. The pupils dilated fully within 5 minutes. The retina was
examined in situ with a standard, clinical indirect ophthalmoscope (Keeler Fision) using a 60, 78,
or 90 diopter condensing lens (Volk, Nikon) depending on the desired magnification and field of
view. Fundus photographs were taken using a Kowa RC-2 hand-held fundus camera and a 60 or
78 diopter condensing lens on Kodak Ektachrome 100 Professional color reversal film (S. Mukai,
manuscripts in preparation).
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Histology and immunohistochemistry
For histological analyses, tissues were removed, fixed in phosphate-buffered 10% formalin,
dehydrated in increasing concentrations of ethanol followed by xylene, embedded in paraffin,
sectioned at 6 mm, and stained with haematoxylin and eosin. For immunohistochemistry, embryo
sections were deparaffinized and rehydrated before a 20 minute incubation in block solution: 2%
goat serum, 1% horse serum, 0.1% Triton X-100 in PBS. Sections were then incubated for 1 hour
with anti-sarcomeric actin monoclonal antibody (Sigma) diluted 1:1,000 in block. After 3 washes
in PBS, antibody was detected with Vecta Stain Elite ABC Peroxidase Kit (Vector Laboratories)
and counterstained with 0.25% methyl green.
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Table 1. Offspring viability of Rb+/-;pl07-/- mice at 3 - 4 weeks of age
A. Rb+l';pl07+ /' x Rb+/';pl07+ /-
Genotypea Rb +1+ +/+ +/+ +/1-+/- +/-
p107  +1+ +/- -/- +/+ +/- -/
expected ratio 0.5 1 1 1 2 1
numbers obtained 4 (0.4) 10 (1.0) 9 (0.9) 14(1.4) 29 (2.9) 3(0.3)
B. Rb+/-;pl07+ /- x p107-1-
Genotype Rb +/+ +/+ +/- +/-
p107 +/I-- +- -/-
expected ratio 1 1 1 1
numbers obtained 148 (1.0) 179 (1.2) 157 (1.1) 38 (0.26)
C. Rb+/l-;pl07-l- , male x p107-1- , female
Genotype Rb +/+ +/-
pl07 -/- -
expected ratio 1 1
numbers obtained 69 (1.0) 14 (0.2)
D. Rb+/-;pl07-/- , male x Rb+/-;pl07+ /-, female
Genotypea Rb +/+ +/+ +/- +/-
pl07 +/- -/- +/- -/-
expected ratio
numbers obtained
1
16 (1.0)
1
16(1.0)
2
42 (2.6)
2
5 (0.3)
Genotype analysis was performed using DNA prepared from tail biopsies of 3 - 4 weeks old live
offspring from each cross. The number of Rb+ / + ;pl07+ /- mice or Rb + / + ;p107-/- mice was
arbitrarily assigned a value of 1.0 and relative ratios of the other genotypes were calculated
accordingly (numbers in parentheses).
a Several genotypes of mice that are embryonic lethal due to an Rb-/- genotype were excluded.
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Figure Legends
Figure 1. Targeted disruption of the mouse p107 gene. (A) The restriction map of targeting
vector, wild-type, and mutant p107 alleles. Homologous recombination would result in
replacement of 2.3 kb fragment from the p107 gene with a PGK-neo expression cassette. The
arrows indicate the direction of transcription of PGK-neo and PGK-tk expression cassette, which
are in the opposite direction to p107. A closed box represents p107 exon sequence containing the
first ATG translation initiation sequence. p107 gene 5' flanking probe and 3' probe used for
screening of ES cell clones and mutant mice are indicated, together with the expected size of
hybridizing restriction fragments resulting from a double digestion with Hpal and Sphl for the
wild-type and mutant alleles. R, EcoR1; P, Pstl; H, HindIII; Hp, Hpal; Sp, Sphl. (B) Southern
blot analysis of Hpal plus Sphl-digested genomic DNA from ES cells. Hybridizing fragments
with the 5' probe are 12 kb for the wild-type allele (wt) and 8 kb for the mutant allele (m), and with
the 3' probe, 12 kb for wild-type allele (wt) and 3.5 kb for the mutant allele (m). (C) A
representative Southern blot analysis of progeny from a heterozygous cross. Tail DNA was
digested with Hpal and Sph 1 and probed with the 5' probe. The genotypes are depicted at the top
of each lane.
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Figure 2 Western blot and Northern blot analysis of pl07 mutant mice and cells. (A) Western
blot analysis of cell extracts prepared from wild-type (+/+), p107+ '-, and p107-1- embryos MEFs
using a monoclonal antibody against to p107. Cell extracts were immunoprecipitated with
monoclonal antibodies against p107 (SD9 and SD15) and the p107 immunoreactive species were
detected by immunoblotting with SD9. Note the absence of p107 in the -/- sample and the reduced
levels in the +/- sample. Positions of molecular weight standards are indicated at left The position
of p107 and cross-reactive IgG is also shown at right. (B) Northern blot analysis of poly(A)+
RNA isolated from wild-type and p107-/ - whole embryos (E1 8), using a 4.8 kb full-length mouse
p107 cDNA probe. Note the absence of p107 transcript in the p107 mutant (-/-) samples. The
positions of RNA molecular weight markers are indicated to the left. The lower panel shows
hybridization with a GAPDH probe as a loading control. (C) Western blot analysis of protein
extracts from wild-type (+/+), p107+/-, and p107-/- embryos (E18), using antibodies against pRB
(upper blot) and p130 (lower blot). Note that pRB and p130 levels are not altered significantly in
pl07-mutant embryos.
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Figure 3. Phenotypes of Rb+/-';pl07- - mice. (A) Growth retardation of Rb+l-;pl07"1- mice.
Two week old littermates from a Rb+/';pl07+/- by p107l/- cross are shown. The animal at left is
Rb+l';pl07-/- and is significantly growth retarded compared to the
Rb+/l-;pl07+/- at right, as well as to wild-type mice of this age. (B) A representative growth
curve of two male Rb+/-;pl07-/- and two male Rb+l-;pl07+/- littermates derived from a Rb+l-
;p107-" - by Rb+l-;pl07+ /- cross. (C) Vaginal atresia in Rb+l';pl07-1- females. Note that the
abdomen and perineum are distended due to fluid accumulation in the uterus.
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Figure 4. Retinal lesions in Rb+/-;pl07 -/- mice. (A) Indirect ophthalmoscopy of
Rb+ 1-;pl07'- retina. White spots (solid arrows) are diagnostic of retinal pathology. One spot at
the center and the crescent-shaped spot at the periphery (open arrows) are due to reflections from
the camera light source. (B - C) Histological sections of retinas of
Rb+/-;pl07-/- adult mice showing regions of retinal dysplasia (arrows); normal retinal structure is
also indicated (N). (D) Higher power magnification of lesion shown in (B). (E - F) Histological
sections of retinas of 4 day old Rb+/';pl07-/ " animals. A region of abnormal (arrow) and normal
(N) retinal architecture is indicated in E. Disruption of photoreceptor layer is apparent in F.
Magnifications: B, C, and E = 100 X; D and F = 400 X.
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Figure 5. Viability of Rb'-';pl07-/- embryos. Survival as a function of gestational age of Rb-1-
;p107-1-, Rb'l-;pl07+ /-, and control embryos. Survival percentage was determined by comparing
the number of embryos with a detectable heartbeat to the total number of embryos collected at each
gestational day (shown in parentheses). Embryos were derived from crosses of Rb+/l-;pl07- -
male mice to Rb+/-;p107+/ - female mice. All others indicates the genotypes of Rb(+I+);pl07+ /-,
Rb(+/+);pl07-l' , Rb+l-;pl07+/-, and Rb+/-;pl07- '-. In addition, 100% (22/22) of Rb-"/ embryo
were recovered alive at E12.5.
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Figure 6. Histopathology of Rb-'';pl07-/- embryos. (A and B) Sections of spinal cord from
Rb"-- (A) and Rb-/-;pl07-/ - (B) embryos at Ell11.5. Note that compared to the normal histology
in A, the Rb-l-;pl07-1- tissue contains areas of acellularity and numerous cells with pyknotic
nuclei indicative of apoptosis. Sections of dorsal root ganglia and peripheral nerves at this stage
show apoptotic cells in both Rb-/- and Rb'l-;pl07-1- embryos (data not shown). (C and D)
Liver sections from Rb'-- (C) and Rb-l-;pl07-1- (D) embryos at E12.5. The Rb-l-;p107-/'
section show areas of acellularity and numerous pyknotic nuclei, while the Rb -1- liver is normal at
this stage of development. (E and F) Immunohistochemical analysis of skeletal muscle in
control, Rb+l';pl07+ /- (E) and
Rb-l-;pl07" " (F) embryos at E12.5 The primary antibody is specific for sarcomeric actin;
reactivity is indicated by brown precipitate. Magnifications: A - F = 100 X.
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This work illustrates that one of the reasons that Rb-deficient embryos progress so far in
development is perhaps due to the redundancy provided by the presence of the related p 107
protein. Interestingly, embryos deficient for both Rb and p130 fail at a similar stage in
development as the Rb-/-;pl07-/- embyros (George Mulligan and Tyler Jacks, unpublished data),
suggesting that p130 may also act in a similar way to p1 0 7 to partially compensate for the absence
of Rb. An analysis of embyros triply deficient for Rb, p107, and p130 is hampered by the
decreased viability and fertility of animals carrying different combinations of mutations, so an
alternative route to answer this question is being pursued (see Appendix E).
The observation of retinal dysplasia in Rb+/-;pl07-/- mice is of special note. Since retinal
dysplasia has not been observed in either Rb+/- or p107 -/- mice, some aspect of retinal
differentiation appears to depend on redundant functions of Rb and p107. In addition, Rb+/-;p53-
/- mice also develop retinal dysplasia. Based on these two observations, it is tempting to speculate
that the induction of retinoblastoma in mice by retinally-directed expression of SV40 Large T
antigen (Windle et al., 1990) or by concomitant retinal expression of HPV E6 and E7 (Howes et
al., 1994) is caused by the inactivation of Rb, p107, and p53. Perhaps the generation of ES cells
deficient for Rb, p107, and p53 and the subsequent generation of chimeras from them will result in
the formation of retinoblastoma and resolve the question of what genetic changes are needed to
induce murine retinoblastoma .
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APPENDIX D
Analysis of Phenotypes Associated with a Hypomorphic Allele of Rb in the Mouse
(Rbl3neo)
255
Introduction
While the generation and analysis of the null alleles of Rb allowed significant insights into the role
of Rb during murine development (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992), the
mid-gestation embryonic lethality precluded examination of the role of Rb during later stages of
development. One method used to overcome this problem, the generation of chimeric mice from
Rb-deficient ES cells, has been discusses earlier in great detail (see Chapters 4 and 5). This
appendix describes the generation and analysis of a strain of mice carrying an allele of Rb that
causes significantly reduced levels of pRb protein, but not complete elimination of full length
protein as the allele described above does (Jacks et al, 1992). Animals heterozygous for this
mutation develop intermediate lobe pituitary tumors histologically indistinguishable from those
which arise in the null allele heterozygotes, albeit after a longer latency period. Almost all mice
homozygous for this allele of Rb die within 6 hours of birth and this neonatal lethality is associated
with a failure of the embryos to properly inflate their lungs. The underlying cause of this is not
known. Thus, this allele has allowed identification of another window in development where Rb
function is required for viability.
256
Materials and methods
Initial Generation of RbI3Neo +/- ES Cells
The initial clone of ES cells used to derive mice was created by Tyler Jacks with the same targeting
vector as described previously (Jacks et al., 1992). A homologous recombination event induced
by this targeting vector was designed to include two stop codons in the third exon of the Rb gene
as well as place the neomycin resistance gene in the third intron to provide for positive selection of
electroporated clones. In most cases the homologous targeting event occurred in such a way that
both the stop codons and the neo gene were included. However, in one clone the homologous
recombination occurred in a way that the neomycin resistance gene was inserted into the third
intron of the Rb gene, but the stop codons were not introduced into the third exon (Figure D-1).
ES cells containing this Rb allele was used to generate chimeras and will be referred to as the
Rbl3neo allele.
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Figure D-1. Schematic of Rbl3Neo allele generation
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Generation of a second independent Rbl3Neo allele
Because all the Rbl3Neo mice examined in the early stages of analysis were derived from a single
ES cell clone, it remained possible that some observed phenotypes could be due to a second,
linked and unknown mutation created in those ES cells. In order to address this possibility, a
second allele of Rbl3Neo was created by electroporation of D3 ES cells with a targeting vector
including only the neomycin resistance gene in the third intron. Clones were electroporated and
selected as previously described. Homologous recombinants were identified as previously
described (Jacks et al., 1992). Analysis of 16 selected clones by Southern blot (as previously
described) revealed 3 homologous recombinants. Two of these clones were used to create
chimeric mice. One line of chimeric mice transmitted the Rbl3Neo mutation through the germline.
The phenotypes of these mice were indistinguishable from the initially derived allele, making it
extremely likely that the phenotypes observed are the result of the mutation in the Rb allele and not
some unknown, linked mutation induced during homologous recombination.
Generation of chimeric mice
Chimeric mice were generated by blastocyst injection as previously described (see Chapters 5 and
6).
Generation of strains
Rbl3Neo mice carrying the mutation on two different genetic backgrounds were derived. The first
background is a mixture of 129/Sv and C57/B16J derived from intercrosses of animals created by
germline transmission by the chimera when mated to purebred C57/Bl6J females. The second
background is purebred 129/SvJ derived from mating chimeras to purebred 129/SvJ females and
identifying pups derived from germline transmission by PCR genotyping (Jacks et al., 1992).
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Western blot analysis
Western blot analysis was performed as previously described (Jacks et al., 1992). Extracts were
taken from fetal brain (12.5 days) as previously described (Jacks et al., 1992).
Southern blot analysis
Southern blot analysis was done as previously described (Jacks et al., 1992). A schematic
representation of the products of the restriction digest and the location of the probe is shown in
Figure D-2. A representative Southern blot is shown in Figure D-3.
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Figure D-2. Schematic of genomic structure and expected restriction digest
pattern using Pstl digested genomic DNA. Pstl sites are denoted by arrows.
The probe used for the analysis is indicated with a black box.
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Figure D-3. Southern blot tissues and tumors from RbX3t and Rbl3Neo heterozygous animals.
The positions of the wild type, Rbl3Neo, and RbX3t alleles are noted on the left. Lane 1, Tail
DNA from an Rbl3Neo heterozygote. Lanes 2-4, Pituitary tumor DNAs from RbI3Neo
heterozygotes. Lanes 5-7, Pituitary tumor DNAs from RbX3t heterozygotes. Note that in all cases
the wild-type allele of Rb is reduced or absent from the pituitary tumor DNA.
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RT-PCR
For RT-PCR, total RNA was isolated from brain, liver, and body wall (carcass) tissue of 13.5 day
embryos via the RNAzol method (BiotecX Laboratories, Houston). Briefly, 13.5 embryonic brain,
liver, and carcass were isolated and disaggregated in 100 microliters of PBS in an Eppendorf tube.
500 microliters of RNAzol B was added to this. 50 microliters of chloroform was added to this
and the whole mixture placed on ice for 5 minutes. Then the tube was placed in an Eppendorf
centrifuge and spun at 14,000 rpm for 15 minutes (at 4 degrees Celsius). The supernatant was
then added to 300 microliters of isopropanol and then stored at -20 degrees Celsius for at least 12
hours. RNA was precipitated by centrifugation and then resuspended in 100 microliters of
distilled water. Reverse transcription was performed in the following manner (recipes for
solutions are included below).
Reverse transcription reaction
2 microliters 10X RT Buffer
2 microliters 10X dNTPs
2 microliters 1 microgram/microliter oligo-dT
1 microliter RNAsin
1 microliter Superscript (GIBCO-BRL)
10 microliters RNA solution
This reaction mix was placed at 37 degrees Celsius for one hour. Then 80 microliters of distilled
water was added and the mixture boiled for 5 minutes. The mixture (cDNA solution) was then
stored at -20 degrees Celsius until use. For PCR the following conditions were used. In this case,
PCR primers were designed to amplify a 150 base pair fragment that would result from a splicing
event from the 3' end of exon 2 into the neomycin resistance gene in the third intron (see Figures
D-6 and D-7). PCR conditions were as follows (again recipes for the ingredients are included
below).
Reaction Mix
19 microliters DNA mix
0.5 microliters oligo mix
0.5 microliters Taq polymerase
The following PCR program was used.
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Temperature (Celsius)
1 94 60
2 94 36
3 55 36
4 72 180
Repeat steps 2-4 30 times
5 72 554
PCR products were then visualized by running them out on a 2% agarose gel.
Recipes for RT-PCR solutions (all quantities are in microliters unless noted)
DNA mix
20 cDNA
48 10X PCR buffer
10 mM dNTPs
378 distilled water
Oligo mix
78 distilled water
6 RbX3 (5'-AATTGCGGCCGCATCTGCATCTTTATCGC-3')
6 Neo 18.5 (5'-TCCTCGTGCTTTACGGTATC-3')
1OX PCR buffer (final concentrations)
500 mM Tris-HCI (pH=8.3)
30 mM MgCl2
750 mM KCl
100 mM DTT
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Step # Time (seconds)
Results
Heterozvgous phenotype
Mice heterozygous for this allele of Rb were viable and fertile. They also developed the
intermediate lobe pituitary tumors characteristic of Rb null heterozygotes (see Figure D-8).
However, the latency of tumor development was significantly increased, both in a 129 and mixed
genetic backgrounds (see Figure D-2). Southern blot analysis and in some cases PCR analysis
revealed that, as in the other previously reported strains of mice, the wild-type allele of Rb was
absent from the pituitary tumors (see Figure D-3).
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Figure D-4. Survival of wild-type mice (50 mice) relative to RbI3Neo (25 mice) and RbX3t (50
mice) heterozygotes. All animals are of a mixed genetic background.
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Homozygous phenotype
While animals homozygous for the null allele of Rb die between days 13.5 and 14.5 of gestation
with defects in fetal liver hematopoiesis and neurogenesis, mice homozygous for the Rb I3 allele
are present at normal levels throughout gestation and survive until birth. However, the vast
majority of homozygotes (and 100% of those derived on a purebred 129/Sv background) die
during the first 4-6 hours after birth (see Table D1-3). These animals appear healthy when born,
but quickly become cyanotic and appear to have difficulty breathing. Pathological analysis reveals
that the mice never expand their alveolar spaces (data not shown). Despite extensive pathological
analysis we have been unable to ascribe the neonatal lethality to any underlying cause. The only
pathological abnormality seen consistently in these mice is the presence of bilateral cataracts (see
Figure D-7). Rare surviving animals (all from a mixed background) are fertile and do not exhibit
any significant histological abnormalities besides cataracts and pituitary tumors (Figure D-7). A
summary of adult animals (defined as 3 weeks of age) derived from crosses of animals
heterozygous for the RbI3Neo allele is shown below (Table D-2). In addition, results from a
limited number of crosses of homozygous mutants by heterozygotes are shown on the following
pages (Table D-3). Finally, litters from crosses between RbX3t heterozygotes and Rbl3Neo
heterozygotes were examined just prior to birth. This analysis showed that Rbl3Neo/RbX3t
compound heterozygotes also appear normal until birth (Table D-4).
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Presence of normal RbI3Neo homozygotes during development
(Derived from Rbl3Neo heterozygous intercrosses of 129 and mixed genetic background)
Developmental stage
12.5 days p.c.
13.5 days p.c.
15.5 days p.c.
18.5 days p.c.
Immediately after birth
(less than 2 hours)
Wild type Rbl3Neo +/- RbI3Neo -/-
Table D-2
Animals surviving to 3 weeks of age derived from RbIl3Neo heterozygote crosses
(data are derived from crosses of the two separately derived alleles)
Genetic Background
Purebred 129/Sv
Mix (129/Sv and
C57/B16J)
Wild-type RbI3Neo +/- RbI3Neo -/-
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Table D-3
Animals surviving to
Genetic Background
Mix (129/Sv and
C57/Bl6J)
3 weeks of age derived from Rbl3Neo -/- by RbI3Neo +/- crosses.
Rbl3Neo +/-
16
RbI3Neo -/-
2
Table D-4
Results of crosses between RbI3Neo heterozygotes and RbX3t heterozygotes (From mixed genetic
background). The number of normal embryos for each genotype is given. No abnormal embryos
were observed.
Developmental stage
18.5 days p.c.
Wild type
3
Heterozygotes (of
either allele)
5
RbI3Neo/RbX3t
homozygotes
5
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Molecular characterization of the RbI3Neo allele
Western blot analysis of lysates made from 12.5 day wild-type and mutant embryo brains revealed
a substantial decrease in the amount of Rb protein in the homozygous Rbl3Neo embryos. 100
micrograms of protein was loaded for each lane. As can be seen in Figure D-5, the levels of pRb
in the Rbl3Neo homozygous mutant animals are substantially reduced relative to a representative
wild-type littermate. In addition, immunofluorescenct analysis of pRb levels in MEFs
homozygous for the Rbl3Neo mutation confirmed a substantial reduction in pRb levels (data not
shown).
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Figure D-5. Western Blot analysis of pRb in intron mutant embryos. 100 micrograms of protein
was loaded onto each lane. The migration of a molecular weight marker (105 kD) in another lane
on the blot is noted.
105 kD*
271
RT-PCR
RT-PCR analysis of RNA extracted from 13.5 day heterozygous and wild-type embryos revealed
an abnormal splice product present in all embryos carrying at least one copy of the RbI3Neo allele
which was absent in all wild-type embryos. This product was consistent with one derived from
splicing into a strong, consensus splice acceptor sequence revealed when the neomycin resistance
gene is included in the opposite transcriptional orientation to the gene being disrupted (Figure D6-7
and Jacks et al., 1994). This abnormally splice product would be predicted to give rise to a
truncated protein and likely explains the reduction of pRb levels in extracts from homozygous
mutant Rbl3Neo embryos.
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Products of the RT-PCR described above were resolved on 2% agarose-TAE gels. (Lane 1, 123
bp ladder, Lane 2, wild-type brain; Lane 3, wild-type liver; Lane 4, wild-type carcass; Lane 5,
Rbl3Neo +/- brain; Lane 6, Rbl3Neo +/- liver, Lane 7, RbI3Neo +/- carcass. The presence of a
non-specifically amplifying band is noted (n). The presence of the band (-150 bp) predicted to
result from the putative abnormal splicing event is noted (s).
1 2345 67
246-o
123-
-m.S
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Figure D-7. Schematic diagram of the normal splicing event and the
abnormal event taking place at some frequency from the Rbl3Neo allele.
Wild type Rb allele
Rbl3Neo allele
(Normal splicing pattern)
(Abnormal splicing pattern)
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Discussion
The data in this appendix show that while complete loss of Rb function results in embryonic
lethality at approximately 13.5-15.5 days, a reduction in the amount of pRb to about 10% of wild-
type levels causes neonatal lethality. This reduced amount is sufficient for embryos to survive past
15.5 days of gestation and no abnormalities in fetal hematopoiesis or in neurogenesis have been
observed histologically. In fact, when compound heterozygotes are produced by mating
Rbl3Neo+/- animals to Rb null heterozygotes, the same neonatal lethality is observed, suggesting
that even smaller amounts of Rb protein are sufficient to allow sufficient fetal hematopoiesis and
neurogenesis.
The genomic structure of this allele has broader implications in the field of gene targeting. The
presence of the putative splice acceptor and splice donor sites within the neomycin resistance gene
when it is in reverse orientation to the targeted gene was first noted during the analysis of the Nf-1
gene knockout(Jacks et al., 1994). In the case described here, the abnormal splicing event would
be predicted to create a severely truncated non-functional protein product. Interestingly, this
abnormal splicing event does not occur with 100% efficiency since RbI3Neo homozygotes still
produce a small amount of full length protein.
The value of this mouse strain will be expanded greatly if the underlying cause of the neonatal
lethality can be understood. Despite extensive histological analysis, an underlying cause has yet to
be determined. If and when the cause of lethality is determined, this mouse will identify another
system which is dependent on the presence of normal amounts of pRb for normal function.
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Figure D-8
Pathology associated with the Rbl3Neo mutation.
(A) Section through eye of newborn Rbl3Neo homozygote (100X). The presence of a cataract (c)
in the lens capsule as well as a normal appearing retina (r) are indicated
(B) Section through intermediate lobe pituitary tumor (100X) from a RbI3Neo heterozygote.
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APPENDIX E
Generation of ES Cells Deficient for Multiple Members
of the Rb Gene Family
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In order to further advance the utility of the chimeric mouse system to study Rb-function, I
initiated efforts to derive ES cells carrying deficiencies in different combinations of the Rb-family
members. Because any mouse (unless somehow dramatically rescued by some suppressor
mutation) carrying a germline homozygous deficiency in the Rb gene will die during mid to late
gestation, these ES cells will prove a valuable reagent to probe the potential overlapping functions
of these proteins in adult tissues. In addition, the neonatal synthetic lethality seen in animals
deficient for both p107 and p130 (Cobrinik et al., 1996) further reinforces the need for such
reagents.
In this appendix I describe my efforts to develop such systems and comment on how these may
be used in the future. I have succeeded in isolating cell lines which are deficient for p107 and p130
as well as cell lines which are deficient for both Rb and p107. George Mulligan, a postdoctoral
associate in the laboratory, has isolated cells which are deficient in both Rb and p130.
Materials and Methods
All procedures for ES cell generation, ROSA-26 genotype determination, Rb-genotype
determination, and ES cell culture and injection in general are described in Chapter 5. Analysis of
p107 genotype status was performed as described in Appendix C. All histological examinations
were performed as previously described.
p130 PCR genotype determination
p130 genotype was determined by a PCR-based assay (Cobrinik et al., 1996). Genomic DNA
was isolated as described above and amplified in the following conditions.
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Results
Generation of ES Cells
The chart below summarizes the generation of ES cells with the desired genotype.
Cross # Females # Blastocysts # ES cell lines
pl07+/-;p130-I- intercrosses 10 36 11
Rb+/-;p107-/-;ROSA-26 3 7 2
male X Rb+/-;pl07+/-
female
From the p107/p130 crosses one p107-/-;p130-/- ES cell line was established. Zfy PCR (Page et
al., 1987; Sah et al., 1995) failed to show a PCR product indicating the line was female. From the
Rb/pl07 crosses one Rb-/-;pl07-/-;ROSA ES cell line was established. Zfy PCR indicated that it
was male.
Generation of Chimeras from p13 0-/-: p107-/- ES cells
Two rounds of injection were performed with these cells resulting in the generation of 5 moderate
to highly chimeric animals. Of these five animals (all born in November 1995) two have died
prior to four months of age. One of these animals exhibited the presence of tingible body
macrophages throughout the white pulp of the liver (see Figure E- 1) and also leakage of
proteinasceous material into the glomerular space of the kidney (data not shown). No other
abnormalities (including bone formation) were detected (see Figure E-1). Histological analysis of
the second animal revealed the presence of a severe stomach ulcer as well as a thrombus of blood
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lodged in the heart, which probably caused the death of the animal (data not shown). Again, no
abnormalities in the formation of bone were observed.
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Figure E-1
p130/p107 Chimera Histology (see following page)
Hematoxylin and eosin stained sections from a 3 month old chimera derived from pl07-/-;p 130-/-
ES cells.
A. Section through femur showing normal bone formation (40X). Despite the fact that p1 07-/-
;p130-/- neonates show severely shortened limbs associated with bone deposition defects, all
chimeras examined so far have normal limbs, and two chimeras (over 80% chimeric as judged by
coat color) have been histologically examined with no noted defects in bone formation.
B-D. Sections through spleen 40X (B), 100X (C), 400X (D). Normal pancreas (p) and abnormal
spleen (s) are shown. Note the presence of abnormal white pulp (arrow in C) in the spleen.
282
LiT1 .*
r. . . ,- . -.
283
Injection of Rb-/-:r;107-/-:ROSA-26 ES cells
Three rounds of injection were performed with these cells. To date, no viable chimeric offspring
have been recovered, although three potential chimeric pups were born only to be cannibalized by
the birth mother.
Discussion
While the analysis of chimeras generated from these ES cells is in very preliminary stages, the
analysis of chimeras derived from the p130/p107 doubly deficient ES cells has already revealed
pathological abnormalities. Experiments following up these observations will no doubt be
valuable in increasing our understanding of these genes' functions. Interestingly, the preliminary
analysis suggests that the bone defect seen in neonates with a germline genotype of pl07-/-;pl30-/-
may be a non-cell autonomous defect as the four very strong chimeras created to date have normal
limbs and have no noticeable histological defects.
In addition to the cell lines described here, George Mulligan, a post-doctoral associate in our
laboratory, has successfully isolated Rb-/-;pl30-/- ROSA-26 ES cells. He is now using the cells
he isolated as well as the cells described above to try to generate ES cells deficient in all three Rb-
family genes via methods similar to those described in Chapters 5 and 6. If and when these Rb-/-
;p130-/-;p107-/- ES cells are created, they will useful in addressing the role of Rb-family functions
in a variety of systems including chimera generation and in vitro ES generation (Robertson, 1987).
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